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Cancer and the immune system
Cancer is one of the biggest health threats globally and is predicted to grow rapidly in in-
cidence and mortality in the remainder of the 21st century. Factors that contribute to this 
growth are complex, but mainly influenced by the increased aging and growth of the global 
population1. As a consequence of these developments and lack of effective treatments, a 
lot of effort is put into research and development of novel effective therapies that can com-
plement or replace existing treatment options, which include surgery, chemotherapy, ra-
diotherapy and immunotherapy. The latter approach was established in the second half of 
the last century and is revolutionizing the field of cancer therapy by exploiting the patient’s 
own immune system to combat cancerous cells. The increasing fundamental knowledge 
on tumor biology, immunology and immunotherapy already translated in several effective 
clinical treatments that underline the potential of this type of therapy2. 
The immune system is an intricate web of various organs, cells and soluble factors that 
evolved to fight off viral and bacterial intruders or diseased and malfunctioning cells. To 
organize this complex network and maintain tissue homeostasis, the immune system is 
cross wired through immune cells and soluble factors, such as chemokines and cytokines. 
The central organizational hub of the immune system is formed by the dendritic cell (DC). 
This cell type has the unique ability to integrate diverse extracellular cues and immune 
contexts and thereby steer the immune response towards a tolerogenic or immunogenic 
outcome. In a cancer setting, this will translate into a pro-tumoral or anti-tumoral immune 
response. To achieve this, the DC maintains close communication through cytokines and 
receptors with cells of the innate immune system such as macrophages, natural killer cells 
and neutrophils, and cells of the adaptive immune system3–5 namely T and B cells. 
In the context of cancer and immunotherapy, an anti-tumor immune response is desired 
as this will instruct immune effector cells to specifically eradicate cancerous cells. Such a 
response can be initiated once a DC encounters immunogenic tumor material in the form 
of necrotic particles or other tumor-derived factors containing tumor antigens. This pro-
cess is considered to be the start of the cancer-immunity cycle6, which is a perpetual order 
of events in which immune cells are instructed by the DC to eliminate tumor cells, causing 
release of new tumorigenic material, leading to the initiation of a new anti-tumor immune 
response by the DC (Fig. 1). The initial release of necrotic particles and other tumor-derived 
factors is mainly triggered by tumor cell necrosis (Fig. 1.1) or tumor cell lysis through innate 
immune cells. Released material will be engulfed by DCs within the tumor micro-environ-
ment and intracellularly processed in endosomal and lysosomal compartments, extracting 
tumor antigen-derived peptides. Subsequently, these peptides might be presented on the 
DC surface in the context of major histocompatibility complex (MHC) molecules if possess-
ing the correct binding affinity. Peptides that are derived from exogenous, engulfed ma-
terials or tumor cells, are presented in MHC class II (MHCII) molecules. In contrast, when 
peptides are derived from foreign cytosolic proteins that were introduced into the cell by vi-
ruses, microbes or are products of mutated genes, they are presented in MHC class I (MHCI) 
molecules. DCs however, also possess the unique ability to present exogenously derived 
peptides in the context of MHCI molecules, in a process called cross-presentation (further 
detailed below). Consequently, tumor-antigen derived peptides can be presented on both 
MHCI and II by the DC (Fig. 1.2). In turn, DCs migrate to lymph nodes where presented MHCI 
and II peptide complexes can be recognized by naïve circulating CD8+ or CD4+ T cells, re-
spectively, through interaction with the T cell receptor (TCR). This interaction is also called 
11
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Figure 1 | The cancer-immunity cycle. (1) Tumor cell death and release of tumor antigens and proinflammatory 
factors such as cytokines or tumor-derived DNA and RNA. (2) Uptake, processing and (cross-)presentation of 
tumor antigens by dendritic cells (DCs) in the context of MHCI and II molecules. DCs will moreover be activated by 
proinflammatory cytokines and express co-stimulatory molecules. (3) DCs travel to the lymph node and activate 
naïve CD4+ and CD8+ T cells by (I) presentation of tumor antigens, (II) expression of co-stimulatory molecules and 
(III) the secretion of cytokines. Activated T cells will also start to secrete cytokines (red and yellow circles). (4) As a 
consequence of activation and secretion of cytokines, T cells get fully activated, proliferate and upregulate migra-
tory molecules to travel to the tumor. (5) At the tumor site, CD8+ T cells can induce tumor cell apoptosis after rec-
ognizing MHCI:tumor antigen complexes (I). CD8+ can use both, soluble (II) or contact dependent (III) cytotoxicity 
to induce tumor cell killing. CD4+ T helper cells assist this activity by the secretion of proinflammatory cytokines.
signal 1 of T cell activation (Fig. 1.3). Full activation of T cells can then be facilitated by the 
DC through expression of costimulatory molecules such as B7 and secretion of pro-inflam-
matory cytokines such as IL-12, referred to as signals 2 and 3 (Fig. 1.3)5. For this to happen, 
the DC also has to be activated via dangers signals or through the innate immune response. 
Once CD8+ and CD4+ naïve T cells have received all three signals, they clonally expand 
and differentiate into cytotoxic and helper T cells, respectively (Fig. 1.4).  Cytotoxic T cells 
will then migrate through efferent lymphatic and blood vessels to the tumor tissue where 
they execute cytolytic effector functions to eradicate tumor antigen-displaying tumor cells, 
while helper T cells support this by the secretion of immunostimulatory cytokines (Fig. 
1.5)4. Concurrent release of tumor particles and antigens after this cytolysis, eventually 
leads to antigen uptake by tissue-resident DC and induction of a new cancer-immunity cy-
cle6. The cycle as described here depicts the ideal situation of an anti-tumor immune re-
12
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sponse. However, tumors have evolved a plethora of strategies such as inhibitory immune 
receptors or checkpoints, downregulation of the presentation of MHC-peptide complexes 
or the secretion of anti-inflammatory cytokines, to name a few, to dampen the anti-tumor 
immune response at the fifth step of the cycle (Fig. 1)7–10. While blocking inhibitory immune 
checkpoints has been shown to be a viable and effective immunotherapeutic strategy to 
unleash the breaks of the adaptive immune system, often an unwanted systemic immune 
response is induced which can damage healthy tissues11–13. To prevent or minimize these 
negative side-effects one might have to intervene at an earlier step of the cancer-immunity 
cycle where the course of the anti-tumor immune response can still be shaped in a more 
controlled way. 
DC-targeting cancer vaccines 
To make use of the immune system in the context of 
cancer immunotherapy, one can intervene at several 
other levels of the cancer-immunity cycle to promote 
the anti-tumor immune response. As DCs play a funda-
mental role at various stages of this cycle, it is a very 
powerful handle to initiate and finetune a strong an-
ti-tumor immune response. In the past two decades, 
pre-clinical and clinical work has focused on the target-
ed delivery of tumor antigens and maturation signals 
(adjuvants) to DCs in vivo to mount a T cell response 
against the tumor, also known as DC-targeted vaccina-
tion14,15. In contrast to un-targeted and systemic DC vac-
cination, this treatment method aims at increasing the local concentration of the vaccine 
on the DCs and not in the vicinity of other cells in order to enhance vaccine uptake and its 
efficacy16,17. This retention effect is achieved by delivering the vaccine directly to the DC 
by targeting DC-specific surface molecules18. This delivery is mainly mediated by antibody 
molecules (Fig. 2) that are conjugated to tumor antigens to form antibody-antigen (AA) 
conjugates. Like a key in a lock, these antibody molecules can bind to a very specific target 
on the DC with high affinity, which also allows selective delivery to DC subsets, activating 
receptors or receptors triggering internalization of its ligand.  
The rise of DEC205-targeting cancer vaccines
The first generation of DC-targeting cancer vaccines was designed by the group of the DC 
pioneer Ralph Steinman19. The vaccine design was based on an anti-DEC205 monoclonal 
antibody (mAb) that was chemical linked to the ovalbumin (OVA) protein via reactive thiol 
groups. Upon co-treatment with an agonistic anti-CD40 mAb as a DC maturations stimu-
lus, mAb DEC205-OVA conjugates were shown to be taken up by DCs leading to the induc-
tion of antigen presentation, which in turn resulted in a strong cytotoxic T cell response in 
mice19. Following studies of Steinman and others further established a critical role of the 
DEC205 receptor on DCs for the future of DC-targeting vaccines. This C-type lectin receptor 
is mainly expressed on cortical thymic epithelium and thymic medullary DCs (CD8+/CD11c+) 
as well as on subsets of peripheral DCs (CD8+/CD11c+ splenic/lymph node DCs, dermal/
interstitial DCs, and Langerhans cells)20–23. Upon binding, DEC205 is internalized, leading 










Figure 2 | Structure of a monoclonal 
antibody.
13
INTRODUCTION AND SCOPE OF THE THESIS
1
of MHCI to CD8+ T cells24,25 (Fig. 3). It 
was moreover shown that DEC205 is 
recycling through MHCII-rich, late endo-
somes resulting in the ability to present 
antigen epitopes in the context of MHCII 
to CD4+ T cells5,26,27. Several pre-clinical 
studies have further emphasized the 
added benefit of targeting antigens to 
DCs via DEC205, leading to higher num-
bers of antigen-specific T cells and an 
improved tumor clearance23,28,29. These 
findings finally culminated in the first 
successful phase I clinical trial complet-
ed in 2014, using an anti-DEC205 anti-
body that is genetically fused to the can-
cer testis antigen NY-ESO (CDX-1401)30,31. 
With three other phase I and II clinical 
trials underway (ClinicalTrials.gov Iden-
tifier: NCT03358719, NCT02129075, 
NCT02166905) CDX-1401 is the furthest developed DC-targeting vaccine until today.
Traditional conjugation methods for AA conjugates
While receptors, including DC-SIGN, CLEC9A or XCR1 (extensively reviewed by others14), for 
DC-targeting vaccines are well explored, robust and standardized methods for conjugation 
of payloads to DC-targeting antibodies are lacking and hindering large-scale manufactur-
ing of new DC-targeting vaccines. In the examples touched upon before, DEC205-target-
ing AA conjugates are formed by varying strategies either using chemical conjugation or 
genetic fusion. Classic chemistry-based strategies commonly use reactive amines or thiol 
groups of lysines, and cysteines scattered throughout the antibody to attach a payload via 
N-hydroxysuccinimide (NHS) esters or maleimides, respectively (Fig. 4A). On a standard Ig 
molecule roughly 40 lysine and 8 cysteines are exposed and accessible for conjugation. To 
these accessible residues, typically 0-8 payload molecules can be attached32. Since these 
reactive groups are distributed over the entire antibody molecule, these conjugation meth-
ods can yield heterogeneous products, with varying antibody to payload ratios and can 
negatively affect the antibody binding affinity32–35. The advantage of chemical conjugation 
is that linkers can be introduced that equip the conjugate with an additional functionality, 
such as being only cleaved by lysosomal proteases, cytosolic-selective cleavage or sen-
sitivity to low pH36. Moreover, certain chemical compounds such as drugs, adjuvants or 
fluorescent molecules can be introduced that can otherwise not be added with genetic 
conjugation only.
Genetic fusion of antigens to antibodies is achieved through transient expression 
through antibody-antigen fusion plasmids in producer cell line such as Chinese hamster 
ovary (CHO) or human embryonic kidney (HEK293) cells37 (Fig. 4B). This type of conjugation 
allows for site-specific attachment of the antigen at the C-terminus of the antibody heavy 
or light chain and makes it possible to control the amount of antigens that are delivered to 


















CD4+ T cell CD8+ T cell
Figure 3 | General overview of DEC205 receptor-mediated 
uptake of antibody-antigen (AA) conjugates. Receptor-me-
diated uptake of AA conjugates leads to presentation of an-
tigens in the context of MHCI and II to CD8+ and CD4+ T cells, 
respectively. For proper MHCI:antigen formation escape of 
the antigen to the cytosol is needed.
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is that they require the identity of the sequence of the variable regions of heavy and light 
chains, which are often unavailable. Moreover, this approach often demands extensive op-
timization to achieve acceptable yields. 
Both conjugation strategies have clear benefits but also limitations that justify further 
research into techniques that enable site-directed conjugation, flexibility as well as robust 
and high production yield of DC-targeting vaccines. 
Towards molecularly defined, tri-functional DEC205-targeting vaccines
Similar to the field of antibody-drug conjugates38, it is important for future success that the 
field of DC-targeted vaccines is moving towards molecularly defined molecules and robust 
production. Ideally the amount of antigens and adjuvants is defined and the targeting moi-
ety is maintained in its functional form. New conjugation methods that empower molecu-
larly defined and site-directed antibody engineering are highly desired to tackle this chal-
lenge. In the search for these strategies, several research groups have sought to combine 
chemical and genetic conjugation. One very promising strategy is pioneered by Swee et 
al.39 and is based on chemo-enzymatic ligation of the payload to the antibody by a soluble 
mutant of an enzyme called sortase A. This enzyme is a cell surface bound transpeptidase 
originating from gram-negative bacteria like Staphylococcus aureus which catalyzes the 
ligation of proteins such as virulence factors or protein A to the bacterial cell surface. This 
reaction takes place in a two-step calcium-dependent mechanism. First, sortase recogniz-
es the LPXTG motif (sortag) on a target protein and establishes a thioester intermediate 
with the threonine, also called acyl-enzyme complex. Then the nucleophilic amino group of 
an N-terminal tri-glycine motif attacks the thioester in order to form a covalent amide bond 
with concomitant sortase release. Because of the specificity, orthogonality and mild reac-
tion conditions sortase A was modified to be expressed as soluble enzyme and is since then 
extensively used. The broad array of possibilities using the sortase reaction range from 
protein-protein, protein-peptide, protein-nucleic acid, protein-lipid to N- or C-terminal and 
internal loop labeling40. To make use of this reaction in the context of DC-targeting vac-
cines Swee et al.39 recombinantly expressed C-terminally sortaggable anti-DEC205 mAbs 


























Figure 4 | General overview of common conjugation strategies for the attachment antigen payloads to an 
antibody. (A) Chemical conjugation is mainly performed via reactive surface residues such as lysines (orange) or 
cysteines (green). (B) Genetic fusion makes use of transient expression of antibody heavy and light chain encoding 
plasmids (1 and 2, respectively) in producer cell lines. The gene of interest can be inserted by cloning at the 3’ end 
of the coding region. (C) For sortase-mediated ligation first a sortag has to be cloned into heavy and light chain 
encoding plasmids. Transient expression of the plasmids in producer cell lines will yield C-terminally sortaggable 
antibodies, that can be modified during the sortase reaction with a nucleophilic (GGG-X) antigen. HC = heavy 
chain, LC = light chain, CH = constant heavy, Ig = immunoglobulin.
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via sortase-mediated ligation (Fig. 4C). Although these strategies enforce the generation of 
molecularly defined AA conjugates for DC-targeted therapy, they rely on transient expres-
sion of antibody molecules which is difficult to realize with acceptable yields in non-special-
ized academic research laboratories and thereby limiting further development. 
An additional hurdle that must be taken by DC-targeting vaccines is the inclusion of a 
DC maturation stimulus for proper induction of T cell activation via antigen presentation, 
expression of co-stimulatory molecules and secretion of cytokines (signal 1, 2 and 3). Most 
studies using DC-targeted AA conjugates make use of systemic co-administration of DC ad-
juvants such as toll-like receptor ligands (TLRs)30,41 or agonistic anti-CD40 antibodies19,39,42, 
that are needed for DC maturation and proper T cell activation43. As already shown by the 
group of Steinman, the lack of adjuvants will leave DCs tolerogenic, which results in T cell 
unresponsiveness and anergy19,42. Studies with soluble adjuvant-antigen conjugates or an-
tigen and adjuvant encapsulated, untargeted nanoparticles have moreover uncovered that 
it is not only important to deliver antigen and adjuvant to the same DC but also at the same 
time to properly induce antigen cross-presentation and T cell activation44,45. Consequently, 
one study so far has designed a DEC205-targeting AA conjugate that additionally contains 
the TLR9 adjuvant CpG46 (further detailed in chapter 5). These antibody-antigen-adjuvant 
(AAA) conjugates were generated by genetic fusion of DEC205 to OVA and chemical con-
jugation of CpG to reactive thiols of the antibody. Although these AAA conjugates were 
superior T cell activators when compared to AA conjugates in combination with soluble 
CpG, the fact that the vaccine also works in a DEC205 knockout model suggest that the 
antibody binding is compromised. A hypothesis is that random conjugation of CpG to thiols 
obstructs the antibody binding region and thereby altered the delivery and uptake of the 
vaccine46. Once again this underlines the need for more defined DC-targeting vaccines, that 
moreover incorporate a DC maturation stimulus without obstructing the antibody binding 
abilities. 
Scope of the thesis - Next generation DC-targeting vaccines 
On the basis of research of the past two decades one can state that DC-targeting vac-
cines have earned their place among other cancer immunotherapies such as checkpoint 
inhibitors and chimeric antigen receptor T cells. Yet, robust, flexible and simple strategies 
for site-directed engineering of DC-targeting antibodies are lacking and preventing DC-tar-
geting vaccines from showing their full potential in the clinic. Only when techniques exist 
that allow for reproducible, controlled and high-throughput generation of AAA conjugates, 
DC-targeting vaccines can be produced that deliver personalized tumor antigens or conju-
gate libraries and thereby tackle the problem of tumor heterogeneity and further improve 
cancer immunotherapy. To address these unmet needs, research presented in this thesis is 
focusing on novel strategies for the generation of molecularly defined AA and AAA conju-
gate DC-targeting vaccines. 
In Chapter 2 we present an overview of the history of cancer vaccines and summarize 
recent developments in the field, that moves towards more personalized treatments using 
patient -and tumor-specific neoantigens. Along this line, we present an overview of studies 
that make use of neoantigen libraries, so called multiplex neoantigen vaccines, which is an 
upcoming trend observed in the field of cancer vaccines. Connected to this, we introduce 
the concept of intratumoral heterogeneity, which describes the presence of genetically and 
phenotypically distinct tumor clones within different regions of a tumor mass. These clones 
16
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express diverse neoantigens, which justifies the use multiplex neoantigen vaccines to in-
crease the breadth of the anti-tumor immune response. Finally, we present a perspective 
for the future of personalized cancer vaccines.
Chapter 3 introduces a novel toolbox of site-directional modification of DC-targeting an-
tibodies with a genetic platform that enables modification of the immunoglobulin (Ig) locus 
of antibody producing hybridoma cell lines. By using clustered regularly interspaced short 
palindromic repeats (CRISPR)-Cas9-guided insertion of CD4+ and CD8+ OVA epitopes in the 
immunoglobulin locus of hybridoma cells we were able to generate molecularly defined 
DC-targeting AA conjugates with high yields in a one-step genetic modification approach. 
These genetically formed vaccines can induce potent T cell proliferation and activation 
in vitro. We furthermore discuss a rational for the design of AAA conjugates using CRIS-
PR-Cas9 Ig locus engineering to additionally include a DC maturation stimulus and enable 
spatiotemporal delivery of an antigen and adjuvant to a DC. 
The ease of genetically modifying the hybridoma Ig locus and its benefits above classi-
cal conjugation methods, has led us to explore further improvement of the CRISPR-Cas9 
genetic hybridoma platform in Chapter 4. Here, we present an additional genetic modi-
fication of the DEC205 Ig locus by CRISPR-Cas9, that is aimed to improve the efficiency 
and speed with which DC-targeting AA conjugates can be generated in hybridomas. This 
modification adds a new selection mechanism that shortens the selection time of hybrid-
oma clones and is aimed to only select clones that have successfully and correctly integrat-
ed the antigen into the Ig locus. In this chapter we show the generation, characterization 
and functionality of this selection mechanism. Although successful in a proof-of-concept 
study, the selection mechanism is not stringent enough, since hybridoma clones were ob-
tained that were incorrectly modified. We hypothesize that this platform is limited by the 
constrains of the current CRISPR-Cas9 technology and propose several improvements for 
future development.
In Chapter 5 we present the first molecularly defined AAA conjugate that has been de-
scribed so far to the best of our knowledge. By using a combination of sortase-mediated 
ligation and orthogonal click chemistry we generated a DEC205-targeting Fab’ fragment 
that is C-terminally linked to a CD4+ or CD8+ OVA epitope and a TLR7 adjuvant. Next to 
characterization of these vaccines we demonstrate that antibody-to-target binding is 
maintained after site-directed modification. Finally, we test their functionality in in vitro T 
cell activation assays and prove their ability to induce antigen-specific T cell proliferation 
and activation. Results obtained in this proof-of-concept study present a rational to further 
refine this approach.
In Chapter 6 we summarize and discuss the findings that were presented in this thesis 
and put them in perspective to the challenges that lie ahead in the field of DC cancer im-
munotherapy.
17
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Abstract  
Tumor vaccines are an important asset in the field of cancer immunotherapy. Whether 
prophylactic or therapeutic, these vaccines aim to enhance the T cell-mediated anti-tumor 
immune response that is orchestrated by dendritic cells. Although promising preclinical 
and early-stage clinical results have been obtained, large-scale clinical implementation of 
cancer vaccination is stagnating due to poor clinical response. The challenges of clinical 
efficacy of tumor vaccines can be mainly attributed to tumor induced immunosuppression 
and poor immunogenicity of the chosen tumor antigens. Recently, intratumor heteroge-
neity and the relation with tumor-specific neoantigen clonality were put in the equation. 
In this perspective we provide an overview of recent studies showing how personalized 
tumor vaccines containing multiple neoantigens can broaden and enhance the anti-tumor 
immune response. Furthermore, we summarize advances in the understanding of the in-
tratumor mutational landscape containing different tumor cell subclones and the tempo-
ral and spatial diversity of neoantigen presentation and burden, and the relation between 
these factors with respect to tumor immunogenicity.
Together, the presented knowledge calls for the investment in the characterization of 
neoantigens in the context of intratumor heterogeneity to improve clinical efficacy of per-
sonalized tumor vaccines. 
Introduction – a short history of tumor vaccines
The beginnings of immunotherapy date back to the late 19th century. In 1891, the American 
bone surgeon William B. Coley started to treat cancer patients with bacterial injections 
with the rationale to stimulate the immune system and thereby enhance tumor cell killing. 
With varying success ‘Coley’s Toxins’ were accepted as treatment for inoperable bone can-
cers but could never fully be clinically established1. In 1909, Paul Ehrlich established the 
concept of protective vaccinations of mice by transplanting them with foreign tumors. He 
described that in 50-100% of vaccinated mice an acquired tumor-directed immunity could 
be observed2. The genetic basis of this type of rejection was discovered in 1914 by Clarence 
Little3, and later linked to histocompatibility antigens on transplanted tumors by Gorer et 
al.4. In line with these findings, Foley5 and Prehn et al.6 investigated the mechanism of 
protection in mice against carcinogen-induced sarcomas after rechallenge with the same 
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tumor, thereby formulating the rational of using tumor tissue as a vaccine. In the following 
years more pieces of the immunological puzzle were solved finally culminating in the con-
cept of immunological surveillance, formulated by Burnet in 1970, further justifying the use 
of cancer vaccines7. 
Nowadays, it is well established that tumor vaccines can effectively mount an anti-tu-
mor immune response. These vaccines can be comprised of whole tumor lysates, recombi-
nant tumor proteins, tumor antigen derived epitope peptides, or antigen encoding mRNA 
and DNA8. Once injected, dendritic cells (DCs) play a crucial role by taking up the vaccine 
and presenting the vaccine-derived tumor epitope in the context of major histocompatibil-
ity class (MHC) I or II complexes to CD8+ or CD4+ T cells, respectively9,10. In turn, ideally tu-
mor specific CD8+ T cells will be activated, proliferate and infiltrate into the tumor to exert 
cytotoxic functions. CD4+ T cells are skewed towards T helper cell subsets and support the 
anti-tumor immune response by the release of cytokines11,12 or tumor cell killing13. 
Despite promising results obtained in 1995 with a DC vaccine pulsed ex vivo with the 
melanoma tumor antigen 1 (MAGE-1)14,15, it was not until 2010 before the first DC-based 
vaccine Sipuleucel-T was approved by the Food and Drug Administration (FDA). This revital-
ized the tumor vaccine field resulting in the initiation of clinical trials to test new formula-
tions and delivery methods of tumor vaccines across multiple types of cancers.
Especially, recent developments in the understanding of the nature of tumor antigens 
have attributed to the improvement of tumor vaccines. Together with new insights into the 
mutational landscape of tumors and their evolution these findings are instrumental for the 
rise of novel, multiplex and personalized tumor vaccines.
The importance of antigen-specificity for tumor vaccines
Since Edward Tyzzer coined the term ‘somatic mutation’ in 1916 for describing ‘modifica-
tions of the somatic tissue’ that determine foreignness and antigenicity of a transplant-
ed tumor, it took until 1991 to discover the first tumor antigen MAGE-116,17. MAGE-1 was 
shown to be expressed on patient-derived melanoma cells and in immune privileged sites, 
such as testis, hence the name cancer/testis antigen (CTA), and therefore qualified as a 
good target for immunotherapy17. Although CTAs are specific targets on tumor cells and 
therefore classify as candidates for tumor vaccines, their expression is limited to a small 
number of tumors and patients18. In contrast to cancer/testis antigens, tumor-associated 
antigens (TAAs), such as gp100, tyrosinase or EGFR, are overexpressed on tumor cells and 
are shared in a bigger patient population19. Their concurrent expression on healthy cells 
however, will result in a weaker antigen-specific immune response, due to negative selec-
tion as a consequence of central tolerance. Furthermore, DCs and regulatory T cells will 
dampen the immune response by inducing peripheral tolerance and inhibiting effector T 
cells20. Together with the potential of inducing auto-immune reactions, these features un-
derline that TAAs are not ideal candidates for effective tumor vaccination and that therapy 
targets are preferably expressed exclusively on tumor cells. 
In 1994, the first report of such tumor-specific antigen (TSA) was published, being a 
mutated version of the membrane protein Connexin-37 in Lewis lung carcinoma21. In the 
following years the rise of next-generation sequencing techniques led to the discovery of 
more TSAs or so called neoantigens. Neoantigens are seen as highly specific tumor anti-
gens that arise 
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TABLE 1 | Summary of neoantigen vaccine studies ordered by the amount of neoepi-
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TABLE 1 continued | Summary of neoantigen vaccine studies ordered by the amount of 



















































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 1 continued | Summary of neoantigen vaccine studies ordered by the amount of 
neoepitopes that are incorporated in the vaccine.
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due to somatic mutations exclusively in tumor cells while being absent in healthy cells 
(for extensive reviews about neoantigens see 22,23). Except of mutations in driver genes, 
such as isocitrate dehydrogenase 1 (IDH1)24 or KRAS25 and in a rare form of hereditary colon 
cancer, called Lynch syndrome26, neoantigens are not shared between individual patients 
and can have differential expression in tumor clones within one patient, as will be discussed 
later. Moreover, the load of neoantigens has been positively correlated with the presence 
of tumor-infiltrating, neoantigen-specific T cells and a good prognosis for checkpoint in-
hibitor therapy and survival across different types of cancers 27,28. In turn researchers have 
made use of sequencing and peptide-based assays combined with computational filtering 
and prediction algorithms for the selection of candidate neoantigens to design the first 
generation of personalized tumor vaccines29,30. An example of such, is a point mutation 
in the gene encoding IDH1, which is shared by about 70% of diffuse grade II and III glioma 
patients, as mentioned above. Using the mutant IDH1 as synthetic long peptide vaccine, 
Schumacher et al. observed reduced tumor growth in vaccinated mice carrying tumors 
with the IDH1 point mutation compared to mice carrying IDH1 WT tumors (Table 1)24. 
From single to multiplex personalized neoantigen vaccines
The IDH1 synthetic long peptide is an example of a rationally designed neoantigen vac-
cine based on a tumor-specific point mutation shared by a large patient population with 
a mildly immunogenic tumor. For more immunogenic tumors with higher mutational load 
such as melanoma, high throughput genome screens are needed. One of the first studies 
applying this strategy used massive parallel sequencing of mouse tumor and healthy tis-
sue combined with RNA expression profiling and immunogenicity tests to obtain potential 
neoantigen sequences for vaccination purposes. Eventually, vaccinations were performed 
with two to five neoantigens in the form of synthetic long peptides or mRNA. These led to 
significant delay of tumor growth and protection of mice in a prophylactic29 or therapeu-
tic setting29,30. Predicted mutations for the B16F10 melanoma, CT-26 colon cancer or 4T1 
mammary carcinoma models by Castle and Kreiter et al. were subsequently used and ex-
tended to generate neoantigen vaccines targeting more than one epitope simultaneously, 
and delivered as synthetic long peptide31, mRNA32, by carrier molecules such as nanopar-
ticles33–36, nanodiscs37,38 or other modalities39–42(Table 1). In addition to this, in pre-clinical 
mouse studies, the concurrent use of checkpoint inhibitors programmed cell death-1 (PD-1) 
or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) at the time of vaccination worked 
synergistically and enhanced the treatment outcome34–36,38. 
In clinical studies of late stage melanoma patients,  multiplex personalized neoantigen 
vaccines have achieved significant results in clinical studies of late stage melanoma pa-
tients, as nicely summarized by Hellmann and Snyder 43. Recently, a similar approach has 
been presented for phase Ib glioblastoma patients. These patients received personalized 
neoantigen vaccines, covering 20 neoepitopes in the form of long peptides, based on mu-
tational profiling and RNA expression analysis of surgically resected tumors. Although all 
patients died due to progressive disease, neoantigen-specific CD8+ and CD4+ T cells could 
be observed which were able to infiltrate into the tumor44. Finally, also DNA has been used 
as a delivery vector for encoding neoantigen vaccines. Duperret et al. used a combina-
tion of intramuscular injection and electroporation of plasmids with strings of up to twelve 
9-mer neoepitopes, derived from lung carcinoma or ovarian cancer. Neoantigen-specific 
immune response were predominantly guided by CD8+ T cells and resulted in a delay of tu-
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mor growth and increased survival in prophylactically or therapeutically vaccinated mice45. 
Concurrently, a general trend that can be observed in recent studies is an increase in 
neoepitope incorporation into tumor vaccines (Table 1). This is mainly the result of the 
increasing improvements of next-generation sequencing and computational tools for pre-
diction of neoantigens, providing a more detailed view on the mutational landscape of tu-
mors.
Argumentation supporting multiplex neoantigen vaccines can be found in a more fun-
damental aspect of tumor evolution which has been elucidated, especially within the last 
10 years. It relates to the understanding of the identity of individual tumor cells within spe-
cific regions in the tumor mass. Although it is well-known that tumors are heterogeneous, 
comprised of different cell types, such as immune cells and stromal cells, more knowledge 
had to be gained at the single cell- and genotypic- level of malignant cells. As such, it was 
elucidated that a certain degree of tumor cell evolution takes place within one tumor lead-
ing to the formation of subclones separated not only spatially, but also by mutational pat-
terns46–50. The latest key findings on the deciphering of intratumor heterogeneity (ITH), its 
relation to neoantigen expression and its effect on the immune system and immunother-
apy present an essential milestone towards the next generation of multiplex personalized 
neoantigen vaccines and offer an outlook on the challenges we face in the future.
Intratumor heterogeneity challenging multiplex personalized neoantigen vaccines
The concept of ITH was first introduced in the 1970’s by Prehn et al. who investigated the 
immunogenicity of methylcholanthrene-induced murine sarcomas. Paired cancer cell sub-
clones from different regions of a primary tumor showed differential induction of immune 
responses after transplantation into recipient mice. These differences were thought to be 
caused by distinct antigenicity and immunogenicity of subclones, hence a heterogeneous 
distribution within one tumor51. In the following years other groups extended this knowl-
edge by delineating the types of immune responses towards heterogeneous tumors based 
on subclonal expression of tumor antigens52. 
The first human study to investigate the extent of ITH within one tumor mass was per-
formed in 2012 by Gerlinger et al46. In this study, several biopsies from a patient-derived 
primary renal-cell carcinoma were analyzed by whole-exome sequencing and aligned to 
healthy tissue. Next to several shared mutations between different subclones, ca. 23% of 
the mutations were only found in specific regions of the tumor. Strikingly, a single biopsy 
of that same tumor only covered around 55% of the total mutational diversity, underlining 
the need for multi-region sampling. Tracing the order of mutations in different subclones 
revealed that they develop in a branching fashion from the primary tumor clone, harboring 
the driver mutation, rather than in a linear model. Remarkably, these differentially branched 
subclones harbored different mutations in the same gene which suggests a mode of con-
vergent evolution46. These findings emphasize the importance of multi-region sampling of 
tumor samples, as it can explain the mutational ancestry of a tumor and thereby aid in the 
selection of neoantigens for tumor vaccination, which ideally target mutations from the 
trunk of the phylogenetic tree. 
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Figure 1 | (A) The impact of low and high intratumor heterogeneity (ITH) on clonal ancestry, neoantigen clonality 
and T cell responses. Tumors that show low ITH (left panel) typically have few branching mutations as indicated in 
the clonal ancestry panel. In turn, more cells in the tumor harbor the same mutation, which is potentially translated 
and presented on the cell as a neoantigen. The overall neoantigen clonality (the number of cells that express 
one specific neoantigen, indicated by black-gray triangle) is therefore higher, leading to a lower neoantigen ITH 
and subsequently in a better neoantigen-specific T cell response. Tumors that have a high ITH in contrast (right 
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subclones with specific neoantigens however decreased the neoantigen clonality and increases neoantigen ITH. 
This will result in a weaker neoantigen-specific T cell response. (B) Workflow for the designing of next generation 
multiplex neoantigen vaccines addressing ITH (1-6). (1) Ideally, the generation of multiplex neoantigen vaccines 
starts with multi-region tumor sampling by preferentially, non-invasive techniques. (2) Acquired data will then be 
analyzed by whole-genome/-exome sequencing for detection of mutations and RNA expression analysis to infer 
whether these mutations are located within transcribed regions. (3-4) From this the subclonal ancestry can be 
inferred to determine the overall neoantigen clonality and ITH. (5) By mapping found neoantigens to subclones in 
the tumor and the ancestral tree, target neoantigen can be chosen that are located in the trunk and/or branching 
regions. (6) Finally, state-off the art prediction algorithms can supplement the aforementioned workflow to cross-
validate found neoantigen vaccine candidates that will be incorporated in the final vaccine or vaccine carrier. 
Panels I-III depict the in vivo processing of multiplex neoantigen vaccines leading to a multi-angled anti-tumor T 
cell response. (I) After injection of multiplex neoantigen vaccines dendritic cells (DCs) will take up and process the 
vaccine and present antigenic epitopes on the cell surface complexed with MHC molecules. (II) Subsequently, T 
cells will interact with DCs via T cell receptor-MHC interaction and co-stimulatory molecules and will be further 
activated under the influence of cytokines. (III) Effector T cells will finally perform cytotoxic effector functions 
targeting several subclones in the heterogenous tumor.
Besides being able to reconstruct the mutational history, it is also important to correlate 
this to the developmental stage of the tumor as shown by De Bruin et al47. In patients 
with non-small cell lung cancer (NSCLC) mutational events in the primary tumor coupled 
to known driver genes could be identified in the context of tobacco-induced carcinogen-
esis, bearing typical C>T transitions in early development. Mutations in driver genes were 
also observed in subclones of later development, however these clones also acquired other 
somatic mutations indicative of a branched evolution and supporting the idea of ITH in 
NSCLC. Knowing that these tumors carry driver mutations in late stage development, in 
different regions of the tumor, emphasizes the benefit of multi-dimensional sampling and 
sequencing for developing tumor vaccines that target these driver mutations47. Important-
ly, in this study less than 5% of the tumor tissue could be analyzed, which probably under-
estimates the extend of observed ITH. 
As growing evidence suggests that diverse sets of mutations occur in subclones in dis-
tinct regions of one tumor, McGranahan et al. asked to what extent these mutations trans-
late into neoantigens and how neoantigen ITH (NITH) relates to the anti-tumor immune 
response48. Analysis of neoantigen burden and NITH in single biopsies from roughly 200 
cases of different types of lung cancers was performed. Using whole-genome and -exome 
sequencing and bioinformatic processing revealed that a high clonal neoantigen burden 
(upper quartile of total neoantigen burden) combined with a low NITH (smaller than 1%) 
correlates with a longer survival in lung adenocarcinoma patients. In contrast, a lower 
neoantigen clonality (higher NITH) characterized the tumor as more heterogeneous which 
correlates with a shorter survival (Fig. 1A). More homogeneous tumors showed genetic 
signatures of an inflamed or hot tumor microenvironment with upregulated genes for anti-
gen presentation, T cell migration and effector functions next to inhibitory molecules such 
as programmed death receptor ligand 1 (PD-L1). As a consequence to this environment, 
active interferon ", granzyme B, H and A producing, PD-L1 and lymphocyte activation gene 
3 (LAG-3) expressing CD8+ T cells specific to clonal neoantigens could be identified within 
the tumors by MHC multimer staining and flowcytometric analysis. Whether earlier in the 
development of the tumor it was more heterogeneous, homogenized by initial neoanti-
gen specific T cell infiltration, leading to attraction of more immune cells and an inflamed 
tumor microenvironment, is however difficult to investigate due to the lack of samples 
from these earlier developmental stages of the tumor. The observation that these tumors 
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harbored an inflamed, PD-1/L1 expressing microenvironment was the rationale to inhibit 
PD-1 by checkpoint immunotherapy, which resulted in a clinical benefit for patients with 
these inflamed tumors. In the same study, similar results have been obtained in a melano-
ma patient cohort treated with PD-1 checkpoint immunotherapy, where patients with high 
clonal neoantigen burden and low NITH showed prolonged survival48. Another example 
supporting combination of multiplex neoantigen vaccines and checkpoint immunotherapy 
is provided by two clinical studies of Ott et al.31 and Sahin et al.32. In these studies, stage 
III-IV melanoma patients are initially treated with RNA -or long peptide-based multiplex 
neoantigen vaccines (Table 1). While most of the patients experienced progression free sur-
vival as consequence of neoantigen specific T cell infiltration into the tumor, some showed 
recurrent disease during multiplex neoantigen vaccination. In these cases, combinatorial 
treatment with PD-1 blocking antibodies was able to remove tumor mediated immunosup-
pression and unleash neoantigen-specific T cells that were generated by the vaccine31,32. 
The discovery that checkpoint immunotherapy results in prolonged survival once neoan-
tigen-specific cytotoxic T cells have infiltrated these tumors, presents a rationale to com-
bine multiplex neoantigen vaccination with checkpoint immunotherapy for tumors with 
low NITH. Based on the aforementioned clinical examples a sequential treatment with first 
multiplex neoantigen vaccines and then, if needed, checkpoint therapy can be suggested 
to reduce the amount of patients that are unnecessarily treated with checkpoint inhibitors.
As already briefly touched upon above, to what extent neoantigen-specific immune re-
sponses shape the heterogeneity of a tumor throughout tumorigenesis by targeting domi-
nant subclones and whether this can lead to tumor escape of untargeted clones remains to 
be determined. By applying multi-color barcoding of male Eµ-myc lymphoma cells, Milo et 
al. studied tumorigenesis and subclonal distribution in a metastatic mouse model49. When 
injected in male recipient mice, the differentially colored tumor cells seeded in different 
proximal niches, ultimately resulting in equally heterogeneous tumors, demonstrating 
equal survival and outgrowth of the injected barcoded tumor cells. When these cells were 
injected in female recipient mice, homogeneous tumors with one or two dominant colors 
established in a CD8+ T cell dependent manner. Part of the explanation for this observation 
can be found in the expression of Y-chromosome derived H-Y antigens, which induced an 
antigen-specific T cell-mediated immune response. However, the injected mix of color cod-
ed tumor cells contained up to 25% non-immunogenic cells due to a loss of the Y-chromo-
some, suggesting additional clonal reduction as a result of epitope spreading, ultimately 
resulting in homogeneous Y chromosome deficient tumors. Additionally, whole genome 
exome-sequencing was applied in this system to infer whether the neoantigen repertoire is 
narrowed as a consequence of the anti-tumor immune response. In line with the reduction 
in color-coded subclones in female recipients also NITH was reduced, underlining that the 
immune system actively shapes subclone diversity and NITH during immunosurveillance, 
resulting in the evolution of one or few escaping subclones49. In a first attempt to study 
the contribution of neoantigen immunogenicity in the emergence of dominant tumor cell 
subclones Gejman et al. developed an artificial antigen-presentation system allowing the 
construction of heterogeneous tumors, expressing up to five thousand defined artificial 
MHCI neoepitopes50. Looking at the clearance of immunogenic subclones within a largely 
heterogeneous tumor in mice, it was revealed that the immune system was incapable of 
eliminating small clonal fractions of immunogenic subclones. It appeared that the percent-
age of neoepitope subclonal tumor cell representation is an important determinant for its 
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clearance. This critical subclonal percentage seemed to differ between individual neoepi-
topes53. The exact mechanisms behind the persistence of tumor cell subclones, although 
partly assigned to absence of antigenicity or clonality, remains to be elucidated in more 
detail. These two studies emphasize the need for controlled systems to investigate the dy-
namic process of immunosurveillance in the context of heterogeneous tumors with known 
mutations or neoepitopes to determine how the immune system can be used to reduce 
subclone diversity and ultimately enable the total clearance of the tumor. 
Conclusion 
The discovery of neoantigens and their use as tumor vaccines generated a lot of momen-
tum in the tumor vaccination field. Personalized neoantigen vaccines hold promise in gen-
erating specific anti-tumor immune responses and durable survival benefits as emphasized 
by several pre-clinical and clinical studies. Especially in the last two years, vaccines com-
prising of not one, but several neoepitopes, so called multiplex neoantigen vaccines, have 
been developed in order to successfully increase the breadth of the anti-tumor immune 
response. 
A rationale that supports this development is obtained from recent insights into the 
dynamic evolution of tumors. This evolution is characterized by the time-dependent acqui-
sition of region-specific mutations and leads to the emergence of genetically distinct tumor 
cell subclones within one tumor, as shown by multi-region sampling and massive parallel 
sequencing. These subclone-specific mutations define the neoantigen clonality, burden 
and therefore the total NITH, which in turn affects the potency of immunosurveillance. 
Tumors with a high neoantigen clonality and a low NITH show a better tumor clearance. 
More heterogeneous tumors with lower neoantigen clonality are more difficult to eradicate 
(Fig. 1A). Depending on this balance between neoantigen clonality and NITH, T cells are 
able to reduce the diversity of subclones within a tumor and thereby actively shape the ITH. 
Two important factors which influence the efficacy with which T cells can clear a specific 
subclone within a heterogeneous tumor seem to be the antigen itself and the percentage of 
tumor cells expressing this antigen. The exact underlying mechanism has still to be uncov-
ered and can possibly aid us in choosing the right antigens for preventing the emergence 
of dominant subclones. In the meanwhile, targeting more neoantigens by multiplex neoan-
tigen vaccines is a feasible approach to induce a specific immune response against several 
subclones in the tumor and thereby address ITH. 
Future perspectives
Although current studies with multiplex neoantigen vaccines (Table 1) seem to tackle ITH 
by including more neoepitopes, they are limited by the snapshot of the mutanome ac-
quired by a single biopsy. We believe that the lack of multi-dimensional tumor information 
in these neoantigen vaccine studies impairs the power of inducing a multi-angled immune 
response against all the subclones in a tumor. Challenging pre-clinical longitudinal studies 
of tumorigenesis are needed, taking into account samples from different locations in the 
tumor at different time points, both before and after treatment. These studies would gain 
insight in the dynamics of tumor evolution in the context of multiplex neoantigen vacci-
nation. Ultimately, this knowledge could be integrated into the process of designing the 
next generation of multiplex neoantigen vaccines. Currently, driving neoepitope selection 
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criteria are predicted MHCI binding as well as T cell receptor affinities. We propose a work-
flow (Fig. 1B) starting with the multi-regional NITH acquisition of available biopsies, to ob-
tain multi-dimensional tumor biopsy information, from which dominant clonal neoepitope 
vaccine candidates could potentially be extrapolated. Attractive, less invasive and prac-
tically more feasible alternatives, such as circulating tumor DNA or tumor exosome DNA 
sequencing, deserve special attention. Varying reports exist about the success of these two 
techniques in comprehending ITH, which underlines the need for further development of 
these tools54–56. Next-generation sequencing and bioinformatic tools that have been devel-
oped in the recent years46,57–61 will then be an essential asset to acquire genomic sequence 
information of high, subclonal resolution. With this information the clonal architecture and 
mutational ancestry of subclones can be reconstructed. Subsequently, neoantigen clonal-
ity and burden can be inferred to predict total NITH and map neoantigens to the subclone 
architecture of the tumor. This dynamic genomic blueprint of the tumor will aid in deter-
mining optimal neoantigen candidates for vaccination purposes and can be complemented 
with bioinformatic prediction algorithms and novel tools to assay T cell reactivity on a large 
scale62. Current vaccine production platforms as described earlier, can then facilitate the 
efficient formulation and delivery of the vaccine to the patient in vivo, where DCs will pro-
cess vaccine content and activate neoantigen specific T cells that will infiltrate and eradi-
cate the tumor (Fig. 1B.1-3).
We are convinced that the development of more refined techniques to sample and pre-
dict the right neoantigens for vaccination can address ITH, and will be essential to fuel the 
progress that is currently made with regard to time efficient formulation, design and de-
livery of multiplex neoantigen vaccines (as extensively reviewed by others 63,64). With these 
techniques in mind, we could create a more detailed map of the neoantigen clonality in 
primary tumors and metastasis to determine shared mutations within these regions as 
shown earlier46. Along this line, combining multiplex neoantigen vaccines with TAA or CTA 
epitopes could  present a handle to increase the chances of epitope spreading and sensitize 
the immune system for a priori low abundant neoantigens. A full comprehension of tumor 
evolution and neoantigen distribution will be the fundament for counteracting the survival 
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Abstract
Dendritic cells (DCs) play an essential part in the anti-tumor immune response by orches-
trating the adaptive immune response. Several pre-clinical and clinical studies have shown 
that an efficient antigen-specific anti-tumor response can be induced by targeting DCs with 
antibody-antigen (AA) conjugates. Yet, there is no streamlined and robust synthetic strate-
gy for the production of AA conjugates, which limits their widespread application. In addi-
tion, the increasing understanding of intratumoral heterogeneity demands to incorporate 
multiple tumor antigens into AA conjugates to increase the breadth and efficacy of the an-
ti-tumor immune response against complex tumors. Taken together, this emphasizes the 
need for a novel engineering strategy that enables the formation of (libraries of) patient- 
and tumor-specific DC-targeted AA vaccines. In this study, we present a CRISPR-Cas9 ho-
mology-directed repair (CRISPR/HDR) based hybridoma platform to generate molecularly 
defined DC-targeted AA conjugate vaccines. As proof of concept, we insert ovalbumin CD4+ 
or CD8+ T cell epitopes (OTIIp and OTIp, respectively) into the hinge region of the immuno-
globulin (Ig) locus of the anti-DEC205-producing hybridoma NLDC-145. Genome modified 
hybridomas hereafter express DEC205-targeting Fab’ fragments C-terminally fused to OTIp 
and OTIIp, that can be efficiently produced and purified from the supernatant with high 
yields. When taken up, processed and presented by DCs in vitro, these conjugates potently 
induce proliferation and activation of IFN" and IL-2 secreting OTI and OTII specific T cells. 
This study for the first time proves feasibility of CRISPR/HDR Ig engineering of hybridomas 
for the generation of DC-targeting vaccines. Currently, we are capitalizing on this technol-
ogy inserting libraries of neoepitope containing HDR templates to generate DC-targeted 
multiplex neoantigen vaccines. We believe that this strategy can address currently unmet 
needs in the field of DC-targeted vaccines by providing a production platform that allows 
site-specific conjugation, is easily adaptable to the type and amount of antigen and DC 
target, and has a high production yield. We think that this approach can give rise to the 
next generation of DC-targeted vaccines and has the potential to advance personalized 
anti-cancer immunotherapies.
Introduction
Immunotherapy has emerged as a promising asset in the treatment of cancer. Unlike sur-
gery and radiation- or chemotherapy, immunotherapy aims to enforce the patient’s own 
immune system to recognize and eradicate tumor cells. One important player for the suc-
cess of immunotherapy is the dendritic cell (DC), which is the main orchestrator of an im-
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mune response. The DC is a professional antigen-presenting cell, capable of taking up, 
processing and presenting tumor-derived antigens to T cells. Peptide epitopes are gener-
ated and loaded onto major histocompatibility complex (MHC) I or II to be scanned by the 
T cell receptors (TCRs) of CD8+ or CD4+ T cells, respectively1,2 (Chapter 1). The fact that DCs 
can activate both CD4+ and CD8+ T cells specific for exogenous antigens through a pro-
cess called cross-presentation, underlines their central role in steering the adaptive arm of 
the immune response. Upon sufficient contact of complementary TCRs with peptide-MHC 
complexes, naïve CD4+ and CD8+ T cells are activated, and become helper or cytotoxic T 
cell, respectively. This differentiation is fine-tuned and boosted by the DC the expression of 
co-stimulatory surface molecules and via secretion of cytokines that determine the fate of 
T helper cells and induce proliferation of cytotoxic T cells. Additionally, this proliferation is 
aided by T helper cells through the secretion of pro-inflammatory cytokines3,4. Following 
activation and proliferation, in an ideal situation, cytotoxic T cells migrate to the tumor 
where they recognize peptide-MHC complexes on target cells, which subsequently leads to 
activation of mechanisms aimed to destroy the antigen containing target cell. Next to this, 
T helper cells are known to exert direct cytolysis and have been shown to be an essential 
variable for the success of immunotherapy5. Within this synergistic network of cytotoxic 
and helper T cells, the DC has a pivotal role in inducing the anti-tumor immune response 
and is therefore an ideal therapeutic target.
To kickstart this response in a cancer therapeutic setting, tumor antigens have to be pro-
vided to the patient’s DCs. This requirement led to the development of DC vaccines, where 
naturally occurring DCs are isolated from the patient’s blood and loaded with tumor anti-
gens ex vivo. After maturation of antigen-loaded DCs by adjuvants, the cells are adoptively 
transferred into the patient to elicit an anti-tumor T cell response. While several studies 
have shown that adoptively transferred DC vaccines are immunogenic and safe6,7, wide-
spread use is hampered by the low frequency of naturally circulating DCs, poor migratory 
capacity to lymph nodes after injection, labor extensive procedures and high costs8–10. The 
latter two issues can be attributed to the fact that each vaccine has to specifically tailored 
to the patient. The discovery of monocyte-derived DCs has partly addressed the scarcity of 
blood DCs11, but failed to further advance clinical application since they do not fully resem-
ble their physiological counterparts12.
Increasing efforts to omit the withdrawal of DCs from the patient have therefore focused 
on the delivery of the vaccine cargo to DCs in vivo. This can be achieved via the adminis-
tration of encapsulated antigens and adjuvants, either in nanoparticles13, liposomes14 or as 
soluble components in the form of mRNAs5 or synthetic long peptides15. In this manner the 
vaccines are systemically injected into the patient where they are predominantly taken up 
by macrophages and eventually DCs16. Antibody-based DC-targeting approaches form an 
elegant alternative to selectively deliver vaccine cargo to professional antigen presenting 
DCs. This approach makes use of antibodies and their ability to specifically bind DC surface 
molecules with high affinity. Spatial retention of a vaccine payload at the surface of DCs 
in vivo through antibodies has been shown to increase the efficiency of antigen delivery 
and subsequent T cell activation17,18. Primarily, surface molecules such as C-type lectins 
or toll like receptors are targeted to deliver the payload to a subset of DCs. In pre-clinical 
DC-targeting studies the most explored target is the C-type lectin receptor cluster of dif-
ferentiation 205 (CD205 or DEC205), which in mice is mainly expressed on myeloid DCs 
(Chapter 1). Binding to DEC205 by anti-DEC205 antibodies results in receptor-mediated 
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endocytosis, endosomal degradation of the cargo and presentation of antigen epitopes 
in the context of MHCII19. Targeting of antigen to DEC205 has also been shown to induce 
cross-presentation of antigen-derived epitopes in the context of MHCI, making it an ideal 
target to activate both, CD4+ and CD8+ T cells (as extensively reviewed20,21).
To facilitate antigen delivery to DEC205 specifically, antigens have to be conjugat-
ed to DEC205 antibodies. Researchers have utilized various approaches, ranging from 
n-hydroxysuccinimide (NHS) or thiol chemistry with limited positional and stoichiometric 
control22, to more site-specific techniques like recombinant fusion expression systems23 
or chemo-enzymatic ligations such as sortagging24. While aforementioned random cou-
pling strategies certainly require less synthesis or modification of peptides, the resulting 
conjugates display varying antibody to antigen ratios and can be affected in their bind-
ing affinity through modification or sterical hindrance of the binding regions of the anti-
body (as extensively shown and reviewed for antibody-drug conjugates25). Recombinant or 
chemo-enzymatic systems address this by allowing for site-directed coupling of antigens, 
while maintaining antibody affinity. Although elegant, chemo-enzymatic systems require 
the addition of excess reagents and enzymes and the subsequent purification is often low 
yielding or can result in loss of product. Recombinant systems moreover require knowledge 
about the sequence of the antibody variable heavy and light chain coding region, which is 
often unavailable, to construct expression plasmids and have to be optimized extensively 
to produce acceptable yields.
To address these issues and extend the toolbox for site-directional coupling of antigens 
to antibodies we developed a CRISPR/HDR platform to genetically fuse antigen epitopes 
to a DC-targeting antibody. As proof of concept we aimed to genetically engineer the an-
ti-DEC205 antibody-producing hybridoma NLDC-145, to secrete monovalent antibody Fab’ 
fragments conjugated to the ovalbumin (OVA) protein derived epitopes recognized by CD4+ 
OTII T cells and CD8+ OTI T cells (OTIIp and OTIp, respectively). Targeting DCs with Fab’ 
fragments is thought to improve tissue penetration and prevents potential non-specific 
uptake via FC receptors which increases the specificity of targeting26,27. We hypothesize 
that CRISPR/HDR-edited hybridoma cell lines produce molecularly-defined antibody-anti-
gen conjugates that can be easily purified with high yields from cell culture supernatant. 
Furthermore, we expect that these vaccines maintain binding to DEC205 due to site-spe-
cific conjugation at the C-terminus and that they efficiently deliver antigen epitopes to DCs 
leading to T cell activation and proliferation. 
We believe that adopting a flexible CRISPR/HDR platform for the creation of DC-target-
ing AA conjugates can pave the way for the development of personalized multiplex vaccines 
that include multiple (neo-)antigen epitopes. Incorporating a set of epitopes that encom-
pass the mutational landscape of a patient’s tumor will enable us to address intratumoral 
heterogeneity and increase the selective anti-tumor immune pressure.
Results
CRISPR/HDR hybridoma platform design for the generation of DC-targeting AA conjugates
For the generation of mouse DC-targeting AA conjugates we aimed to engineer the rat hy-
bridoma NLDC-145 which produces monoclonal antibodies against murine DEC205 of the 
immunoglobulin (Ig) G2a isotype. The genetic strategy for homologous DNA repair based 
modification of hybridoma cells was described earlier28. In short, we induce a double strand 
break (DSB) in the hinge region of the IgG2a locus by CRISPR-Cas9 (Fig. 1i, ii). This 
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DSB will be repaired using an HDR template with two homology arms of 500 base-pairs 
(bp), homologous to the region around the DSB. The 5’ end of the 3’ homology arm contains 
protospacer adjacent motif (PAM) silencing mutations and a shortened hinge sequence to 
remove two of the three cysteines to prevent inter-heavy chain disulfide bridge formation, 
resulting in the production of monomeric Fab’ fragment. The insert between the two ho-
mology arms consists of (i) a glycine-serine linker (G4S) and a phenylalanine-arginine (FR) 
di-peptide for improved proteasomal processing24, (ii) the sequence of the desired epitope 
with a C terminal hexa-histidine tag (histag) and stop codon, (iii) an internal ribosomal entry 
site (IRES) for multicistronic expression of the gene elements, (iv) a blasticidin-S deaminase 
to confer resistance to blasticidin and (v) a bovine growth hormone polyadenylation (bGH 
poly A) signal sequence to initiate polyadenylation and terminate transcription (Fig. 1iii). 
The latter is necessary to prevent production of the antibody FC tail (constant region 2 and 
3 (CH2 and CH3), Fig.1iii) and to generate Fab’ fragments28. The design of the HDR template 
was furthermore adapted for a scarless cloning strategy, meaning that antigen sequences 
can be inserted easily, without modifying the amino acid sequence of the antibody, via 
BamHI and BsmBI sites that are located in the G4S linker and stop codon, respectively. 
Generation of Fab’ DEC205-OTIp and -OTIIp by CRISPR/HDR
As a proof of concept, we set out to insert the CD4+ and CD8+ epitope of the model antigen 
ovalbumin (OVA) protein, OVA323 - 339 (ISQAVHAAHAEINEAGR - OTIIp) and OVA257-264 synthet-
ic long peptide (SIINFEKLAAAAAK, OTIp) respectively, into the hinge region of NLDC-145 
cells. We used the penta-alanine and lysin C-terminally flanked version of SIINFEKL to favor 
proteasome-dependent processing and increase antigen presentation29–31. NLDC-145 cells 































Figure 1 | CRISPR/HDR approach in hybridomas for the generation of Fab’ fragment-antigen fusions. General 
approach of CRISPR/HDR engineering of the Rat IgG2a NLDC-145 heavy chain locus on chromosome six (i) with 
the sgRNA_Hinge targeting the hinge region upstream of CH2 (ii). After DSB generation the HDR template will 
integrate, thereby inactivating transcription of CH2 and CH3 and enabling the transcription and translation of 
CH1-hinge-antigen mRNA (iii). Correctly modified clones are selected by antibiotic pressure and limiting dilution, 
yielding a monoclonal cell line, producing the desired target molecules (iv). Numbers 1-3 indicate the forward and 
reverse primer locations used in this study. PAM = Protospacer adjacent motif, HC = Heavy chain, HA = Homology 
arm, HDR = Homology directed repair, I = internal ribosomal entry site (IRES), B = Blasticidin-S deaminase, P = 
Poly A signal. 
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quences and the sgRNA_Hinge plasmid, after which blasticidin was added to the culture. 
Blasticidin resistant clones were separated by a limiting dilution to create monoclonal cell 
lines (Fig. 1iv). The supernatants of monoclonal populations were subsequently screened 
for antibody products able to bind DEC205 on a mouse DC cell line (JAWSII) by anti-kappa 
light chain staining and flow cytometric analysis (Suppl. fig. 1A,B). In contrast to earlier 
version of Fab’ fragments produced with this technique but without an antigen sequence28, 
these antibody products were negative for anti-histag stainings on FACS (data not shown). 
High producing clones were further verified by anti-histag/anti-rat western blot (Suppl. Fig. 
1C). For both OTIp and OTIIp single cell clones showing the highest production and expres-
sion of a modified, histag-containing heavy chain and a light chain were chosen as pro-
duction clones (hereafter NLDC-OTIp and NLDC-OTIIp). The fact that histag signals can be 
observed on reducing western blots but not on FACS, where the Fab’ conjugates are in their 
native form, suggests that the antigen could mask the histag. NLDC-OTIp and NLDC-OTIIp 
were then analyzed by genomic PCR and sequencing. An antigen insert-specific genomic 
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Figure 2 | Genomic and protein-based characterization of NLDC-OTI/-OTII and Fab-OTIp/-OTIIp. (A) Genomic 
PCR of NLDC-145 (-), Fab’DEC205-sortag-histag28 (+), NLDC-OTI and -OTII DNA with primers 1,2 and 3. (B) Sanger 
sequencing of NLDC-OTI and -OTII amplicons from PCR 1+3 (Fig. 2A) zoomed in at the (1) 5’ and (2) 3’ junction 
of the HA’s and (3) the insert region. Black and gray letters indicate the insert and unedited region, respectively. 
Gray boxed letters are indicating the 5’ or 3’ terminal sequences of the HA’s that have integrated in the locus by 
HDR. (C) Sanger sequencing of the insert region (Fig. 2B,3) of NLDC-OTI and -OTII DNA form PCR 1+2 (Fig. 2B) 
with the corresponding amino acids. (D) Western blot of histag-purified Fab’DEC205-sortag-histag28(+), Fab’-OTIp 
and -OTIIp, stained for histag (green) and rat IgG2a (blue). Protein G isolated NLDC-145 antibodies were used as 
negative control (-) while Fab’DEC205-sortag-histag28 was used as positive control (+). (E) MALDI mass analysis 
of NLDC-145, Fab’-OTIp and -OTIIp antibodies with a magnified picture (F) showing the difference in mass of the 
Fab’-OTIp and -OTIIp heavy chain. M = Marker.
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(Fig. 2A, primers 1 and 2). A genomic PCR with primers outside of the HDR region shows, as 
expected, an increased amplicon size compared to DNA extracted from unedited NLDC-145 
cells, which corresponds with the HDR template insert size (Fig. 2A, primers 1 and 3). Se-
quencing of amplicons from this PCR shows successful integration of OTIp/OTIIp sequenc-
es and modification of the hinge region (Fig. 2B, 1 and 2), as well as correct breakpoints 
at the 5’ and 3’ overhangs of the homology arms (Fig. 2C, 3). After selection and genomic 
confirmation, NLDC-OTIp and -OTIIp were seeded in Celline Bioreactors for five consecutive 
production cycles of one-week time, each yielding ± 2 mg of final product after isolation 
with NiNTA-bead gravity columns and purification by size excluding spin centrifugation 
(Suppl. Fig. 1D). Anti-histag and -rat Ig western blots furthermore underline the structur-
al integrity and presence of the histag on the heavy chain of the purified Fab’ fragments 
from NLDC-OTIp and -OTIIp (hereafter Fab’OTIp and Fab’OTIIp)(Fig. 2D). Comparison of the 
molecular weights of Fab’OTIp and Fab’OTIIp using mass analysis by matrix-assisted!laser 
desorption/ionization (MALDI) furthermore indicates a heavy chain mass difference of ap-
proximately 306 ± 75 Da, which aligns with the predicated mass differences (327 Da) (Fig. 
1E). These results collectively show that CRISPR/HDR can be used to insert OVA antigen 
epitopes to the hinge region in the immunoglobulin locus of the NLDC-145 hybridoma, 
yielding a cell line which produces molecularly-defined Fab’ fragment-antigen conjugates 
that can be easily purified from cell culture supernatant. 
T cell proliferation and activation induced by Fab’OTIp and Fab’OTIIp exposed DCs
Next, we set out to test the functionality of Fab’OTIp and -OTIIp conjugates. For this we 
investigated the proliferation and activation of antigen-specific OTI and OTII T cells after 
co-culture with Fab’OTIp and -OTIIp conjugate treated DCs. To this end, we first generated 
murine bone marrow derived DCs (BMDCs) in a co-culture system with OP9-DL1 cells and 
FMS-related tyrosine kinase 3 ligand (Flt3L) to obtain DEC205+CD8+ DCs32. BMDCs were 
subsequently incubated with different concentrations of Fab‘OTIp and -OTIIp (1, 0.2, 0.04 
µM), OVA (1 (23 µM), 0.2 (4.6 µM), 0.04 (0.23 µM) mg/ml), OTIp (5 nM) or OTIIp (5µM) pep-
tides or were left untreated and subsequently cultured with cell-trace violet (CTV) labelled 
OTI or OTII cells for three days. 
To analyze T cell proliferation, we measured the fluorescence intensity of CTV in T cells 
after three days of co-culture. Since in every division cycle CTV intensity is halved, CTV 
histograms can be used to infer the division cycles and calculate a division index. FACS 
analysis of T cells, shown here for the highest concentration only (complete dataset can 
be found in suppl. Fig. 2), indicated that BMDCs exposed to Fab‘OTIp and -OTIIp could 
induce proliferation of OTI and OTII T cells, which is also reflected in the division index 
(Fig. 3A,C). Soluble OVA-treated BMDCs showed minor induction of proliferative capacity 
for OTI cells, while OTII cells were potently induced (Fig. 3A,C). Furthermore, FACS analysis 
of T cell surface markers CD25, CD44, CD69 and CD137 was conducted to determine the 
activation status after co-culture with Fab’OTIp and -OTIIp-treated BMDCs. In both cases, 
Fab’ conjugate-treated BMDCs induce the expression of all activation markers in similar 
levels as induced by peptide-loaded BMDCs (Fig. 3B,D). Only CD69 expression on OTI T 
cells was significantly higher than in OTI T cells from OTIp-treated BMDCs (Fig. 3B). Finally, 
we analyzed the level of the secreted cytokines interferon " (IFN") and interleukin-2 (IL-2) 
of T cells to further underline their activation and functionality. Fab’OTIp induced antigen 
presentation by BMDCs resulted in high secretion of both IFN" and IL-2 by OTI T cells, in line 
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with the proliferation data and the expression of activation markers (Fig. 3E). OTII T cells 
also robustly secreted IFN" and IL-2 in response to BMDCs exposed to Fab’OTIIp, overlap-
ping with the pattern seen for proliferation and activation markers (Fig. 3F). 
These results underline that Fab’OTIp and -OTIIp conjugates are taken up by BMDCs and 
induce antigen (cross-)presentation of the OVA-derived epitopes. These BMDCs are subse-
















































































































































































































Figure 3. Functional characterization of Fab’OTIp and -OTIIp with respect to their in vitro T cell activation 
capacity. (A) Proliferation analysis of Fab’OTIp-treated BMDC-OTI T cell co-culture showing FACS proliferation 
plots and the derived division index. (B) Marker expression of OTI T cell surface molecules CD25, CD44, CD69 
and CD137 after co-culture with Fab’-OTIp-treated BMDCs. (C) Proliferation analysis of Fab’-OTIIp-treated BMDC-
OTII T cell co-culture showing FACS proliferation plots and the derived division index. (D) Marker expression of 
OTII T cell surface molecules CD25, CD44, CD69 and CD137 after co-culture with Fab’-OTIIp-treated BMDCs. For 
FACS expression analysis, geometric means of three independent experiments including two technical replicates 
were normalized to the average geometric mean of peptide (OVA257-264 or OVA323-339) treated groups to account for 
donor variability. (E) and (F) depict IFN" and IL-2 cytokine expression by OTI T cells and OTII T cells, respectively, 
after incubation with treated DCs. The measured amount of cytokines in pg/ml was normalized and expressed as 
fold change to the average of OVA257-264 or OVA323-339 treated control groups, for Fab’-OTIp and -OTIIp respectively, 
to correct for donor dependent effects. Color coding indicated in A and C is also valid for B and D. Statistical 
significance was determined by one-way ANOVA tests with Tukeys correction, alpha = 0.05, ns: P>0.05, *P#0.05, 
**P#0.01, ***P#0.001, ****P#0.0001., n = 3.
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OTI and OTII cells are activated, as reflected by the expression of activation markers CD25, 
CD44, CD69 and CD137 and functional as shown by the secretion of pro-inflammatory cy-
tokines IFN" and IL-2. Taken together, these results prove functionality of AA conjugates in 
an in vitro setting and justify to further investigate their function in vivo. 
Discussion and conclusion
In this study we set out to develop a CRISPR/HDR hybridoma platform to generate AA con-
jugates that can be used for DC-targeted immunotherapy. We show for the first time that 
CRISPR/HDR can be harnessed to genetically introduce CD4+ and CD8+ epitopes into the 
NLDC-145 hybridoma Ig locus thereby generating DEC205 Fab’ fragment-antigen conju-
gates. In line with our hypothesis, these AA conjugates are molecularly defined, with a 
C-terminal antigen and histag, and can be easily purified from the cell culture supernatant 
by gravity column chromatography with high yields. Moreover, in vitro T cell assays show 
that purified AA conjugates are processed and presented by BMDCs. In turn, these BMDCs 
are capable to induce activation and proliferation of CD4+ and CD8+ T cells, underlined by 
expression of canonical surface activation markers and secretion of IL-2 and IFN". These 
results collectively support that this CRISPR/HDR platform is suited to generate functional 
and molecularly defined DC-targeting AA conjugates.
With this study, we contribute to a growing field of CRISPR/HDR guided genome en-
gineering of the Ig locus that has only recently been added to the assets of immunoengi-
neering. In 2015 the first report of Ig engineering was described for hybridomas by Cheong 
et al., exploring the use of CRISPR-Cas9 for the introduction of DSB in Ig genes, thereby 
fostering class switch recombination and the production of different isotypes and Fab’ 
fragments33. This technology has been advanced with CRISPR/HDR for the purpose of ex-
changing antibody variable heavy chain regions with single-chain antibody fragments for 
altered target specificity34, the introduction of a sortag and FLAG tag at the C-terminus of a 
murine anti-ICAM monoclonal antibody35, or the generation of chimeric B cell receptors36. 
Recently, we also have described a CRISPR/HDR approach in hybridomas for the insertion 
a C-terminal sortag and histag and the switch from rat to any other desired murine iso-
types28. While the use of CRISPR/HDR in Ig genes is not novel in itself, to our knowledge, 
the current study is the first of its kind that demonstrates the generation of DC-targeting 
antibody-antigen conjugates by CRISPR/HDR in hybridomas. We believe that this approach 
is highly valuable for the field of antibody engineering in the context of DC-targeting vac-
cines and the challenges we face with intratumor heterogeneity and patient-specific muta-
tions because of several reasons.
First, this method enables the generation of a stable, vaccine-producing cell line, 
where molecularly defined, uniform vaccines can be harvested easily from the superna-
tant with high yields. Second, this approach can be easily adapted to different hybridomas 
and DC-targeting antibodies. This in turn enables the delivery of antigens to different DC 
subsets, such as myeloid and plasmacytoid DCs, by targeting distinct surface markers21. 
Given that these subsets are equipped with complementary qualities, their crosstalk and 
concerted action is desired and can further boost the anti-tumor immune response. The 
engineering of other hybridomas is possible since CRISPR/HDR is performed in the Ig 
constant regions. Therefore, hybridomas of the same isotype but specific for different DC 
receptors can be modified with the same HDR template and sgRNAs while maintaining 
antibody affinity. Third, the platform is primarily based on basic molecular cloning tech-
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niques, transfections, the selection with antibiotics and limiting dilutions for the genera-
tion of monoclonal producer cell lines. This underlines that it can be adopted in any basic 
research laboratory without the need for expensive equipment in contrast to adoptively 
transferred DC vaccines. Finally, we think that this approach could be adapted to facilitate 
the generation of multiplex DC-targeting antigen vaccines that encompass the mutational 
landscape of a patient’s tumor. Culminating knowledge on the subcellular complexity of 
tumors indicates that they are highly heterogeneous, even within a patient and within one 
tumor mass, and that tumor cells express diverse tumor specific neoantigens in distinct tu-
mor subclones (Chapter 5). These findings ask for a strategy that can deliver multiple neo-
antigens to the patient’s DCs in order to increase the repertoire of tumor antigen specific T 
cells. Several studies have stressed the added value of multiplex neoantigen vaccines5,37–44, 
however none has yet shown specific delivery to DCs, which is known to boost the efficacy 
of such multiplex tumor vaccines even further. In this study we show examples of conjuga-
tion of one antigen to a DC-targeting antibody. In the same way, the conjugation of multiple 
antigen epitopes to one antibody can easily be realized by inserting different neoantigen 
epitopes in a row flanked by flexible and/or cleavable linkers. Alternatively, we can generate 
libraries of antibodies with different neoantigens, comprised of only one neoantigen epi-
tope on every antibody. The fact that antigens are encoded in the DNA makes production of 
a multiplex neoantigen vaccine moreover easily scalable. Currently we are creating such a 
library for neoantigens of the B16F10 mouse melanoma model that have been described by 
Castle45 and Kreiter et al.5, in order to uncover the potential benefits of delivering multiple 
neoantigens to DCs by antibody-mediated targeting. Similarly as discussed in chapter 2, we 
are moreover investigating the possibility to genetically introduce adjuvant proteins or pep-
tides, such as high-mobility group box 146–48 or flagellin49, to the light chain of DC-targeting 
AA conjugates. In this way, we enable the spatiotemporal delivery of a maturation stimulus 
and tumor antigen to the same DC, which is necessary for the induction of a proper T cell 
response50,51. 
All in all, we here describe for the first time, a genetic platform for the generation of 
DC-targeting AA conjugates via CRISPR/HDR in hybridomas. We believe that this platform 
can contribute to the field of DC vaccines, by empowering easy production of molecularly 
defined AA conjugates for multiple targets. By exploiting this system for the generation of 
multiplex neoantigen DC-targeting vaccines, it can advance the field of personalized cancer 
vaccines and support the fight against complex, heterogeneous tumors. 
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The anti-DEC205 secreting NLDC-145 hybridoma cell line (ATCC, HB-290) was purchased 
from ATCC and cultured in RPMI1640 (Thermo Fisher Scientific, 11875093) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, GE Life Science, sv30160.03), 2mM 
ultraglutamine (Lonza, Be17-605E/u1), antibiotic-antimycotic (AA) (Gibco, 2211104, 100x) 
and 50uM 2-mercaptoethanol (Sigma Aldrich, STBH7709), hereafter called hybridoma me-
dium.
The DEC205 expressing cell line JAWSII (ATCC, CRL-11904) was purchased from ATCC 
and cultured in MEMa  (Gibco, 2099595) supplemented with 20% FBS, NEM (Gibco, 
2165257, 100x), AA, Sodium pyruvate (Gibco, 1881816, 100x), sodium bicarbonate (Gibco, 
2078819, 100x), 50 µM 2-mercaptoethanol, 2 mM Ultraglutamine and freshly added gra-
nylocyte-macrophage colony-stimulating factor (GM-CSF, Miltenyi Biotec, 130-095-735) 
(5ng/ml). NLDC-145, its engineered subclones and JAWSII were tested negative for the 
presence of mycoplasma (Lonza, LT07-418).
Mice 
All animal procedures were approved by the Animal Welfare Body of the Animal Research 
Facility (Radboudumc, Nijmegen). For the generation bone-marrow derived DCs, 5-15 
weeks old female WT C57BL/6J mice (Charles River, France) were sacrificed and bone mar-
row cells were isolated from hindlegs as described below. CD4 and CD8 T cells, reactive to 
ovalbumin, were isolated from lymph nodes and spleens from 5-15 weeks old female trans-
genic OTI and OTII mice, respectively (Charles River, France) as described below.
sgRNA and HDR donor template design
The genomic makeup of the rat IgG2a immunoglobulin locus was extracted from the 
Ensemble database (transcript ID: ENSRNOT00000066209). Three potential sgRNAs 
targeting exon 2 (hinge region) were designed by CRISPOR (http://crispor.tefor.net52) 
and ordered as single-stranded DNA (Integrated DNA technologies) with BbsI restriction 
enzyme overhangs to be cloned in the Cas9 plasmid PX330-SpCas9-NG (Addgene plasmid: 
117919). To do so, single-stranded DNA was phosphorylated by T4 PNK (New England 
Biolabs (NEB), M0201L, 10045209) for 30 minutes at 37 °C and annealed by increasing the 
temperature to 95 °C for 5 minutes and subsequently lowering the temperature by 5 °C/
minute to 25°C in a thermocycler. Annealed and phosphorylated oligos were ligated in BbsI 
(NEB) digested, dephosphorylated and gel purified Cas9 plasmids. 
HDR donor templates were designed with 500 bp homology arms (HAs) up- and down-
stream of the sgRNA target site, containing PAM inactivating mutations. The insert be-
tween the two HAs contains a modified hinge sequence with a deletion of two cysteines 
necessary for heavy-heavy chain interaction (GTGCCAAGGGAATGC), a glycine-serine linker 
containing a BamHI restriction site (GGAGGCGGTGGATCC), a stuffer with a terminal BsmBI 
restriction site and a stop codon, and the common genetic elements IRES, Blasticidin S 
deaminase and a bGH poly A signal sequence. This synthetic gene cassette was ordered 
at IDT and inserted into the PCR2.1 TOPO TA vector (Thermo Fisher Scientific, K-450001) 
according to the manufacturers’ protocol. 
Antigen donor plasmids for generation of Fab’ fragment DEC205-OTIp and -OTIIp (here-
after Fab-OTIp and -OTIIp) with a terminal hexa-histidine tag were created by sequential 
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digestion of the HDR donor templates by BamHI and BsmBI (both NEB) and ligation of 
the OTIp (GATCCTTCCGCTCCATCATCAATTTTGAGAAACTCGCTGCCGCTGCTGCTAAGCACCAT
CAC CATCACCAT) and OTIIp (GATCCTTTCGGATAAGCCAAGCAGTTCACGCCGCTCACGCTGAAA-
TAAACGAAGCTGGACGCCACCATCACCATCACCAT) inserts (IDT). All plasmids were purified by 
midiprep, containing endotoxin removal steps (Macherey-Nagel, 740420.50) and validated 
by sanger sequencing (Sequence Facility, Radboudumc). Full sequences of HDR donor tem-
plates used in this study can be found in Supplementary Table 1.
sgRNA-Cas9 cutting efficiency
Cutting efficiency of Cas9 and the three potential sgRNAs was analyzed by TIDE (https://
tide.deskgen.com53) (data not shown). In short, three days after transfection of NLDC-145 
cells with plasmid sgRNA, DNA was isolated as described below and amplified by PCR to 
obtain approximately 700bp amplicons containing the sgRNA target region in the center. 
Purified PCR amplicons were sequenced and compared to the WT sequence by TIDE. This 
indicated the highest efficiency (ca. 15%) for sgRNA_Hinge (CCAAGGGAATGCAATCCTTG), 
which was used in all subsequent transfections.
Generation of Fab’ DEC205-OTIp and OTIIp hybridoma cell lines
Prior to transfection, NLDC-145 cells were cultured as described above, to ensure high via-
bility (>95 %). For all transfections the LONZA nucleofector system was used together with 
the appropriate SF transfection kit (Lonza, V4xc-2024) and Lonza cuvettes. On the day of 
transfection, 1x106 cells per condition were washed with PBS + 0,5 % BSA and resuspend-
ed in SF transfection buffer. 1 µg of antigen donor template containing the OTIp or OTIIp 
sequences and 1 µg of Cas9-sgRNA_Hinge plasmids were added to the cell suspension 
and transferred to the nucleofection cuvette. Nucleofection performed using the program 
QV-104. Subsequently, cells were transferred to a 6-well plate with pre-warmed hybrid-
oma medium and incubated at 37 °C for 3 days. On day 3, cells ware scraped gently and 
re-plated with fresh medium supplemented with 15 µg/mL blasticidin in 10 cm petri dishes. 
Until a viable confluent culture was obtained, blasticidin containing medium was refreshed 
every 4 days. After ca. 10 to 14 days, a limiting dilution was performed to create single cell 
clones (SCCs). At that same time, DNA was isolated (Macherey Nagel, 740952.250) for a 
PCR screening to confirm integration of the donor template in the target locus. Once SCC 
were grown out, after another 14 days, the medium was refreshed and after two days 50 
µl of supernatant was sampled by flow cytometry for the presence of antibodies and the 
rate of production. Highest producing clones, secreting the desired product were chosen 
as final clones and used for large scale production of the target molecules. The genomic 
make-up of the target locus of the two producing clones was furthermore investigated by 
PCR and sequencing.
DNA isolation, genomic PCR and sequencing
For PCR, genomic material from cultured cells was isolated using NucleoSpin columns 
(Macherey Nagel, 740952.250) according to the manufacturer’s protocol. PCR were per-
formed with 100 ng of template DNA, using the high-fidelity Q5 polymerase (NEB, M0491) 
and the recommended concentrations for Q5 enhancer, reaction buffer, dNTPs and forward 
and reverse primers. Insert specific DNA amplification using primers 1 (TGTAGGAGCTTGG-
GTCCAGA) and 2 (ATACATTGACACCAGTGAAGATGC) was performed in a thermocycler with 
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following cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 20 s, 66 °C for 20 
s, 72 °C for 120 s], followed by a final amplification at 72 °C for 5 min. Whole insert region 
DNA amplification using primers 1 and 3 (CTGTGGACCTCGTGGTGTG) was performed in a 
thermocycler with following cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 
20 s, 69 °C for 20 s, 72 °C for 180 s], followed by a final amplification at 72 °C for 5 min. For 
sequencing purposes, PCR amplicons were purified from the reaction mixture by Nucle-
oSpin columns (Macherey-Nagel) and sequenced with 6 pmol of primers as indicted in the 
results section (Sequence Facility, Radboudumc).
SDS-PAGE and western blot
Cell culture supernatants or purified and concentrated antibodies were analyzed by SDS-
PAGE and western blot to verify the size of heavy and light chains and the presence of a 
histag. For SDS-PAGE, samples were resolved under reducing conditions 12 % SDS-PAGE 
and visualized by SYPRO Ruby Protein Gel Stain (Thermo Fisher Scientific, S12000) on the 
Typhon Trio+ gel scanner (GE Healthcare Life Sciences) and analyzed with Fiji54. For western 
blot, SDS-PAGE gels were transferred to a polyvinylidene difluoride membrane and blocked 
with 3 % bovine serum albumin in PBS-Tween20 0.1 %. Blots were subsequently stained 
with monoclonal rabbit anti-his-tag antibody (Abcam, ab213204, dilution: 5000x), goat 
anti-rabbit IgG (H + L) (IRD800) (LI-COR, 926-32211), and goat anti-rIgG (H + L) (AF680) 
(Thermo Fisher Scientific, A-21096). Western blots were imaged on the Odyssey CLx imag-
ing system (LI-COR) and analyzed in ImageStudio lite (v5.2.5).
Production and isolation of antibodies
The selected producing cell lines NLDC-OTIp and -OTIIp were cultured in hybridoma medi-
um in T175 flasks (Greiner Bio one, e19043hy) until confluent. Approximately 20x106 cells 
were transferred into CELLine Bioreactors (Argos, 900-05) and cultured for five weeks. 
Every week the supernatant within the cell compartment was extracted by centrifugation 
(90 g, 5 min) and filtered through 20 µm filters (Whatman). Cells were re-seeded in fresh 
hybridoma medium. 
Fab’DEC205-OTIp and -OTIIp were subsequently isolated from the supernatant by NiN-
TA-bead chromatography (Qiagen, LOT160044511). First 10 ml disposable chromatogra-
phy columns (Biorad, 732-1010) were loaded with 1 ml of NiNTA agarose beads and washed 
with PBS. NLDC-OTIp and -OTIIp supernatants were supplemented with elution buffer (50 
mM NaH2PO4, 300 mM NaCl2, 250 mM imidazole, pH 8.0 in MQ) to reach 10 mM of imidaz-
ole, loaded on the columns three times, by recycling of the flow through, and then washed 
with 10 CV of washing buffer (50 mM NaH2PO4, 300 mM NaCl2, 20 mM imidazole, pH 8.0 in 
MQ). Antibodies were eluted three times with 0.5 CV of elution buffer. The eluted fractions 
were concentrated, and buffer exchanged to PBS by ultracentrifugation in Amicon Ultra-15 
Centrifugal Filter Devices (Merck Millipore, UFC9030) with a molecular weight cutoff of 30 
kDa (3x [25 min, 4°C, 4000 rpm). NLDC-145 antibodies were isolated from the supernatant 
by Protein G Sepharose Fast Flow (GE Healthcare Life Sciences, 17-0618-01) according to 
the manufacturer’s protocol and concentrated in PBS as described above. Final antibody 
concentration was determined by Nanodrop at 280 nm with an extinction coefficient of 
1.4. Protein purity and successful isolation was monitored by SDS-PAGE of 10 µl samples of 




Screening of antibody production by NLDC-OTIp and -OTIIp limiting dilution clones was 
performed by incubating JAWSII DEC205 expressing DCs with 50 µl undiluted or 10x di-
luted supernatant for 30 min at 4 °C. Secondary antibody staining was performed in FACS 
buffer (PBS + 1 % FBS) with PE conjugated anti-rat Kappa LC (Biolegend, 407806, dilu-
tion: 400x) for 20 min at 4 °C in the dark. DEC205 expression of JAWSII cells was verified 
by staining with PE conjugated anti-DEC205 (Biolegend, 138214, dilution: 100x). Samples 
were acquired on the MACS Quant Analyzer 10 (Miltenyi Biotec) flow cytometer using the 
MACSQuantify software.
Viability of T cells was visualized by staining with e780 eFluor (eBioscience, 65-0865-
18, dilution 1000x)  in PBS for 30 min at room temperature in the dark. For analysis of T 
cell activation, T cells were subsequently stained for 30 min at 4 °C in the dark in FACS 
buffer with anti-CD25-FITC (Biolegend, 101908, dilution: 100x), CD44- PE/Cy7 (Biolegend, 
103030, dilution: 100x), anti-CD69-PE (BD, 553237, dilution: 100x), CD137-biotin (Bioleg-
end, 106104, dilution: 100x) and finally for 30 min with PerCP-streptavidin (Biolegend, 
405213, dilution: 100x). Samples were acquired on the BD FACSLyric (BD) using the BD 
FACSuite. Acquired samples analysis and proliferation modelling for calculating the division 
index were performed with FlowJo (Treestar, V10.4.0).
Matrix-assisted laser desorption ionization time of flight mass spectrometry
Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF) 
was carried out on a Bruker Microflex LRF MALDI-TOF equipment. The matrix used for pro-
tein and peptide analysis was Sinapinic acid (trans-3,5-dimethoxy-4-hydroxycinnamic acid) 
from Sigma Aldrich (MERCK) in a 10 mg/mL solution in H2O/MeCN (1/1) + 0.1 % TFA. Sam-
ples were analysed within a concentration range of 0.3-0.5 mg/mL in MiliQ using 1 µL each 
of matrix-sample-matrix sown on the MALDI plate. 
Generation of BMDCs
DEC205 expressing BMDCs were generated as described by Kirkling et al32. In short, bone 
marrow cells were flushed from femur and tibia of WT mice and red blood cells were lysed 
in ammonium chloride buffer. Subsequently 2x106 isolated cells were seeded in 2 ml of 
BMDC medium (RPMI1640 (Thermo Fisher Scientific, 11875093) supplemented with 10 % 
heat-inactivated fetal bovine serum (FBS), 2 mM ultraglutamine (Lonza, BE16-605E/U1), 
1$ antibiotic-antimycotic (AA) (Thermo Fisher Scientific, 15240062) and freshly added 50 
uM 2-mercaptoethanol (Thermo Fisher Scientific, 21985023)) and supplemented with hu-
man Flt3-ligand (80 ng/ml) (Miltenyi Biotec, 130-096-479) in a 24-well plate. Cells were 
incubated for three days at 37 °C and 5% CO2. On day two after bone marrow cell isolation 
12.5x103 OP9-DL1 cells (gift from Dr. M. Dalod, Centre National de la Recherche Scientifique 
(CNRS), Paris, France) were plated in a 24-well plate in 500 ul of !-MEM GlutaMAX sup-
plemented with HEPES (10 mM), sodium Pyruvate (1 mM), AA (1x), ultraglutamine (2 mM), 
"-mercaptoethanol (50 µM), NEAA (1x) and FBS (20 %). On day 3, supernatant of OP9-DL1 
was removed and 1 mL of isolated bone marrow cells was added per well on top of the OP9-
DL1 monolayer. On day 8, cells were harvested from the wells by gentle scraping. DEC205 
expressing BMDCs were isolated from the co-culture using CD11c MicroBeads following the 
manufacturer’s protocol (Miltenyi Biotec, 130-108-338). Purity and expression of DEC205 
was assessed by FACS, staining with PE conjugated anti-DEC205 (Biolegend, 138214, dilu-
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tion: 100x) and anti-CD11c (BD, 553802, dilution: 100x).
In vitro T cell proliferation
OTI and OTII T cells were isolated from lymph nodes and spleen by CD4+ and CD8+ MACS 
(Miltenyi Biotec, 130-104-454 and 130-104-075). Cells were then stained with CellTrace 
Violet (CTV, Invitrogen, C34557A, dilution: 500x) by resuspending in 500 µL PBS + 2 % FBS 
and adding 500 µL of PBS with CTV. Cell suspensions were subsequently incubated for 30 
min in a water bath at 37 °C while manually shaking for the first 5 min and finally quenched 
with 10 ml of BMDC medium followed by 10 min of incubation in the water bath. Cells 
were pelleted and resuspended in BMDC medium with fresh BME until further use. Purity 
and CTV staining efficiency were assessed by FACS, staining with APC conjugated anti-CD8 
(Biolegend, 100712, dilution: 600x) and FITC conjugated anti-CD4 (Biolegend, 100510, di-
lution: 600x). Purity of T cells used in these experiments ranged from 90-05%.
For investigating in vitro T cell proliferation, 2x104 BMDCs were incubated in a 96-round 
bottom well plate for 2h at 37 °C with different concentrations of antibody-antigen conju-
gates, OVA and OVA peptides, as indicated in the results section. Afterwards, BMDCs were 
washed and 1x105 isolated and stained OTI or OTII T cells were added in a total volume of 
200ul of LPS supplemented BMDC medium. Subsequently, the BMDC-T cell co-culture was 
incubated for 3 days at 37 °C. After 3 days, cells were retrieved from the wells and stained 
for FACS as mentioned before. For reducing the donor variability, MFI values were normal-
ized to the averaged values of peptide treated conditions, that served as a positive control 
for the maximum effect that can be observed.
Enzyme-linked immunosorbent assay (ELISA)
Cytokine secretion by activated OTI and OTII cells after co-culture with BMDCs was mea-
sured by IL-2 (Invitrogen, 88-7024) and IFNy (Invitrogen, 88-7314) ELISA. To do so, 50 µL of 
supernatant of the BMDC-T cell co-culture were removed after 3 days and diluted 50 times 




Supplementary Figures and tables
 
Supplementary Figure 1 | Selection of NLDC-OTIp/-OTIIp producer cell lines and isolation of Fab’OTIp/-OTIIp. 
(A) FACS screening of Kappa LC signals in undiluted or 100x diluted supernatant of outgrowing NLDC-OTIp SSC. 
(B) FACS screening of Kappa LC signals in undiluted or 100x diluted supernatant of outgrowing NLDC-OTIIp SSC. 
Because only few clones showed high Kappa LC signals in undiluted form, only SCC 25, 32, 61 and 68 were 
further analyzed by dilution. For both (A) and (B) Fab’DEC205-sortag-histag28 was used as positive control (+) and 
a sample without primary staining was used as negative control (-). (C) Western blot of supernatant from SCC, 
corresponding to numbers in (A) and (B), stained for histag (green) and rat IgG (red). Fab’DEC205-sortag-histag28 
was used as positive control (+). (D) SDS-PAGE gel, stained with SYPRO Ruby Protein Gel Stain, of 10 µL samples 
from NiNTA bead isolation of 1 cycle of NLDC-OTIp/-OTIIp production culture. Fab’DEC205-sortag-histag28 (+), 
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Supplementary Table
Supplementary Figure 2. Functional characterization of Fab’DEC205-OTI and -OTII with respect to their in vitro 
T cell activation capacity including three different concentrations. This figure is accompanying Fig. 3 by showing 
also the lower two dilution steps of OVA, Fab’OTIp and -OTIIp for the division index (A,C) the activation marker 



















OVA257-264: 5 nMOVA: 1, 0.2, 0.04 mg/mL
Untreated Fab‘OTIp:1, 0.2, 0.04 µM 
OVA257-264: 5 nM
OVA: 1, 0.2, 0.04 mg/mL
Untreated
Fab‘OTIp: 1, 0.2, 0.04 µM 
OVA257-264: 5 µM
OVA: 1, 0.2, 0.04 mg/mL
Untreated
Fab‘OTIIp: 1, 0.2, 0.04 µM 
OVA323-339: 5 µMOVA: 1, 0.2, 0.04 mg/mL























































































Supplementary Table 1. DNA Sequence of NLDC-OTIp/-OTIIp HDR donor templates. The 
table depicts the different elements of the HDR donor templates from the 5’ to 3’ end of the 
template. The OTIp and OTIIp sequences, indicated in italics, are interchangeable,meaning 

























OTIp - Histag - Stop TTCCGCTCCATCATCAATTTTGAGAAACTCGCTGCCGCTGCTGCTAAGCACCATCACCATCAC-
CATTGA
OTIIp - Histag - Stop TTTCGGATAAGCCAAGCAGTTCACGCCGCTCACGCTGAAATAAACGAAGCTGGACGCCATCAT-
CATCATCATCATTAG
IRES-Blasticidin-S 
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Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technologies can 
be used to insert genetic elements into a genomic locus of choice by a process called ho-
mology-directed repair (HDR). To date, the efficiency of this process is low and influenced 
by cell type, cell cycle phase, HDR template size or mode of delivery, to name a few.!As a 
consequence, antibiotic resistance-based selection is performed to enrich for edited cells. 
However, this selection can yield cells that are resistant but not correctly edited, for in-
stance due to off-target integration of the resistance gene. In addition, antibiotic-based 
selection requires large HDR templates, antibiotic dose optimization and can occupy up 
to two weeks. Although antibiotic-based selection systems allow to obtain cells with the 
desired edit, current limitations complicate their use in combination with high-throughput 
modifications such as the insertion of gene libraries. 
Recently, we have used CRISPR/HDR and antibiotic-based selection to modify the immu-
noglobulin (Ig) locus of hybridoma cells and to create antibody-antigen conjugates for den-
dritic cell-targeted immunotherapy. As a next step we aimed to develop a high-throughput 
engineering platform for the  generation of multiplex antibody-antigen conjugates through 
insertion of (neo)antigen libraries. Considering the aforementioned limitations of antibiot-
ic-based selection we set out to develop a novel selection system that facilitates stringent 
selection of correctly edited clones after gene library insertions. This selection system, 
called iSuicide, is based on an inducible caspase 8 gene that can be activated upon addi-
tion of a small molecule, leading to apoptosis of unedited or wrongly edited cells within 24 
hours. In this proof-of-concept study we describe the mechanisms of this system and show 
a characterization of the iSuicide hybridoma cell line and the selection process. While being 
able to positively select correctly edited cells, we observed that the selection efficiency is 
very low due to outgrowth of undesired mutant clones due to non-homologous end-join-
ing (NHEJ) in the iSuicide cassette, which in turn inactivates the inducible caspase 8. The 
insight we gained from this study into the fundamental mechanisms of CRISPR/HDR in the 
context of the iSuicide platform will enable us to adapt the genetic makeup of the iSuicide 
cassette and prepare this platform for the next generation of hybridoma engineering.
Introduction
CRISPR-Cas9, originally discovered as a prokaryotic defense mechanism against viruses, 
has evolved to a multi-purpose Swiss knife for the manipulation of DNA or RNA. For most 
purposes its basic mechanism is the same: a synthetic guide RNA (sgRNA), which is com-
plementary to the target location in the genome, is complexed with the unspecific endonu-
clease called Cas9 (Fig. 1.1). As such it can bind the target DNA or RNA strand and induce a 
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double strand break (DSB) after recognition of the protospacer adjacent motif (PAM) (Fig. 
1.2). The DSB in the DNA is facilitated by the two nuclease domains of Cas9 RuvC and HNH1 
which are exposed upon binding to the DNA. Under physiological circumstances, cells will 
try to repair a DSB by HDR or NHEJ (Fig. 1.3). The latter is primarily occurring during the 
M and G1 phase of the cell cycle and involves random insertion of base pairs into the cut 
site to repair the break, which predominantly leads to insertions or deletions (INDELS). 
This process can result in frameshift mutations, premature termination codons (PTCs) or 
translocations that inactivate a gene or deregulate the function of a protein, leading to an 
aberrant cell phenotype and function1–4. During the S phase of the cell cycle, the cell can 
make use of a homologous sister chromatid to repair the DSB by HDR, during which the 
homologous sequence is first inserted into one strand of the DSB site and then copied so 
that both strands contain the wild type (WT) sequence4. In an artificial setting, this process 
can be used to insert genes of interests or small tags into the genome by flanking these 
with a sequence, homologous to regions up- and downstream of the DSB5 (Fig. 1.3). These 
so-called HDR templates can be provided in the form of plasmids or linear DNA and trans-
fected into the cell. In the past, HDR with DNA templates has been used extensively in cell 
lines or embryonic stem cells to establish knock-ins, knock-outs and transgenic mice6,7. 
Integration of HDR templates with a site-specific DSB induced by CRISPR-Cas9 moreover 
allowed the precise repair of disease-causing mutations as can be found in Duchenne mus-
cular dystrophy8. Depending on the type of edit, HDR templates can reach sizes of several 
kilobases and since the cell has to cope with these large pieces of DNA to resolve the DSB, 
the efficiency and frequency of this process is low (0.5-20%)9. 
Consequently, many efforts are made to improve CRISPR/HDR outcomes and often ad-
ditional laborious selection steps are required to enrich cellular clones that have integrated 
the HDR template. The most common selection systems are based on antibiotic pressure 
and resistance. In such systems, first antibiotic resistance genes such as blasticidin-s de-
aminase or puromycin N-acetyltransferase are integrated with the HDR template in order 
to confer resistance to blasticidin or puromycin, respectively. In turn, the selection of ed-
ited cells can be performed by using antibiotic-supplemented culture medium. Typically, 
this selection process takes one to two weeks until a selected, viable cell population arises 
which can be further screened and separated into monoclonal cell lines. Often however, 
this timeframe varies based on the type and dose of antibiotic, performed edit and target 













Figure 1 | Schematic overview of CRISPR-Cas9 genome editing. (1) Complex formation of the Cas9 endonuclease 
and a synthetic or single guide RNA (sgRNA). (2) Cas9:sgRNA complex binds to target DNA facilitated by sgRNA 
hybridization with the target DNA near a PAM sequence (red). HNH1 and RuvC nucleases are exposed and will in-
duce a double strand break (DSB). (3) DSB resolution by NHEJ or HDR, aided by an HDR template. HDR templates 
can be used to insert an element of interest (green). NHEJ leads to insertion of random bases in the break site (red, 
orange, blue, purple stripes).
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resistance gene in an off-target locus, which underlines the inefficiency and lack of robust-
ness of this selection system. 
Recently we employed CRISPR/HDR and antibiotic-based selection to engineer the Ig 
locus of hybridoma cells for the production of dendritic cell (DC)-targeted antibody-antigen 
conjugates for immunotherapy (Chapter 3). As a proof-of-concept, we inserted the CD4+ and 
CD8+ T cell epitopes of the ovalbumin protein in the hinge region of the Ig locus of DEC205 
antibody-expressing hybridomas, thereby generating Fab’ fragments C-terminally fused to 
antigen peptides. Although the selection process was laborious, it was manageable for 
these two antigen sequences, yielding functional vaccines that induced antigen-specific T 
cell proliferation and activation in vitro. In the future, however, we want to use this platform 
to insert genetic libraries of patient specific tumor neoantigens by CRISPR/HDR to generate 
libraries of antibody-neoantigen conjugates that resembles the mutational landscape of a 
patient’s tumor. The antibiotic-based selection system that we currently use after CRISPR/
HDR however does not support the selection after high-throughput multiplex edits with 
genetic libraries due to the limitation addressed above. To enable a more stringent and fast 
selection of correct cellular clones after multiplex CRISPR/HDR modifications, we set out to 
develop a platform based on an inducible suicide switch directly downstream of the heavy 
chain locus, that can be activated by the addition of a small molecule and leads to apopto-
sis of incorrectly edited clones within 24 hours. Here we describe the concept behind this 
platform, its generation and characterization and initial functional experiments. We believe 
that this system will allow us to answer to the need of a selection platform for CRISPR/HDR 
and the possibility to generate personalized anti-tumor vaccines in a timely manner to con-
tribute to a faster treatment of patients after diagnosis. 
Results
iSuicide - an inducible caspase 8 for clone selection after CRISPR/HDR in hybridomas
Previously, we have shown that the IgG2a heavy chain locus of the NLDC-145 hybridoma, 
expressing anti-DEC205 antibodies, can be modified by CRISPR/HDR to express Fab’OTI-
p/-OTIIp (Chapter 3). For the selection of these clones we inserted an internal ribosom-
al entry site (IRES) and a blasticidin-S deaminase gene downstream of the tumor antigen 
sequence for the CD4+ and CD8+ epitope of ovalbumin, to confer antibiotic resistance to 
edited clones. 
In the iSuicide system, we design a two-step platform (Fig. 2). In the first step, we inte-
grate the iSuicide cassette in the heavy chain locus, adding a C-terminal sortag (LPETAAG) 
and hexa-histidine tag (histag), an IRES, a pair of B/B homodimerizer (DmrB) binding do-
mains, based on the iDimerize system (Takara Biotech), followed by a caspase 8, hereafter 
called iCasp, and a puromycin N-acetyltransferase (Fig. 2A.1). Once produced in the cell, 
two iCasps can be dimerized by the addition of DmrB and will induce the canonical caspase 
signaling pathway leading to apoptosis of the cell (Fig. 2A.1), which will be instrumental for 
the selection of successfully engineered clones. Next to this, the cell will secrete sortagga-
ble, histagged mAb-DEC205. Although not further detailed here, we included the sortag 
motif to enable site-directed modification of the antibodies by sortase-mediated ligation 
(Chapter 1 and 2). The histag functions as a handle for antibody purification and visual-
ization via flow cytometry and western blot. In the second step, we can insert the desired 
antigen sequence as described previously (Chapter 3), here replaced by a myctag since it 
can be easily visualized, followed by a polyadenylation signal, leading to the transcriptional 
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inactivation of the gene elements downstream of this second HDR insert (Fig. 1A.2). This 
inactivates iCasp, making correctly edited cells resistant to DmrB induced apoptosis and 
selecting them for further outgrowth. The selected population will produce myctagged 
mAb-DEC205. Cells that have not integrated the HDR template, will undergo apoptosis due 
dimerization of iCasp with DmrB, typically within 24h, and can be removed from the cul-
ture by washing or Ficoll density gradient centrifugation, yielding a population of correctly 
edited cells that can, if needed, be separated further into monoclonal cell lines by a limiting 
dilution (Fig. 1B). 
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Generation of the iSuicide hybridoma by CRISPR/HDR
In order to insert the iSuicide cassette into the IgG2a locus of the NLDC-145 hybridoma 
(Fig. 3A.i) we constructed an HDR template containing the iSuicide cassette with a termi-
nal puromycin N-acetyltransferase flanked by two homology arms (HAs) that align with 
the CH2-CH3 and the 3’ intron of the CH3 (Fig. 3A.ii). After electroporation of NLDC-145 
cells with the iSuicide HDR template and sgRNA_CH3_1 and _3, we selected cells that have 
integrated the HDR template by puromycin pressure and performed a limiting dilution to 
separate monoclonal cell lines (Fig. 3A.iv). Screening the supernatant of the clonal cell lines 
for the presence of DEC205-binding, histag-containing antibodies on a mouse DC cell line 
(JAWSII) by FACS revealed that both sgRNA_CH3_1 and _3 yielded clones with a histag sig-
nal comparable to the positive control Fab’DEC205-srt-his10 (Suppl. fig. 1A). Cells transfect-
ed with sgRNA_CH3_2 did not show any histag-containing antibodies in the supernatant 
Figure 2 | Overview of the iSuicide generation and approach. (A) Procedure outline of creating the iSuicide 
and iSuicide-Myc hybridoma with a graphic representation of the changes in the immunoglobulin locus and the 
consequences for the secreted antibodies. (B) Transfection timeline using the iSuicide hybridoma. 4 days after 
transfection DmrB selection will be started, where incorrect clones will be removed within 24h by apoptosis in-
duction, and then let for 14d to form the bulk population. Finally, monoclonal cell lines will be generated by a 
limiting dilution. CH = Constant heavy, mAb = Monoclonal antibody, srt-his = sortag-histag, I = internal ribosomal 
entry site (IRES), DmrB = B/B homodimerizer, Casp8 = caspase 8, F = Flag tag, T2A = T2A cleavable peptide, P = 
puromycin N-acetyltransferase, PA = bGH poly A signal.
68
4
Figure 3 | Generation and characterization of the iSuicide hybridoma. (A) Graphical representation of the target 
locus (i), the exact Cas9 target region, including the protospacer adjacent motif (PAM) and sgRNA sequence (ii), 
the final locus after HDR template integration with primers 1-4 (iii) and the transfection setup including time in-
dications for puromycin selection, limiting dilution and antibody production (iv). (B) Genomic PCR of the iSuicide 
clone with different primer pairs compared to a PCR with DNA from the NLDC-145 hybridoma. (C) Sequencing 
results of PCR amplicons from (B) and corresponding amino acid sequence (region 3 only) for three different 
regions of interest (1-3) as indicated in the schematic figure above by rectangles with dotted lines. Sequencing 
reads were compared to NLDC-145 reference sequence. Deviation from the native sequence is indicted by red 
letters. (D) Histograms showing the Histag-PE signal of fab’DEC205-srt-his and NiNTA-bead purified mAb iSuicide 
bound to DEC205 expressing JAWSII cells visualized by FACS. (E) Western-blot of mAb DEC205 (-) and NiNTA-bead 
purified mAb iSuicide stained for rat IgG2a (r2a) and histag (his), as can be seen in two separate images on the 
right, while the left image represents the merged image. (F) Percentage of viable NLDC-145 and iSuicide cells 
treated with increasing concentrations (1x10-12 to 1x10-7 M) of DmrB for 24h. Viability was assessed by propidium 
iodide staining and FACS, n = 2. CH = Constant heavy, srt-his = sortag-histag, I = internal ribosomal entry site 
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indicated by Histag-PE signals comparable to the negative control (Suppl. fig. 1A). Clone 38 
of the sgRNA_CH3_3 transfection was chosen as platform clone, hereafter called iSuicide, 
and was further characterized by genomic PCR (Fig. 3B). To do so, we used different primer 
pairs, that either span the whole insertion region binding outside of the homology arms 
(primers 1,4) or that amplify the 5’ or 3’ terminal regions of the HAs and native sequence 
of the locus (primers 1,2 and 3,4). The PCR using primer pair 1,4 yielded an amplicon with 
increased size for the iSuicide clone, corresponding to the size of the insert in the HDR tem-
plate, when compared to the unedited NLDC-145 amplicon (Fig. 3B). PCRs sampling the 5’ 
and 3’ insertion regions also yielded the expected amplicon size (Fig. 3B) and were further 
used for Sanger sequencing of the break points (Fig. 3C). Here we observed no deviations 
from the native sequences comparing sequencing reads from iSuicide DNA with NLDC-145 
(Fig. 3C.1 and .2). Sequencing of the insert region revealed that the insert has correctly been 
integrated. As expected, also PAM and sgRNA inactivating mutations that we incorporated 
in the HAs can be observed by sequencing (Fig. 3C.3). 
Having characterized the newly formed Ig locus of the iSuicide hybridoma, we set out 
to verify that the correct antibodies are formed and secreted. Therefore, we isolated an-
tibodies from the cell culture supernatant by NiNTA-bead chromatography as described 
in chapter 3 (Suppl. fig. 1B) and tested DEC205 binding and histag expression by flow 
cytometry and western blot. FACS analysis revealed that binding of mAb iSuicide to the 
DEC205 expressing DC cell line JAWSII was maintained after Ig engineering and that bound 
antibodies contain a histag, as indicated by similar levels of histag signal of the positive 
control fab’DEC205-srt-his and mAb iSuicide (Fig. 3D). This was moreover confirmed by 
histag positive staining overlaying with the mAb iSuicide heavy chain on western blot and 
the increased size of the heavy chain of mAb iSuicide compared to mAb DEC205 (Fig. 3E).
As a final step, after having verified the genomic presence of the iSuicide cassette and 
correct formation of tagged antibodies, we asked whether functional iCasp components 
are produced and the iSuicide system can function as envisioned. To do so, we titrated 
DmrB in iSuicide and NLDC-145 cultures and measured cell viability after 24h by propidium 
iodide staining and FACS (Fig. 3F). While NLDC-145 are unaffected by increasing concen-
trations of DmrB, the viability of iSuicide cells is reduced to 0% starting at around 3 nM of 
DmrB. A working concentration of 50 nM was chosen to ensure complete apoptosis. These 
results suggest that iCasp is produced and functional and that DmrB can be used to induce 
apoptosis in iSuicide cells. 
DmrB selection yields genetically heterogeneous iSuicide bulk population after myctag 
integration 
After having validated the genetic makeup and functionality of the genomically integrat-
ed iSuicide cassette, we asked whether we can use the platform for selection of correctly 
edited clones after CRISPR/HDR with a model HDR template. This model HDR template 
contains a myctag (Myc, EQKLISEEDL) or a double myctag (Myc2, EQKLISEEDLEQKLISEEDL) 
sequence and replaces the C-terminal histag of mAb iSuicide once integrated (Fig. 4A). 
Measuring the presence of his- or myctag in turn allows us to easily monitor success of the 
selection. We started off by analyzing the genomic locus of the bulk population after DmrB 
selection by PCR using primer pairs that either amplify DNA from iSuicide cells, anneal-
ing on the sortag (primers 1,5), or iSuicide-Myc/Myc2 cells, annealing on the poly A signal 
(primers 1,6) (Fig. 4A). Screening for the presence of the Myc or Myc2 HDR template in the 
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DNA of the bulk population with primers 1,6 we observed an amplicon of the expected 
size for the transfection with sgRNA_iSuicide_2, but not sgRNA_iSuicide_1 (Fig 4B). We 
hypothesized that transfections with sgRNA_iSuicide_1 failed and that iSuicide cells remain 
unedited, which was confirmed by a PCR with primers 1,5, showing clear amplicons for 
sgRNA_iSuicide_1 transfection of similar size as unedited iSuicide (Fig. 4C). Surprisingly, we 
also observed amplicons for transfections with sgRNA_iSuicide_2, indicating that the bulk 
Figure 4 | Integration of Myc and Myc2 HDR templates in 
the iSuicide hybridoma and subsequent analysis of the bulk 
population and SCCs of sgRNA_iSuicide_2 only transfected 
iSuicide cells. (A) Graphical representation of the sgRNA target 
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4population contains both, iSuicide and iSuicide-Myc/-Myc2 cells, after selection with DmrB 
(Fig. 4C). These results reveal that the desired modification is present in the bulk population 
of Myc and -Myc2 transfected iSuicide cells, but that also unedited cells remain that must 
have survived DmrB selection.  
DmrB selected clones express polyclonal antibodies
Next, we asked whether the observed genetic changes also translate to the protein level. 
We therefore isolated antibodies from the bulk cell culture supernatants of iSuicide-Myc 
and -Myc2 (mAb-iSuicide-Myc and -Myc2, respectively) by protein G chromatography and 
stained samples on western blot with anti-his- or myctag antibodies (Fig. 4D). Compared 
to mAb-DEC205 and mAb-iSuicide (Fig. 4D, lane 1,2), mAb-iSuicide-Myc and -Myc2 showed 
expression of two types of HCs, one that is at the height of the mAb-DEC205 HC and does 
not contain a histag, and one that is slightly higher and shows a faint myctag signal (Fig. 
4D, lane 4 and 5). Notably, the myctag signals on mAb-iSuicide-Myc and -Myc2 also differ 
in height, with signals of mAb-iSuicide-Myc2 running slightly higher than mAb-iSuicide-
Myc, which could be due to the extra myctag that is inserted. As additional control next to 
mAb-DEC205 and mAb-iSuicide we took along antibodies from a transfection with sgRNA_
iSuicide_2 only without HDR template, hereafter called mAb-iSuicide-sg. This control was 
used to show the efficiency of DmrB selection. Since no HDR template is integrated, iCasp 
should still be active and all cells should induce apoptosis. Contrary to our expectations, 
we observed that cells survived this selection and that mAb-iSuicide-sg could be isolated 
containing an untagged HC, hinting at a reversal to WT HC or deletion of the iSuicide cas-
sette (Fig. 4D, lane 3). 
These results indicate that a small portion of cells in the Myc and Myc2 transfected bulk 
population secretes myctagged antibodies, while the rest secretes untagged, mAb-DEC205 
like antibodies. This suggests that on the one hand correctly edited clones have been se-
lected with DmrB but that on the other hand also clones survived that do not express the 
desired product. 
Genetic and phenotypic diversity of DmrB selected clones stems from NHEJ events after 
CRISPR/HDR
PCR and western blot have shown that a geno- and phenotypically heterogeneous bulk 
population is present after the transfection of iSuicide cells with Myc and Myc2 HDR tem-
plates and selection with DmrB. The survival of cells in sgRNA_iSuicide_2 only transfect-
Figure 4 continued | annealing locations of primers used for genomic PCR and sequencing. Genomic PCR of 
sgRNA_iSuicide_1 (sg1) or sgRNA_iSuicide_2 (sg2) transfected bulk populations with primers for visualizing the 
HDR template insertion (B) or the presence of residual iSuicide cells (C). (D) Western blot of protein G purified 
antibodies mAb-DEC205 (1), mAb-iSuicide (2), mAb-iSuicide-sg (3), mAb-iSuicide-Myc (4) or mAb-iSuicide-Myc2 
(5) stained for rat IgG2a (Rat, gray), histag (His, green) and myctag (Myc, red). (E) Graphic representation of primer 
locations (top) used for a genomic PCR of SCC obtained after transfection of iSuicide with sgRNA_iSuicide_2 only 
(bottom). (F) Sanger sequencing of amplicons from the 6 SCC that were analyzed by PCR. The left part of the 
figure shows a graphical representation of the sequencing results comparing the sequenced SCC to the iSuicide 
reference. Red color indicates the location where mutations were observed. The boxed parts indicated the region 
that is depicted in the right part of the figure, showing the sequencing reads obtained by sequencing compared 
to the iSuicide reference sequence. Dashed lines indicate absence of sequence, vertical lines indicate sequence 
match, * indicates mismatch. (G) Western blot of protein G isolated antibodies from the 6 SCC stained for rat 
IgG2a (r2a) and histag (his).
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ed cells moreover supports the hypothesis that DmrB selection is not complete and calls 
for further investigation of the underlying mechanism. Although incorrect clones might be 
separated from the correctly edited clones by a following limiting dilution, DmrB resistance 
is not desired in a setting where multiplex library transfections are performed and the ef-
ficiency of selection needs to be very high to counteract the inefficiency of CRISPR/HDR. 
We hypothesize that resistance to DmrB could be obtained due to erroneous repair of 
the DSB by NHEJ, leading to mutations that inactivate or distort the expression of iCasp. 
In line with current knowledge about the low frequency and efficiency of HDR, it is very 
likely that primarily NHEJ is occurring1–3. To test this hypothesis, we set out to investigate 
the mechanism of DmrB resistance in clones that were edited with sgRNA_iSuicide_2 only, 
since we expect to see the most NHEJ events occurring here. We prepared monoclonal 
lines from this bulk population by a limiting dilution and analyzed the Ig locus by PCR and 
Sanger sequencing. A PCR covering the region around the sgRNA_iSuicide_2 target site 
(primers 7,2) of 6 single-cell clones (SCC) shows amplicons differing in size (Fig. 4E). SCC 1 
and 2 showed no PCR amplicon. Congruent with results from western blot (Fig. 4D), where 
we saw WT-sized HC in the edited and selected bulk population supernatants, we hypothe-
sized that SCC 1 and 2 are reversed to a WT genotype and we therefore performed another 
PCR with primers annealing at the native regions of the Ig locus (primers 1,4). This PCR 
indeed shows amplicons that are similarly sized as the amplicon of WT NLDC-145 cells 
(Fig. 4E). Amplicons from both PCR reactions were subsequently isolated and analyzed 
by Sanger sequencing (Fig. 4F). In line with PCR results, SCC 1 and 2 align the WT NLDC-
145 sequence and lack the iSuicide cassette. We hypothesize that reversal from iSuicide to 
NLDC-145 genotype is caused by DSB-induced HDR with a homologous sister chromatid of 
a WT allele that is still present in iSuicide cells.
SCC 3 and 6 showed an amplicon similar to the size of the iSuicide amplicon (Fig. 4E). 
Sanger sequencing of these amplicons revealed that both have a 2 base pair deletion in 
the G4S linker (Fig. 4F). This deletion results in a frameshift and PTC 36bp downstream 
of the mutation at the start of the IRES. PCR of SCC 4 DNA produced a much smaller PCR 
amplicon compared to the iSuicide amplicon (Fig. 4E). Sequencing of the SCC4 PCR prod-
uct showed that it contains a deletion in the terminal section of the CH3 that spans up to 
the beginning of the IRES, also leading to a PTC after 40bp (Fig. 4F). PCR and sequencing 
of SCC 5 DNA showed an increased size compared to the iSuicide amplicon caused by a 
230bp substitution starting at the end of the CH3 and ending in the first part of the IRES. 
These results suggest that NHEJ could introduce various types of genetic alterations in the 
sgRNA target region. 
Finally, protein G purified supernatant of these six SCC was analyzed by western blot and 
anti-histag staining (Fig. 4G) to investigate whether mutational signatures found by se-
quencing are reflected in the inability to produce correct antibodies. SCC 1 and 2 show pro-
duction of a mAb-DEC025 like antibody, without a Histag. SCC 3 and 4 seem to produce an 
altered HC indicated by higher and lower bands compared to mAb-DEC205 and mAb-iSui-
cide. SCC 5 and 6 do not display rat IgG2a HC signal indicating absence of antibodies. To-
gether these findings support the hypothesis that mutations in the Ig locus of iSuicide cells 
caused by NHEJ of the DSB break during the CRISPR-Cas9 procedure leads to the inability 
to produce the desired antibody. Additionally, and more importantly, these mutations also 
seem to effect downstream gene elements by introducing frameshift mutations and PTCs. 
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Discussion and conclusion
Current antibiotic-based selection systems that are used to enrich correctly edited cells af-
ter CRISPR/HDR procedures are laborious, time-consuming and not efficient in the context 
of inserting genetic libraries in a target locus. In chapter 3 we have used such a selection 
system in combination with a CRISPR/HDR approach in hybridoma cells to create antibod-
ies that are genetically fused to a tumor antigen for DC-targeted immunotherapy. To an-
swer the pressing need for more complex and personalized DC-targeted vaccines (Chapter 
5) we aim to create libraries of antibody-tumor antigen fusions. To achieve this, we need a 
novel selection system that enables fast and correct selection of clones after CRIPSR/HDR 
with genetic libraries. 
In this study we therefore aimed to replace current antibiotic-based selection systems by 
an apoptosis-based selection system, that allows us to select correctly edited clones within 
one day and is compatible in a high-throughput CRISPR/HDR setting. 
We show successful integration of a dimerizable caspase 8 (iCasp) into the Ig locus of 
the NLDC-145 hybridoma downstream of the CH3 exon, enabling us to induce apoptosis 
within 24h after addition of the dimerizing small molecule DmrB. During this step we also 
integrated a histag that was used for the isolation of antibodies and the visualization of 
antibody binding to DEC205 on JAWSII DCs by FACS. Western blot moreover confirmed 
the unaltered expression and structural integrity of the secreted antibodies. As a second 
step, to test the selection efficiency of our iSuicide platform with DmrB, we set out to in-
tegrate a model HDR template containing a myctag, replacing the histag in the Ig locus. 
The integration of the myctag was genetically confirmed and myctagged antibodies could 
be observed in the DmrB selected bulk population. However, this population appeared  to 
be pheno- and genotypically heterogeneous, displaying also NLDC-145 like PCR amplicons 
and antibody HCs. This suggested that not all cells that underwent DmrB selection were 
repaired through HDR. In line with our hypothesis, we found that repair events during DSB 
resolution governed by NHEJ lead to various genotypes such as reversal to NLDC-145, point 
mutations, deletions or substitutions. The latter three events result in frameshift mutations 
and PTCs that could halt the production of iCasp, rendering cells resistant to DmrB. These 
results were supported by the observation that no or truncated antibody HC production 
was detected in clones that contain PTCs or mutations in the terminal CH3 region (Fig. 5A).
The data presented in this study supports our hypothesis that NHEJ events lead to the 
inactivation of iCasp and survival of incorrect clones after DmrB treatment (Fig. 5A). In 
line with the current understanding of CRISPR-Cas9 repair mechanisms this study shows 
that next to HDR, as shown by knockin of the myctag in the Ig locus and production mAb-
iSuidide-Myc, also NHEJ occurs1–3, that introduces genetic and phenotypic heterogeneity 
in the bulk population. Following that line of reasoning, we identified differential repair 
outcomes after NHEJ that are in line with a study of Kosicki et al.11 investigating repair out-
comes after DSBs in mouse and human cell lines. Next to small insertions and deletions, 
they observed larger insertions, deletions, and inversions11. As a consequence of the muta-
tions we discovered in and around the IRES sequence, mRNA is likely to be flagged for non-
sense mediated decay leading to degradation of the mRNA and absence of the encoded 
protein, as described by Shi and Holbrook et al.12,13. In our settings this means that aberrant 
mRNA encoding the antibody HC and iCasp is degraded and cells will produce aberrant 
or no antibodies and will lack expression of iCasp. In turn, these cells will be resistant to 
selection by DmrB, which reduces the chances of obtaining correctly edited clones. Next 
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to mutated SCC we also obtained NLDC-145 WT clones after CRISPR/HDR. Lalonde et al.14 
have shown that frameshift mutations can cause the skipping of exons, which, in our case, 
could be an explanation for loss of the iSuicide cassette and reversal to the WT sequence. 
Another possibility would be that during HDR the DSB is repaired with a silenced NLDC-145 
WT allele that is present in the form of a sister chromatid instead of the donor HDR tem-
plate15. To fully support this argumentation more experiments are needed that investigate 
the effects of mutations on the production of iCasp, starting with measuring the presence 
of iCasp at different timepoints after CRISPR/HDR, before adding DmrB. 
As delineated above, the failure of the current iSuicide generation is rooted in the fun-
damental CRISPR/HDR mechanism and not in the inducible suicide switch strategy. To im-
prove the current iSuicide generation we therefore have to adjust the CRIPSR/HDR mecha-
nism or adapt the strategy to be resistant to NHEJ.
By modifying the CRISPR/HDR mechanism to improve HDR efficiency and prevent NHEJ 
we might increase the chance to select a correct clone and prevent mutational events that 
inactivate iCasp (Fig. 5B). Several groups have tried to increase the efficiency of HDR and 
the selection of clones that have successfully integrated the HDR template. One can think 
of synchronizing the target cells in the S phase with cell cycle modulators such as cyclin 
D16 or microtubule movement inhibitors such as Nocodazole17. Moreover, NHEJ inhibitors18 
or HDR enzyme potentiators can be used either soluble or fused to the Cas9 protein to 
increase the chance of HDR19,20. Other approaches to increase HDR efficiency would entail 
to reduce the HDR donor plasmid9 size or use linearizing donor templates21,22. Also different 
techniques could be explored that show higher frequencies of HDR such as PCR tagging23 
or the relatively new prime editing, that allows direct transcription of the sequence of inter-
Figure 5. Summary of results 
of bulk population analysis and 
schematic representation of ap-
proaches for the improvement 
of the iSuicide platform | (A) The 
transfection of iSuicide cells with 
myctag HDR templates yielded a 
heterogeneous bulk population, 
after DmrB selection, with cells 
expressing WT antibodies and 
myctagged antibodies. Cells in 
this population survived DmrB 
selection because of inactivation 
of iCasp either by HDR or by NHEJ 
induced INDELS. (B) Proposed 
options for the adjustment of the 
iSuicide platform, to increase the 
efficiency and frequency of HDR 
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est into the locus from a RNA template attached to Cas924. However, for larger insertions 
such as gene elements or fluorescent tags, this technique is not suited yet. Increasing the 
on-target specificity of Cas9 could also be explored to reduce unwanted side effects due to 
off-target DSBs. To this end, more evolved and engineered variants of Cas9 such as Cas9 
nickase variants25,26, high-fidelity Cas9 (SpCas9-HF1)27, enhanced specificity Cas9 (eSp-
Cas9(1.1))28, hyper-accurate Cas9 (HypaCas9)29, Sniper-Cas930 or evo-Cas931 can be used. 
Next to CRISPR/Cas9 also other engineering approaches exist including traditional genetic 
modification tools such as zinc finger nucleases or transcription activator-like effector nu-
cleases (TALENs). However, these tools also induce DSBs and rely on HDR and NHEJ repair, 
besides being more complex and time-consuming to set up. To date, therefore no suited 
tool exists that allows precise and scarless insertion of antigen sequences in the Ig locus.
Taken together, we believe that a selection platform based on an inducible suicide 
switch is interesting for the field and much needed for a more efficient Ig locus engineering 
to generate libraries of antibody fusions. Certainly, it can also be adapted to other cell lines 
and loci that are often modified such as safe harbor sites, to facilitate a better and faster 
selection. Improving the efficiency of HDR and preventing NHEJ will be pivotal to create the 
next generation of iSuicide and open up new possibilities for generating multiplex DC-tar-




General cell culture conditions
As described in chapter 3, the anti-DEC205 secreting NLDC-145 hybridoma cell line was 
purchased from ATCC (HB-290) and cultured in RPMI1640 (Thermo Fisher Scientific, 
11875093) supplemented with 10 % heat-inactivated fetal bovine serum (FBS, GE Life Sci-
ence, sv30160.03), 2 mM ultraglutamine (Lonza, Be17-605E/u1), antibiotic-antimycotic 
(AA) (Gibco, 2211104, 100x) and 50uM 2-mercaptoethanol (Sigma Aldrich, STBH7709).
The DEC205 expressing cell line JAWSII was purchased from ATCC (CRL-11904)  and 
cultured in MEMa (Gibco, 2099595) supplemented with 20 % FBS, NEM (Gibco, 2165257, 
100x), AA, Sodium pyruvate (Gibco, 1881816, 100x), sodium bicarbonate (Gibco, 2078819, 
100x), 50 µM 2-mercaptoethanol, 2mM Ultraglutamine and freshly added granylo-
cyte-macrophage colony-stimulating factor (GM-CSF, Miltenyi Biotec, 130-095-735) (5 ng/
ml). NLDC-145, its engineered subclones and JAWSII were tested negative for the presence 
of mycoplasma (Lonza, LT07-418).
sgRNA and HDR donor template design for generation of iSuicide
The genomic makeup of the rat IgG2a immunoglobulin locus was extracted from the 
Ensemble database (transcript ID: ENSRNOT00000066209). For the integration of the 
iSuicide-HDR donor template three potential sgRNAs targeting the region around the stop 
codon of exon 3 (constant region heavy 3) were designed by CRISPOR (http://crispor.tefor.
net32) and ordered as single-stranded DNA (Integrated DNA technologies) with BbsI restric-
tion enzyme overhangs to be cloned in the Cas9 plasmid PX330-SpCas9-NG (Addgene plas-
mid: 117919). To do so, single-stranded DNA was phosphorylated by T4 PNK (New England 
Biolabs (NEB), M0201L, 10045209) for 30 minutes at 37 °C and annealed by increasing the 
temperature to 95 °C for 5 minutes and subsequently lowering the temperature by 5 °C/
minute to 25 °C in a thermocycler. Annealed and phosphorylated oligos were ligated in BbsI 
(NEB) digested, dephosphorylated and gel purified Cas9 plasmids. 
iSuicide HDR donor templates were designed with 550 bp homology arms (HAs) up- and 
downstream of the sgRNA target site, containing PAM inactivating mutations. The insert 
between the two HAs contains a glycine-serine linker, a LPETAAG sortag and a histag and a 
stop codon in frame of the CH3. After this coding region we inserted an internal ribosomal 
entry site (IRES), two homodimerizer B/B (DmrB) binding sites fused to the human caspase 
8 (NBCI reference sequence: NP_001358980.1) followed by a Flag tag, a 2A peptide and a 
puromycin N-acetyltransferase. This synthetic gene cassette was ordered at IDT and insert-
ed into the PCR2.1 TOPO TA vector (Thermo Fisher Scientific, K-450001) according to the 
manufacturer’s protocol. All sgRNA sequences and full HDR donor template sequences can 
be found in supplementary table 1. 
sgRNA and HDR donor template design for generation of iSuicide-Myc
To insert a myctag or double myctag in the iSuicide hybridoma Ig locus, three potential 
sgRNAs targeting the sortag-histag region downstream of the iSuicide-CH3 were designed 
and cloned as described above. iSuicide-Myc and -Myc2 HDR donor templates contain 550 
bp HAs flanking the DSB in the sortag-histag region. Since insertion of HDR template leads 
to removal of this the sgRNA target region, no PAM inactivating mutations were included. 
In between the HAs a glycine-serine linker containing a BamHI restriction site, a stuffer with 
a terminal BsmBI restriction site and a stop codon, a multiple cloning site and a bGH poly 
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A signal were included. This synthetic gene cassette was ordered at IDT and inserted into 
the pSMART HCAmp plasmid (Lucigen, 40041-2) according to the manufacturer’s protocol. 
Full sgRNA and HDR donor template sequences can be found in supplementary table 2.
Generation of iSuicide hybridoma
To generate the iSuicide hybridoma, NLDC-145 cells were nucleofected as described in 
chapter 3, using 1 µg of iSuicide HDR donor template and 1 µg of one of the three poten-
tial sgRNAs. One of the three sgRNAs produced the final iSuicide clone (sgRNA_CH3_3: 
GGATCATTTACCAGGAGAGT, hereafter called sgRNA_CH3). In contrast to the description in 
chapter 3, the transfected population was further selected by the addition of puromycin (3 
µg/mL) every 4 days. Once a puromycin resistant population was established (day 10-14 
after transfection), monoclonal cell lines were generated by a limiting dilution. Subsequent-
ly, two-day old supernatant was sampled from single cell clones (SCC) for the presence of 
histagged, DEC205 binding antibodies by flow cytometry. The clone showing the highest 
Histag signal was selected as the iSuicide clone and was further characterized on DNA and 
protein level. For further experiments and transfections, the iSuicide hybridoma was cul-
tured at 37 °C and 5 % CO2 in CD Hybridoma medium (Thermo Fisher Scientific, 11279023) 
supplemented with 10% heat-inactivated FBS, 2 mM ultraglutamine, AA and 50 µM 2-mer-
captoethanol, hereafter called hybridoma medium.
Transfection and subsequent DmrB selection of iSuicide hybridoma to generate iSuicide-Myc
To insert a Myctag in the iSuicide locus by CRISPR/HDR, iSuicide cells were nucleofected 
with 1 µg of sgRNA_iSuicide_1 or _2 and 1 µg of HDR donor template iSuicide-Myc or -Myc2 
as described in chapter 3. 2 days after transfection cells were transferred to a 10 cm petri 
dish containing serum-free hybridoma medium. On day 4 after transfection, B/B homod-
imerizer (AP20187, Clonetech) was added to a final concentration of 50 nM. Cells were 
subsequently cultured in hybridoma medium with or without FBS, when Protein G based 
isolation of antibodies was required, until a selected population was obtained (bulk popu-
lation). Monoclonal cell lines were obtained by limiting dilution and cultured in serum-free 
hybridoma medium (SCC). 
DNA isolation, PCR and Sanger sequencing
For PCR and sequencing purposes, DNA was isolated from cultured cells by NucleoSpin 
columns (Machery Nagel, 740952.250) according to the manufacturer’s protocol. PCR 
were performed with 100 ng of template DNA, using the high-fidelity Q5 polymerase (NEB, 
M0491) and the recommended concentrations for Q5 enhancer, reaction buffer, dNTPs 
and forward and reverse primers. PCRs covering the whole edited region of the iSuicide 
hybridoma outside of the HAs were performed using primer 1 (CAGAGGCCCATGTTAGAG-
GATGA) and primer 4 (CCTTTTGCCCTCAGTGTTGC) in a thermocycler with following cycling 
conditions: 98°C for 30 s, then 30 cycles of [98°C for 20 s, 68°C for 20 s, 72°C for 150 s], 
followed by a final amplification at 72°C for 5 min. To investigate the locus around the 5’ 
integration site an insert specific PCRs was performed with primers 1 and 2 (CACATTGC-
CAAAAGACGGCA) with following cycling conditions: 98°C for 30 s, then 30 cycles of [98°C 
for 20 s, 68°C for 20 s, 72°C for 60 s], and 72°C for 5 min. To cover the region at the 3’ in-
tegration site a PCR with primers 3 (ATCCAGTCACTTTGCCAGAG) and 4 was performed with 
following cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 20 s, 66 °C for 20 
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s, 72 °C for 150 s], and 72 °C for 5 min. Analysis of Myc and Myc2 HDR donor template in-
tegration in iSuicide cells was performed using primer 1 and 6 (GCTGGCAACTAGAAGGCAC) 
with following cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 20 s, 67 °C for 
20 s, 72 °C for 60 s], and 72 °C for 5 min. Presence of residual iSuicide cells was confirmed 
with a sortag specific PCR using primers 1 and 5 (AAACCCTCCTCCGCTAGCTTTCCC) with fol-
lowing cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 20 s, 69 °C for 20 s, 
72 °C for 60 s], and 72 °C for 5 min. PCR amplification of sgRNA_iSuicide_2 only treated 
iSuicide cells was performed with primers 7 (TTGACTTAACTAGACTTCTGCCCT) and primer 2 
with following cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 20 s, 66 °C for 
20 s, 72 °C for 60 s], and 72 °C for 5 min. 
For sequencing purposes, amplicons were gel purified with NucleoSpin columns (Mach-




Screening of histag presence on antibodies secreted by iSuicide SSCs was performed by in-
cubating JAWSII DEC205 expressing DCs with 50 µl of supernatant for 30 min at 4°C. Sec-
ondary antibody staining was performed in FACS buffer (PBS + 1% FBS) with PE conjugated 
anti-rat Histag (Biolegend, 362603, dilution: 25x) for 20 min at 4° in the dark. DEC205 
expression of JAWSII cells was verified by staining with PE conjugated anti-DEC205 (Bi-
olegend, 138214, dilution: 100x). Binding and histag expression of the selected iSuicide 
clone was verified similarly, using 500 ng of NiNTA-bead purified mAb-iSuicide as primary 
staining. Samples were acquired on the MACS Quant Analyzer 10 (Miltenyi Biotec) flow cy-
tometer using the MACSQuantify software.
Antibody isolation
mAb-iSuicide was isolated from the supernatant of confluent iSuicide production hybrid-
oma culture in T175 culture flasks (Greiner Bio one, e19043hy) by NiNTA-bead chromatog-
raphy (Qiagen, LOT160044511). First 10 ml disposable chromatography columns (Biorad, 
732-1010) were loaded with 1 ml of NiNTA agarose beads and washed with PBS. iSuicide su-
pernatants were supplemented with elution buffer (50 mM NaH2PO4, 300 mM NaCl2, 250 
mM imidazole, pH 8.0 in MQ) to reach 10 mM of imidazole, loaded on the columns three 
times, by recycling of the flow through, and then washed with 10 CV of washing buffer (50 
mM NaH2PO4, 300 mM NaCl2, 20 mM imidazole, pH 8.0 in MQ). Antibodies were eluted 
three times with 0.5 CV of elution buffer. The eluted fractions were concentrated, and buf-
fer exchanged to PBS by ultracentrifugation in Amicon Ultra-15 Centrifugal Filter Devices 
(Merck Millipore, UFC9050) with a molecular weight cutoff of 50 kDa (3x [25 min, 4°C, 
4000 rpm). WT NLDC-145 antibodies or antibodies from modified iSuicide hybridomas, 
either after Myc/Myc2 knockins or after sgRNA_iSuicide_2 only transfections, were iso-
lated from serum-free supernatants of bulk populations or SSC by protein G GraviTrapTM 
columns (GE Healthcare life sciences) according to manufacturer’s protocol. Final antibody 
concentration was determined by Nanodrop at 280 nm with an extinction coefficient of 
1.4. Protein purity and successful isolation was monitored by SDS-PAGE of 10 µl samples of 
every step of isolation.
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SDS-PAGE and western blot
Antibody containing samples such as crude supernatant or purified and concentrated an-
tibodies were resolved on 12% reducing SDS-PAGE gels to visualize heavy and light chain 
sizes. Proteins were stained with SYPRO Ruby Protein Gel Stain (Thermo Fisher Scientific, 
S12000). Subsequently gels were analyzed by fluorescent scanning on the Typhon Trio+ gel 
scanner (GE Healthcare Life Sciences) and analyzed with Fiji33. For western blot, SDS-PAGE 
gels were transferred to a polyvinylidene difluoride membrane and blocked with 3% bovine 
serum albumin in PBS-Tween20 0.1 %. Blots were subsequently stained with monoclonal 
rabbit anti-Histag antibody (Abcam, ab213204, dilution: 5000x), goat anti-rabbit IgG (H + 
L) (IRD800) (LI-COR, 926-32211), and goat anti-rIgG (H + L) (AF680) (Thermo Fisher Scien-
tific, A-21096). Myctag stainings were performed with a mouse anti-Myctag antibody (Kind 
gift from Jieqiong Qu, RIMLS) (IRD800). Western blots were imaged on the Odyssey CLx 
imaging system (LI-COR) and analyzed in ImageStudio lite (v5.2.5).
Viability assay
To investigate the DmrB concentration at which 100% of target cells are dead a DmrB 
titration was performed. Therefore, 0.03x106 iSuicide cells were seeded in 200ul in duplo 
of serum-free hybridoma medium in a v-shaped 96-well plate and incubated with different 
concentrations of DmrB ranging from 1x10-12 to 1x10-7 M for 24 h at 37 °C. Cells were sub-
sequently stained with propidium iodide (Miltenyi Biotec, 130-093-233, dilution: 100x) by 
MACS Quant automated labeling and directly acquired and analyzed as described before. 
Concentrations were transformed to logarithmic values and plotted against the percentage 
of life cells compared to an untreated control using GraphPad Prism (v8.1.1).
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Supplementary figures and tables
Supplementary Figure 1 | SCC FACS screen and NiNTA-bead isolation of mAb-iSuicide (A) Histag signal (gMFI) 
of antibodies in the supernatant of iSuicide SCC from transfection of NLDC-145 with sgRNA_CH3_1/-_2/-_3 
and iSuicide HDR donor template. 2-day old supernatant of limiting dilutions was incubated with the DEC205 
expressing cell line JAWSII and stained with anti-Histag-PE to verify presence of the C-terminal histag. - = mAb-
DEC205 primary staining, + = fab’DEC205-srt-his10 primary staining. (B) Reducing SDS-PAGE gel stained with 
SYPRO Ruby of samples taken during NiNTA-bead isolation of antibodies from iSuicide producing clone (sgRNA_
CH3_3.38). The right gel shows the final concentrated and buffer exchanged mAb-iSuicide, compared to mAb-
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Supplementary table 1 | Genetic elements and sequences used for the generation of the iSuicide hybridoma. The 
table depicts the sequences for the HDR donor templates used for creating the iSuicide hybridoma. Moreover, the 



















































































































Supplementary table 2 | Genetic elements and sequences used for the generation of iSuicide-Myc and -Myc2. 
The table depicts the sequences for the HDR donor templates used for creating the iSuicide-Myc and -Myc2 hy-
bridomas. Moreover the 2 sgRNA sequences that were used for the insertion of Myctag templates and the induc-
tion of NHEJ are depicted. The Myc and Myc2 sequences, indicated in italics, are interchangeable, meaning either 
one or the other is present in the template.  MCS = Multiple cloning site.
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Abstract
Dendritic cell (DC)-targeting vaccines have evolved as promising assets of cancer treat-
ment. In vivo targeting of DCs is facilitated by antibody-antigen (AA) conjugates that target 
DC surface receptors and help to initiate an anti-tumor immune response. Advances in 
antibody engineering and chemistry, have led to the generation of AA conjugates that are 
linked together in a predefined site-specific manner, in order to safeguard antibody affin-
ity, vaccine uniformity and guarantee reproducibility. The use of AA conjugates enables 
efficient antigen delivery and subsequent presentation in specific DC subsets, as shown in 
numerous studies. However, such AA complexes lack the essential adjuvant to induce DC 
maturation, resulting in suboptimal T cell responses.
Here, we developed a molecularly defined DEC205-targeting antibody-antigen-adjuvant 
conjugate (AAA) by a combination of genetic engineering, chemo-enzymatic ligation and 
bioorthogonal chemistry. Our results demonstrate the feasibility of site-specific conjuga-
tion of both the peptide antigen and the adjuvants using CRISPR based antibody engineer-
ing and chemistry. We show that AAAs are able to bind DEC205 of a DC cell line and can 
induce T cell proliferation in vitro, underlining the potential of this concept. We anticipate 
that our DEC205-targeting AAA will set an example for the next generation DC-targeting 
vaccines resulting in highly effective T cell priming. 
Introduction
Dendritic cell (DC)-targeted immunotherapy is a form of cancer treatment that aims at de-
livering tumor antigens to DCs. The desired result would be CD4+ and CD8+ T cell activa-
tion to mount an antigen-specific anti-tumor immune response. The targeted delivery of 
antigens in vivo to DCs can be facilitated through antibodies that bind to specific/endocytic 
DC surface receptors. A commonly targeted receptor on DCs is the C-type lectin DEC205 
(CD205), which internalizes once bound by an antibody-antigen (AA) conjugate and leads to 
presentation of antigen epitopes in the context of major histocompatibility complex I and 
II (MHCI and II)1–6. By exploiting this principle, several groups have shown successful anti-
gen and/or adjuvant vaccine delivery, Although promising results were obtained in these 
studies, DC-targeting AA conjugates never reached wide-spread clinical applicability due 
to several challenges. First and foremost, it is challenging to create a molecularly defined 
vaccine. This entails having full control over the molecular components of the vaccine, how 
they are linked together, and at which location of the antibody this is performed. In the 
past, primarily random coupling of antigens to antibodies has been used, using reactive 
amine or thiol groups on accessible lysines and cysteines of the antibody3,13. These ran-
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dom approaches inherently yield heterogeneous antigen-to-antibody ratios and antibody 
binding affinity can be compromised due to payload conjugation near the N-terminus re-
sulting in steric hindrance of the antibody binding site (Fig. 1A). In the past, site-directional 
approaches have been developed, making use of recombinant expression of fusion pro-
teins, introduction of unnatural amino acids or the use of chemo-enzymatic ligation9,11,14,15 
(Chapter 1). These approaches allow for the linkage of antigen payloads at specific sites in 
the antibody, yielding molecularly defined vaccines with a lower risk of impaired antibody 
binding affinities (Fig. 1A). Another challenge within this context is the lack of adjuvancy. 
Adjuvants are necessary for complete maturation of DCs and induction of the expression of 
co-stimulator molecules to unleash full T cell activation. 
Currently, adjuvants are administered together with AA conjugates. In turn, due to dif-
ferences in pharmacokinetics, adjuvants and AA conjugates might not reach the same DCs 
which can result in immature and tolerogenic DCs. These DCs will not express co-stimulato-
ry molecules and will be incapable of fully activating T cells. Consequently, T cells can enter 
a state of unresponsiveness and anergy, which decrease the efficacy of the vaccine16,17. In 
order to solve this issue, synchronized spatiotemporal delivery of antigens and adjuvants 
is desired to localize both components at the same DC. To achieve antigen and adjuvant 
codelivery and thereby maturation and activation of the antigen-presenting DC, a tri-func-
tional molecule is needed that contains a DC targeting moiety, an antigen payload and an 
adjuvant (Fig. 1B).
Although the advantage of co-delivering antigens and adjuvants is well established in 
carrier-based vaccination using for example nanoparticles18,19, there is only one report so 
far addressing the synthesis of tri-functional antibody-antigen-adjuvant (AAA) DC-target-
ing vaccines20. In that study recombinant anti-DEC205 monoclonal antibodies (mAb) were 
C-terminally fused to the egg-white protein ovalbumin (OVA) and chemically linked to a 
short form of the toll-like receptor (TLR) 9 adjuvant CpG via reactive amines on the an-
tibody. Although these antibody-antigen-adjuvant (AAA) conjugates showed enhanced T 
cell activation capabilities compared to AA conjugates, the binding of these conjugates to 
DCs was observed to be primarily mediated by CpG and not anti-DEC205. We hypothesize 
that this effect could have been caused by the non-directed coupling of CpG to the anti-
body, thereby impairing the binding sites of mAb DEC205 leading to the loss of targeting 
functionality and altered uptake. In order to facilitate DEC205-mediated uptake, proper 
cross-presentation of antigens to guarantee optimal effectiveness of the vaccine, we be-
lieve that the targeting functionality has to be maintained by using site-directional conju-
gation approaches for both, antigens and adjuvants. 
In this study, we developed a synthetic strategy for the generation of molecularly de-
fined AAA vaccines using genetic engineering, site-specific chemoenzymatic conjugation 
and bioorthogonal chemistry (Fig. 1C.1). In this way, we built a DEC205-targeting AAA vac-
cine that is site-specifically conjugated with both antigen and adjuvant. To achieve this 
goal, we made use of anti-DEC205 Fab’ fragments containing a C-terminal LPETGG (sortag) 
motif obtained through CRISPR-Cas9 genome editing in the DEC205 hybridoma NLDC-145, 
as described earlier21 (Fig. 1C.1). By using Fab’ fragments we aim to accommodate tissue 
penetration and prevent Fc-mediated uptake by off-target cells, as observed with intact 
antibodies22. Subsequently, we use the sortag motif to attach an azido-lysine-containing 
CD4+ or CD8+ antigen epitope of OVA via sortase-mediated ligation (Chapter 1) (Fig. 1C.2). 
Finally, a dibenzocyclooctyne (DBCO)-functionalized TLR7 ligand is introduced as adjuvant 
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AAA synthesis strategy: hybridoma engineering, antigen sortagging, adjuvant click chemistry
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Figure 1 | Graphical representation of coupling strategies and synthetic strategy developed in this study. 
(A) Random vs. site-specific coupling of antibodies with a payload molecule. (B) Structure of a molecularly defined 
tri-functional antibody including its binding regions (1), adjuvants (2) and tumor antigens (3)(AAA conjugate). The 
right image shows how these AAA conjugates are targeted to a dendritic cell (DC), taken up via DEC205-mediated 
endocytosis (1) and lead to DC maturation via TLR stimulation in the endosome (2). At the same time antigens are 
processed in the endosomal compartment and presented on the DCs surface (3). (C) (1) Overview of the synthetic 
strategy for the generation of molecularly defined AAA conjugates as described in this study based on genetic 
engineering of the NLDC-145 hybridoma immunoglobulin heavy chain locus, sortase-mediated ligation with 
antigens and copper-free click chemistry of adjuvants. (2) Steps and intermediates of sortase-mediated ligation 
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via a strain-promoted azide%alkyne cycloaddition (SPAAC) reaction (Fig. 1C.2). We chose to 
trigger TLR7 since it is localized in endosomal compartments that coincide with the inter-
nalization route of DEC205, which eventually leads to presence of both adjuvant and TLR 
in the same compartment. In this proof-of-concept study, we built and characterized these 
constructs and show for the first time that molecularly defined tri-functional DC vaccines 
can be produced by a combination of genetic and chemical techniques. In vitro experi-
ments underline the functionality of our AAA-vaccines in terms of T cell proliferation, but 
further in vivo studies have to evaluate the added benefit of the covalent attachment of the 
adjuvant molecules to the AA-conjugates. 
Results
AAA conjugate synthesis, characterization and DEC205 binding
In order to build DEC205-targeting AAA conjugates we combined genetic and chemical 
antibody engineering. First, we produced anti-DEC205 Fab’ fragments (Fab’DEC205) con-
taining a C-terminal tetra-glycine and serine linker, a LPETGG sortag motif and a hexa-his-
tidine tag (histag) by CRISPR-Cas9 editing of the NLDC-145 hybridoma heavy chain locus21. 
We inserted the glycine-serine linker for extra flexibility, the LPETG sortag motif to enable 
sortase-mediated site-directional ligations and the histag for screening and isolation pur-
poses. Next, sortaggable antigenic peptides containing dominant CD4+ and CD8+ OVA 
epitopes were synthesized by standard solid-phase peptide synthesis (GGGK(N3)FRISQA-
VHAAHAEINEAGR (IH7) and GGGK(N3)FRSIINFEKL, (IH1), respectively. These peptides con-
tain an N-terminal triglycine sortase recognition motif that acts as the nucleophile in the 
sortase reaction, an #-azido-lysine that can be used to attach an adjuvant by copper-free 
click chemistry, a phenylalanine-arginine di-peptide to increase proteasomal processing11 
and the respective OVA antigen epitope. IH1 and IH7 were subsequently conjugated to 
Fab’DEC205 by calcium-dependent 3M sortase mediated ligation23 using optimized reac-
tion conditions (25 equivalents IH1 and 0.75 equivalents 3M sortase or 75 equivalents IH7 
and 1 equivalent 3M sortase, respectively). After 1h reaction, the ligation was terminated 
by the addition of EDTA. The excess sortase and potential unreacted starting material were 
removed via Ni-NTA bead gravity flow chromatography, followed by removal of excess pep-
tide by fast protein liquid chromatography (FPLC). The conjugates Fab’IH1 and Fab’IH7 were 
obtained in good yield (50 % and 33 %, respectively) by concentration of fractions contain-
ing the desired Fab’ fragments by spin filtration (Fig. 2A and C). Having the azide-function-
alized AA-conjugates in hands they were reacted with a 25 equivalent molar excess of the 
TLR7 ligand functionalized with a strained alkyne (TLR7-DBCO24,25 (Fig. 1B)) for 2 h at 37 °C 
to obtain the AAA-conjugates Fab’IH1-TLR7 and Fab’IH7-TLR7. Subsequent purification by 
FPLC and concentration by size-exclusion spin filtration gave the final products in modest 
to good yield (Fab’IH1-TLR7 23 % and Fab’IH7-TLR7 52 %). 
The obtained intermediate and final conjugates were analyzed by sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis (SDS-PAGE). In absence of a nucleophilic donor 
the sortag containing heavy chain of Fab’DEC205 is hydrolyzed by sortase and decreases 
in size as compared to the starting material (Fig. 2A and C, lane 1 and 2). Addition of IH1 
Figure 1 continued | and click reactions depicting the involved amino acids in colored circles. Chemical structures of 
the TLR7-DBCO   adjuvant and IH1 and IH7 peptides are indicated on the right. IH1 contains the CD8+ OVA epitope 
(OTI) (GGGK(N3)FRSIINFEKL). IH7 contains the CD4+ OVA epitope (OTII) (GGGK(N3)FRISQAVHAAHAEINEAGR).
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or IH7 prevents hydrolysis of the thioester sortase-heavy chain intermediate and leads to 
conjugation, illustrated by a small shift in size of the heavy chain (Fig. 2A and C, lane 3). In 
both cases the addition of TLR7-DBCO to Fab’IH1 and -IH7 increases the size of the heavy 
chain slightly (Fig. 2A and C, lane 4). To confirm that the click reaction was complete and 
all free azido-lysines have been reacted with TLR7-DBCO we performed a second, analytical 
click reaction with a 5kDa poly-ethylene glycol-DBCO (PEG5000-DBCO). This reaction with 
Fab’IH1 and -IH7 indeed increased the size of the heavy chain (Fig. 2A lane 6 and fig. 2C lane 
5). However, for both Fab’IH1-TLR7 and Fab’IH7-TLR7 we did not observe a shift in size after 
the click reaction with PEG5000-DBCO, underlining that all azides are occupied with adjuvant 
(Fig. 2A lane 7, fig. 2C lane 6). Further structural validation was obtained by matrix-assisted 
laser desorption ionization time of flight mass spectrometry (MALDI-TOF). Both Fab’IH1-
TLR7 and Fab’IH7-TLR7 show the expected differences in heavy chain mass relative to un-
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Figure 2 | Characterization of 
Fab’IH1-TLR7 and Fab’IH7-TLR7. (A) 
Sypro Ruby stained reducing SDS 
page gel showing different products 
of a sortase and click reaction of 
Fab’IH1 with TLR7 reaction. (B) 
MALDI-TOF chromatogram showing 
masses of Fab’DEC205, Fab’IH1 and 
Fab’IH1-TLR7. (C) Sypro Ruby stained 
reducing SDS page gel showing 
different products of a sortase and 
click reaction of Fab’IH7 with TLR7 
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Finally, we investigated the ability of our modified Fab’ fragments to bind the target 
DEC205 receptor. We incubated increasing concentrations of the intermediates and final 
conjugates with  DEC205-expressing JAWSII cells (a mouse DC cell line) and quantified an-
tibody binding by a secondary anti-Kappa LC staining. We observed a decrease in geomet-
ric mean fluorescence intensity (gMFI) of the Kappa LC signal across the concentration 
range the more components were attached to the Fab’ fragments (Suppl. fig. 1A). While 
the plateaus of the curves of Fab’IH1/-IH7 and Fab’IH1/-IH7-TLR7 are lower, they have a 
similar slope and trajectory as the binding curve of Fab’DEC205. We hypothesize that this 
is rather caused by the sterical hindrance of the Kappa LC epitope by the added antigen and 
adjuvant, resulting in fewer anti-Kappa LC antibody bound, than by a decreased binding af-
finity. Therefore, we normalized the gMFI to the highest signal obtained for each condition 
and observed a similar binding pattern for different forms of Fab’ conjugates compared 
to Fab’DEC205 (Fig. 2E). The AAA concentration where halve of the binding is observed 
(EC50) is moreover comparable for the different constructs (Fig. 2E). This suggests that the 
antibody binding ability of AAA conjugates is maintained through positional coupling of the 
payloads.
AAA conjugates suboptimally mature DCs and can induces T cell proliferation in vitro
After having confirmed successful synthesis of the AAA conjugates and the binding to 
DEC205, we asked whether these constructs can be used to mature DCs, induce antigen 
presentation and subsequently activate T cells. To test this, we incubated JAWSII DCs with 
0.04, 0.25 or 1 µM of AAs and AAAs for 24h and analyzed the expression of maturation 
markers CD80, CD86, CD83 and MHCI by FACS (Fig. 3A). For CD80, CD83 and MHCI no ob-
vious differences in expression levels could be obtained. All values are either below or close 
to the expression levels of untreated controls. Although mildly, CD86 expression levels are 
increased upon incubation with increasing concentrations of Fab’IH1-TLR7. For Fab’IH7-
TLR7 a similar but weaker trend can be observed. To verify whether epitopes can be liber-
ated from the AA and AAA conjugates and presented to T cells, we performed an in vitro T 
cell proliferation assay. We incubated granylocyte macrophage colony-stimulating factor 
(GM-CSF) bone marrow-derived DCs (BMDCs) for 2h with 0.04, 0.2 and 1 µM of Fab’IH1 
with or without soluble TLR7, or Fab’IH1-TLR7, as well as control conditions incubated with 
LPS and OVA257-264 (5nM) or OVA (0.04, 0.02 and 1 mg/ml). After two hours, BMDCs were 
washed and incubated with OVA257-264:MHCI recognizing, fluorescently labelled T cells (OTI). 
After three days of co-culture, the proliferation of T cells was assessed by FACS measuring 
the dilution of the fluorescent signal in T cell (Fig. 3B). This revealed that BMDCs that were 
incubated with Fab’IH1-TLR7 induced a stronger dilution of fluorescence in OTI T cells than 
BMDCs that were pre-incubated with Fab’IH1 alone or together with soluble TLR7. Although 
the latter two conditions also induced several division cycles in T cells, a population of un-
proliferated cells remained, suggesting incomplete T cell activation. When calculating the 
division index based on the fluorescence dilution it can be observed that all three concen-
trations of Fab’IH1-TLR7 induce strong division in OTI T cells (Fig. 3C). Interestingly, higher 
concentrations of Fab’IH1 alone or together with soluble TLR7 do show reduced prolifera-
Figure 2 continued | reaction. (D) MALDI-TOF chromatogram showing masses of Fab’DEC205, Fab’IH7 and 
Fab’IH7-TLR7. (E) Binding capacity of different intermediates of AAA conjugates to the DCE205 receptor on JAWSII 
DCs, visualized with a secondary anti-Kappa light chain antibody. n = 1.
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Figure 3 | Proof-of-concept functional characterization of AAA conjugates. (A) Expression levels (gMFI) of CD80, 
CD83, CD86 and MHCI on JAWSII DCs after incubation with different concentrations of reagents as indicated in 
the color coding. (B) Fluorescence dilution of the CTV dye in OTI T cells after incubation with GM-CSF BMDCs 
that have been incubated with different reagents as shown next the histogram. (C) Division index analysis of OTI 
T cells incubated with treated GM-CSF BMDCs. Marker expression of OTI T cell surface molecules CD25 (D), PD-1 
(E) and CD44 (F) after co-culture with treated BMDCs. Color coding referring to the different treatments for (C), 
(D), (E) and (F) is depicted below the figure. Concentrations for OVA are given in mg/ml, while other reagents are 










































































tion stimulatory capacity. Next to the proliferation of OTI T cells we also investigated T cell 
activation markers CD25, CD44 and PD-1. Expression levels of CD25 (Fig. 3D) and PD-1 (Fig. 
3E) show a similar pattern as observed for the division index, with Fab’IH1-TLR7 inducing 
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the highest expression of activation markers. CD44, typically upregulated after antigen ex-
perience in mature T cells, remains lower in OTI T cells incubated with Fab’IH1-TLR7 treated 
BMDCs, whereas it shows increased expression of OTI T cells incubated with Fab’IH1 alone 
or in combination with soluble TLR7 (Fig. 3F).
Collectively, these results suggest that Fab’IH1-TLR7 and Fab’IH7-TLR7 can induce a slight 
increase in CD86 expression in JAWSII DCs. Moreover, Fab’IH1-TLR7 leads to enhanced pro-
liferation and activation of T cell in vitro compared to Fab’IH1 alone or in combination  with 
equimolar amounts of soluble TLR7. These results are preliminary and certainly require 
more extensive functional in vitro and in vivo experiments with more repeats and controls 
to support the added value of site-directionally attached adjuvants to DC-targeted AA con-
jugates. 
Discussion and conclusion
Currently, the only report describing an AAA conjugate for DC-targeted immunotherapy in-
volves random coupling of a CpG adjuvant to native lysine residues on an anti-DEC205-OVA 
fusion protein. Due to heterogenous localization of lysines on antibodies, these ligations 
are destined to produce heterogeneous AAA conjugates, with varying amounts of CpG at-
tached (1-10) to different portions of the antibody. This in turn can impede the pharmacoki-
netics and targeting efficacy underlined by the lack of DEC205-mediated uptake26. In order 
to produce homogeneous AAA conjugates with predictable antibody-to-payload ratios and 
controlled conjugations sites, this project set out to explore site-directional functionaliza-
tion of Fab’ fragments with antigens and adjuvants. 
With this in mind, we used sortase-mediated ligation to introduce the CD4+ or CD8+ 
epitope of OVA at the C-terminus of Fab’DEC205, containing an #-azido-lysine click han-
dle. Using click-chemistry we then bio-orthogonally inserted a TLR7 adjuvant to the 
Fab’DEC205-antigen conjugate. In line with our hypothesis, the combination of sortase-me-
diated ligation of an azide-functionalized antigen to Fab’DEC205 and the subsequent click 
reaction with TLR7-DBCO enabled us to create a molecularly defined AAA conjugate. The 
structural integrity and correct positional coupling was validated by analysis on SDS-PAGE 
gels and MALDI-TOF. As expected, these conjugates also maintained binding capacity to 
DEC205 on JAWSII DCs, comparable to unmodified Fab’DEC205. In preliminary functional 
experiments, we moreover showed that AAA conjugates can induce a slight increase in 
CD86 expression on DCs and that these DCs in turn can induce T cell proliferation, yielding 
activated CD25+, PD-1+, CD44+/- T cells. 
To our knowledge, this is the first description of a DC-targeting vaccine that contains a 
site-specifically conjugated antigen and adjuvant. Although the generation and structural 
characterization of these AAA conjugates was achieved, we require repeats and controls 
for proper immunological and functional evaluation of the vaccines, and to draw definite 
conclusions. With the knowledge we gained from this proof-of-concept study we can 
moreover adjust the experimental design to better investigate the working mechanism of 
the vaccines. First of all, we only observed a mild effect on DC maturation, when we in-
cubated JAWSII DCs with three concentrations of conjugates. We hypothesize that this 
can be partly attributed to the usage of a DC cell line rather than primary DCs or BMDCs, 
which better resemble the natural kinetics of maturation. Even the use of LPS, the potent 
TLR4 agonist, did not induce the expected CD80 or CD83 upregulation, which hints at this 
cell line dependent effect. Second, the quantity of adjuvant certainly matters. As opposed 
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to non-positional coupling where multiple adjuvants can be introduced, we only add one 
adjuvant molecule to the antibody fragment, which can lead to fewer triggers of the TLR 
signaling cascade. Therefore, we are currently constructing a clickable TLR7 multimer to 
increase the adjuvant quantity on our AAA conjugates. To get a better impression of DC 
maturation besides surface marker expression, we could moreover investigate the secre-
tion of cytokines such as IL-12 by an enzyme-linked immunosorbent assay after the incu-
bation with AAA conjugates27. Third, it is important to investigate whether the observed 
effects are mediated by DEC205 targeting and uptake using a DEC205 knockout cell line, 
blocking of the DEC205 receptor or using AAA conjugates that target an unspecific recep-
tor. To address the latter point we started constructing AAA conjugates specific for human 
DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN) or murine 
CD20, expressed on B cells, that both not target murine DCs. Finally, we think that the 
benefits of a site-specifically generated tri-functional AAA conjugate above non-positional 
AAA conjugates or systemic adjuvant injection can only be appreciated in an in vivo setting 
where all of the three functions can fully unfold.
Once established, this system can also be employed for other murine or human DC 
targets, antigens and adjuvants. One can envision to target different subsets of DCs with 
respective targeting antibodies and specialized adjuvants to enhance DC crosstalk and 
finetune the resulting immune response28. Using our genetic engineering platform of hy-
bridomas, we can easily produce new sortaggable antibodies against other DC receptors 
as long as the isotype of the hybridoma is known or possible to determine. In this way we 
have already produced sortaggable DC-SIGN and CLEC9A Fab’ fragments. Moreover, differ-
ent patient specific neoantigen epitopes can be introduced through sortagging in different 
quantities, which could result in a more efficient anti-cancer immune response29(Chapter 
5). To explore this, we have already synthesized sortaggable neoantigen peptides that are 
described for the B16F10 melanoma model30,31. Similarly, we are investigating site-direc-
tional coupling of antigen encoding messenger RNA (mRNA) to DC-targeting antibodies, 
given the clinical success of untargeted, multiplex mRNA neoantigen vaccines32–34. Both 
approaches have advantages and disadvantages that have to be taken into account when 
evaluating their potency. While peptide antigens are easy to manufacture and available 
off-the-shelf, they are limited in length, require HLA matching and have a low MHC-peptide 
half-life35,36. In contrast, mRNA encoded antigens are actively translated by the cell, which 
increases the antigen load and prolongs antigen presentation. Additionally, the mRNA mol-
ecule can be sensed by endosomal TLRs of the DC and lead to their activation and matu-
ration. Although multiple antigen epitopes can be encoded in one mRNA the size of the 
final antibody-mRNA conjugate will be bigger than that of the antibody-peptide equivalent, 
which potentially impacts the pharmacokinetics of the vaccine37. These few examples un-
derline the diverse opportunities that this plug-and-play platform presents and indicates 
how it can be used in the future to push DC-targeted immunotherapy to new frontiers.
Taken together, we here present a proof-of-concept for constructing the next generation 
of single-molecule DC-targeted vaccines for cancer immunotherapy. We believe that using 
chemo-enzymatic strategies for site-directional antibody modification with antigens and 
adjuvants is crucial to maintain full control over the vaccine structure and efficacy. From 
an immunological perspective, this vaccine structure facilitates the co-delivery of antigens 
and adjuvants to the same DC, which is necessary for proper T cell maturation and func-
tion38–40. This spatiotemporally synchronized delivery of antigen and adjuvant has been 
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shown to be important for the induction of antigen cross-presentation to CD8+ T cells, 
which further potentiates the resulting immune response41. For this reason, we are confi-
dent that this platform can contribute to a more efficient DC-targeted immunotherapy and 





The DEC205 expressing cell line JAWSII (ATCC, CRL-11904) was purchased from ATCC and 
cultured in !MEM (Gibco, 2099595) supplemented with 20 % FBS, NEM (Gibco, 2165257, 
100x), AA, Sodium pyruvate (Gibco, 1881816, 100x), sodium bicarbonate (Gibco, 2078819, 
100x), 50 µM 2-mercaptoethanol, 2mM Ultraglutamine and freshly added granylo-
cyte-macrophage colony-stimulating factor (GM-CSF, Miltenyi Biotec, 130-095-735) (5 ng/
ml). JAWSII were tested negative for the presence of mycoplasma (Lonza, LT07-418).
Solid-phase peptide synthesis (SPPS) of antigens
20-75 mL polypropylene syringes with a porous disc were used for SPPS. For short reaction 
times (<5 min), the reactions were manually stirred with a Teflon stick, and for long reac-
tions times (>30 min) the reactions were stirred on a Unimax 1010 shaker. In between cy-
cles, solvents were removed by vacuum filtration. All the reactions were carried out at room 
temperature (RT) (at ca. 25 °C). Wang resin with pre-loaded amino acids was used for pep-
tide synthesis. Peptide coupling was performed by adding a pre-activated (5 min) solution 
of Fmoc-Aaa-OH/DIPCDI/Oxyma Pure (3 equiv. each respect to resin loading) into the free 
amino-peptidyl resin. Each coupling was carried out at RT for 40 min with constant shak-
ing. Kaiser or chloranil test for N-terminal primary amines or proline derivatives respective-
ly, were performed after each coupling to evaluate coupling completion. Re-couplings were 
performed after positive Kaiser/chloranil test to ensure coupling. After cleavage peptides 
were precipitated by ultracentrifugation using an Allegra™ 21 R (Beckman Coulter) centri-
fuge and purified on Preparative-HPLC-ESI system (Waters) using C18 reverse phase col-
umn. Peptide masses were initially predicted by ChemDraw Professional 15.0 (PerkinElmer, 
Massachusetts, USA) and compared to acquired masses after LC-MS measurements. 
IH1: GGGK(N3)FRSIINFEKL. Isolated 198 mg, Analysis C18 column, gradient from 95:5 
to 0:100 H2O/ACN in 37min, RT  = 18.33 min, purity 98.7 %. Mass expected: C72H114N22O19 
= 1591.84 g/mol. Mass observed: 1592.52, 796.64, 531.32 corresponding to M+H+, 
M+2H2+/2 and M+3H3+/3 respectively.
IH7: GGGK(N3)FRISQAVHAAHAEINEAGR. Isolated 145 mg, Analysis C18 column, gradient 
from 95:5 to 0:100 H2O/ACN in 37min, RT  = 16.21 min, purity 97.2 %. Mass expected: 
C101H160N38O31 = 2402.63 g/mol. Mass observed: 1202.08, 801.76, 601.64, 481.76 corre-
sponding to M+2H2+/2, M+3H3+/3, M+4H4+/4, M+5H5+/5  respectively.
Sortase-mediated ligation of antigens to Fab’DEC205
Sortaggable Fab’DEC205 was obtained as described in previous work21. A trimutant sortase 
A '59 (3M) was produced and purified as reported earlier42,43. These and other reagents 
were added in the following order to the sortase buffer (TRIS): CaCl2 (10 mM), DMSO (5-
10 %), GGGK(N)FRISQAVHAAHAEINEAGR (IH7) or GGGK(N)FRSIINFEKL (IH1) (0.5-1.5 mM), 
Fab’DEC205 (20 µM) and 3M sortase A (10-20 µM). The reaction mixture was incubated at 
37°C for 1 h. To terminate the sortase reaction, EDTA (10 mM) was added to the mixture. 
Subsequently, the mixture was loaded onto Ni-NTA beads to remove histagged products 
(sortase and unreacted Fab’DEC205) and the excess of peptide was then removed by FPLC. 
The product was then analyzed on SDS-PAGE (12% acrylamide), MALDI-TOF and LC-MS.
99
DC!TARGETING ANTIBODY!ANTIGEN!ADJUVANT CONJUGATE VACCINES
5
Generation of Fab’IH1 and -IH7-TLR7 through click reactions.
Click reactions to attach TLR7-DBCO (kind gift from Dr. Esser-Kahn group) to purified AA 
conjugates were performed in 10 % DMSO using 25 and 50 equivalents of TLR7-DBCO for 
Fab’IH1 and -IH7, respectively. Reaction mixture was incubated at 37 °C for 2h (Fab’IH1) or 
2.5 h (Fab’IH7) and afterwards purified and buffered in PBS by FPLC with a collection win-
dow of 15-50 min. Both final products were furthermore validated to be free of endotoxins 
(Radboudumc, Pharmacy).
SDS-PAGE
Purified and concentrated antibodies and conjugates were analyzed by SDS-PAGE to verify 
the size of heavy and light chains and the attached molecules. Therefore, samples were re-
solved under reducing conditions 12 % SDS-PAGE and visualized by SYPRO Ruby Protein Gel 
Stain (Thermo Fisher Scientific, S12000) on the Typhon Trio+ gel scanner (GE Healthcare 
Life Sciences) and analyzed with Fiji44.
DEC205 binding assay
To determine whether modified Fab’DEC205 conjugates maintain binding capacity to 
DEC205 we incubated 0.02x106 JAWSII DCs with titrating amounts of Fab’DEC205 and 
Fab’DEC205 conjugates in for 25 min at 4 °C in FACS buffer. After washing, we stained 
bound antibodies with anti-Kappa-LC-PE (Biolegend, 407806, dilution: 400x) for 25 min 
at 4 °C in the dark. Samples were washed again with FACS buffer and measured by flow 
cytometry as described below.
DC maturation assay
To assess maturation of DCs cells by AA and AAA conjugates, 0.04x106 JAWSII cells were 
seeded in a 96-well U-bottom-shaped plate and incubated with different concentrations 
of conjugates as indicated in the results section. As positive control LPS was added at a 
concentration of 1 µg/mL. Untreated JAWSII cells were used as negative control. Cells were 
subsequently cultured for 24 h at 37 °C. After overnight incubation cells were removed by 
incubation with cold PBS/FBS/EDTA buffer and scraping.!Maturation markers were then 
analyzed by flow cytometry.
Flow cytometry
DEC205 expression of JAWSII cells was verified by staining with PE conjugated anti-DEC205 
(Biolegend, 138214, dilution: 100x). Maturation of JAWSII after incubation with AA and AAA 
conjugates was assessed by staining with anti-CD80-488 (Biolegend, 104716, dilution: 
1000x), anti-CD86-APC/Cy7 (Biolegend, 105030, dilution: 100x), anti-CD83-BV510 (BD 
Biosciences, 563222, dilution: 100x) and anti-H-2Kb/H-2Db(MHCI)-PE (Biolegend, 114608, 
dilution: 800x).
Viability of T cells was visualized by staining with e780 eFluor (eBioscience, 65-0865-18, 
dilution 1000x) in PBS for 30 min at room temperature in the dark. For analysis of T cell ac-
tivation, T cells were subsequently stained for 30 min at 4°C in the dark in FACS buffer with 
anti-CD25-FITC (Biolegend, 101908, dilution: 100x), anti-CD44-PE/Cy7 (Biolegend, 103030, di-
lution: 100x) and anti-PD-1-PE (BD Bioscience, 551892, dilution: 50x). Samples were acquired 
on the BD FACSLyric (BD) using the BD FACSuite. Acquired samples analysis and proliferation 




All animal procedures were approved by the Animal Welfare Body of the Animal Research 
Facility (Radboudumc, Nijmegen). For the generation bone-marrow derived DCs, 5-15 
weeks old female WT C57BL/6J mice (Charles River, France) were sacrificed and bone mar-
row cells were isolated from hindlegs as described below. CD8 T cells, reactive to ovalbu-
min, were isolated from lymph nodes and spleens from 5-15 weeks old female transgenic 
OTI mice, (Charles River, France) as described below.
Generation of BMDCs
DEC205 expressing BMDCs were generated by supplementation with GM-SCF. In short, 
bone marrow cells were flushed from femur and tibia of WT mice and red blood cells were 
lysed in ammonium chloride buffer. Subsequently 4x106 isolated cells were seeded in 13 mL 
of BMDC medium (RPMI1640 (Thermo Fisher Scientific, 11875093) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 2 mM ultraglutamine (Lonza, BE16-605E/U1), 
1$ antibiotic-antimycotic (AA) (Thermo Fisher Scientific, 15240062) and freshly added 50 
µM 2-mercaptoethanol (Thermo Fisher Scientific, 21985023)) and supplemented with 20 
ng/mL GM-CSF. Cells were incubated for three days at 37 °C and 5% CO2. On day 3, 4 mL of 
BMDC medium was added containing 37.2 ng/mL GM/CSF. On day 6, 1 mL of BMDC medi-
um was added with 158 ng/mL GM-CSF. On day 7, floating cells were harvested. Purity and 
expression of DEC205 was assessed by FACS, staining with PE conjugated anti-DEC205 
(Biolegend, 138214, dilution: 100x) and anti-CD11c (BD, 553802, dilution: 100x).
In vitro T cell proliferation
OTI T cells were isolated from lymph nodes and spleen by CD8+ MACS (Miltenyi Biotec, 130-
104-454 and 130-104-075). Cells were then stained with CellTrace Violet (CTV, Invitrogen 
C34557A, dilution: 500x) by resuspending in 500 µL PBS + 2% FBS and adding 500 µL of 
PBS with CTV. Cell suspensions were subsequently incubated for 30 min in a water bath at 
37 °C while manually shaking for the first 5 min and finally quenched with 10 mL of BMDC 
medium followed by 10 min of incubation in the water bath. Cells were pelleted and resus-
pended in BMDC medium with fresh BME until further use. Purity and CTV staining effi-
ciency were assessed by FACS, staining with APC conjugated anti-CD8 (Biolegend, 100712, 
dilution: 600x). Purity of T cells used in these experiments was 95%.
For investigating in vitro T cell proliferation, 2x104 BMDCs were incubated in a 96 round 
bottom well plate for 2 h at 37 °C with different concentrations of antibody-antigen conju-
gates, OVA and OVA peptides, as indicated in the results section. Afterwards, BMDCs were 
washed and 1x105 isolated and stained OTI T cells were added in a total volume of 200 µl 
of BMDC medium. Subsequently, the BMDC-T cell co-culture was incubated for 3 days at 
37 °C. After 3 days, cells were retrieved from the wells and stained for FACS as mentioned 
before. 
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concentrations of Fab’DEC205 fragments and conjugates incubated with JAWSII DCs. Binding to DEC205 is 
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Summary
Research of the last three decades has established the potential of dendritic cell (DC)-tar-
geted cancer immunotherapy exploring various DC targets, tumor antigens, antibodies 
and conjugation methods. Despite successful pre-clinical studies, widespread clinical im-
plementation is, among other things, hampered by the lack of standardized methods to de-
sign defined DC-targeting vaccines. Site-directed modification of DC-targeting antibodies is 
necessary for the design of molecularly defined vaccines, that contain a controlled amount 
of payload at a pre-determined site of the antibody without limiting its binding affinity. 
Next to this, the need for the spatiotemporal delivery of an adjuvant for DC maturation 
together with the tumor antigen in one molecule has been raised. 
Research presented in this thesis has therefore focused on the development of novel 
synthetic strategies for the design of molecularly defined antibody-antigen (AA) as well as 
antibody-antigen-adjuvant (AAA) conjugates for DC-targeting vaccination. 
In Chapter 1, the central role of the DC in the cancer-immunity cycle is presented, em-
phasizing the rationale to develop DC-targeting cancer vaccines. Here, I discuss pioneering 
studies in the field of DC-targeted vaccines, focusing on the DEC205 receptor on DCs, and 
present common conjugation strategies that are used to create DEC205-targeting AA con-
jugates, including chemical conjugation, genetic fusions and sortase-mediated chemoen-
zymatic ligation. By delineating the current status and limitations of DC-targeting vaccines 
I moreover stress the need for new site-directed approaches that allow for the inclusion of 
both diverse tumor antigens and adjuvants for DC maturation into the antibody conjugate 
molecule. Chapter 1 concludes with an outline and scope of this thesis. 
In Chapter 2, I introduce an overview of the development of cancer vaccines and sum-
marize the most important studies of the last decade that made use of personalized, 
neoantigen-containing vaccines. I describe a trend towards the use of multiple different 
neoantigens in one vaccine, so called multiplex neoantigen vaccines, which were able to 
increase the breadth of the anti-tumor immune response in pre-clinical as well as in clinical 
studies. Along this line, I introduce the hypothesis that the success of multiplex neoantigen 
vaccines is dependent on a better understanding of tumorigenesis and the possibility to 
dissect the subclonal architecture of a tumor mass, to yield a better picture of intratumoral 
heterogeneity and of the neoantigens that have to be targeted. Chapter 2 concludes with a 
perspective on the future of multiplex neoantigen vaccines and provides a rational to invest 
in this concept in the context of DC-based/targeted vaccination.
In Chapter 3, we present a toolkit for designing molecularly defined DC-targeting vac-
cines by introducing a genetic fusion platform for the use in hybridoma cells. We apply the 
CRISPR-Cas9 technology to insert OVA antigen sequences in the immunoglobulin (Ig) locus 
of the anti-DEC205 antibody-producing hybridoma NLDC-145. By doing so, we create a 
stable hybridoma cell line that secretes anti-DEC205 Fab’ fragment-antigen conjugates. 
These conjugates are easily purified with high yields from cell culture supernatant and are 
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molecularly characterized by protein-based analytical assays and mass spectrometry. Us-
ing in vitro assays, we demonstrate their capability to be taken up, processed and pre-
sented in MHCI by DCs in order to induce T cell activation and proliferation, marked by 
expression of canonical T cell activation markers and secretion of IL-2 and IFN". The results 
presented in this chapter underline the robustness, simplicity and flexibility of this genetic 
platform, which we are currently capitalizing on to create AAA conjugates and multiplex 
neoantigen vaccines. 
To further improve our genetic platform, we explore the generation of a refined selection 
system for CRISPR-Cas9 mediated homology directed repair (CRISPR/HDR) events in Chap-
ter 4. Here, we develop an inducible apoptosis switch in the NLDC-145 hybridoma to be 
able to induce cell death of incorrectly edited hybridoma cells after CRISPR/HDR and there-
by select correctly edited cells. While this selection system was established and shown to 
be functional in a small portion of edited cells, we observed that it is limited by the fact that 
mostly non-homologous end joining is occurring after CRISPR-Cas9 double-strand break, 
by-passing the selection mechanism and resulting in false positives. For this reason, the 
platform will need to be further improved, for which the theoretical framework and knowl-
edge obtained in this chapter provide sufficient options to achieve this. 
In Chapter 5, we present a novel approach using sortase-mediated ligation and click 
chemistry to create the first molecularly defined AAA conjugate. We incorporate azide-func-
tionalized CD4+ or CD8+ OVA epitope at the C-terminus of anti-DEC205 Fab’ fragments 
by sortase-mediated ligation. Subsequently, we use click chemistry to introduce the DB-
CO-functionalized TLR7 ligand imidazoquinoline. The resulting AAA conjugates are charac-
terized by SDS-PAGE and mass spectrometry to confirm correct formation via site-directed 
attachment of both antigen and adjuvant to the antibody fragment. In preliminary in vitro 
assays we moreover showed proof of their target binding and functionality to underline the 
potential of this conjugation strategy. 
Discussion and future perspectives
The research presented in this thesis provides new possibilities for the generation of molec-
ularly defined DC-targeting vaccines. Both chemical and genetic approaches were success-
fully employed to create first-of-its-kind site-specific antibody conjugates that were able 
to elicit a T cell response in vitro. Having provided a proof-of-concept we are now looking 
forward to putting these platforms into practice in in vivo functional assays investigating T 
cell proliferation and effector functions in the context of tumors. In addition, the flexibility 
and accessibility of both approaches will allow us and others to further investigate ques-
tions fundamental to the field of DC-targeted therapy. 
First of all, we can adapt both systems to also produce full mAb AAA conjugates, that 
will differ from Fab’ fragments in terms of affinity, isotype and FC tail functions, antigen 
load, distribution and pharmacokinetics. Comparing both formats side-by-side can give 
us new insights about the optimal antibody format to choose for DC vaccination. Second, 
we can explore the combination of DC vaccines and checkpoint inhibitors such as anti-CT-
LA-4 or anti-PD-1 antibodies, which has already successfully been applied in untargeted DC 
vaccination studies3,4. Such combination can enhance T cell activation via DCs and simul-
taneously remove the tumor-mediated inhibition of these activated tumor-specific T cells 
through immune checkpoints. Third, it has to be investigated how helper and cytotoxic 
T cells can optimally be activated to support each other. Using both antigen epitopes on 
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distinct DC-targeting vaccines or on the same molecules, given at different timepoints or 
together can shed first light on this dynamic interplay during DC vaccination and help to 
maximize T cell synergy. Side-by-side comparisons of CD4+ and CD8+ T cells have indi-
cated cell extrinsic and intrinsic differences with regard to activation kinetics, MHC signal 
dependency, migration capacities and more, which justifies tailoring DC vaccines to make 
use of these differences5–7. Along this line, we have to compare different length of antigen 
epitopes, ranging from the minimal epitope for MHC binding to synthetic long peptides or 
even whole proteins, that could contain multiple epitopes for both CD4+ and CD8+ T cells. 
Current successful clinical studies with personalized cancer vaccines make use of RNA lipo-
plexes that display the mutation in the middle of the sequence surrounded by ten to twelve 
flanking amino acids to facilitate differential processing of CD4+ and CD8+ epitopes3,8. The 
advantage of mRNA above peptide encoded antigens is that it can be recognized by en-
dosomal TLRs of DCs and act as an adjuvant next to encoding the antigen9–11. Since it is 
actively translated in the DCs it can moreover lead to a higher amount of antigens within 
the DCs which in turn leads to a prolonged and more robust expression of MHC:epitope 
complexes12,13. The downside of using mRNA is that the expression of the encoded anti-
gens by the DC cannot be predicted and controlled, since mRNA translation is influenced 
by many factors such as the energy state of the cell, accessibility of ribosomes, transfer 
of RNAs and amino acids or a differential preference for certain codons within the mRNA 
sequence14. Eventually this can impede robustness of the approach. Furthermore, because 
three nucleotides translate into one amino acid, the size of an mRNA encoded antigen is 
bigger than that of a peptide antigen. The size might also increase when mRNAs are com-
plexed with protecting molecules such as protamine to prevent degradation by RNAses15. 
These factors have to be taken into account when designing targeted mRNA vaccines, to 
ensure reproducibility and proper pharmacokinetics and allow fair comparison with other 
DC-targeted vaccination approaches. 
Apart from answering these fundamental questions with regard to DC-targeted therapy 
and testing the existing vaccines in functional in vivo experiments in the future, in the 
following, we explored ways to enhance the AA conjugates presented in Chapter 3. 
As discussed before, especially in Chapter 5, for obtaining a strongly activated DC it is 
crucial to include an adjuvant molecule in the vaccine design, which is essential for a full-
blown T cell activation resulting in immunity. While this can be achieved through a combi-
nation of chemoenzymatic sortase-mediated ligation and click chemistry as demonstrated 
in Chapter 5, we were also interested in incorporating adjuvants into our hybridoma plat-
forms to allow fully genetic production of AAA conjugates. One way to do so, is to geneti-
cally introduce adjuvant encoding sequences in the light or heavy chain locus of DC-target-
ing antibody producing hybridomas, to fuse the antibody to the adjuvant. One promising 
candidate for this is the TLR2, 4 and 9 or RAGE receptor ligand high-mobility group box 1 
(HMGB-1) protein and its derived peptides. This ligand was shown to activate immature DCs 
indicated by upregulation of MHCII, CD80/CD86 and CD83 as well as secretion of IL-6, IL-
12 of TNF-a and induction of DC migration16–20. Similarly to the CRISPR/HDR approach pre-
sented in Chapter 3, we inserted the HMGB-1 protein, or two derived peptides containing 
the TLR/RAGE binding motif (HP91: DPNAPKRPPSAFFLFCSE, UC1018: SAFFLFCSE)17,18 in the 
hinge region of a DEC205 antibody expressing hybridoma NLDC-145 to form DEC205 Fab’ 
fragments that are C-terminally linked to the adjuvants (Fig. 1A). Thus, obtained monoclo-
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nal cell lines were screened for the presence of a histag (data not shown) and the amount 
of antibody produced by staining of the ( light chain and a flow cytometry readout, as 
described in Chapter 3 (Fig. 1B). For all three genetic modifications several clones were 
found to produce sufficient amounts of antibodies and were further validated by a genomic 
PCR using primers 1 and 2 (Fig. 1A and C). All selected clones showed a PCR product of the 
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Figure 1 | Generation of antibody-
adjuvant conjugates through CRISPR/
HDR in NLDC-145 hybridomas. (A) General 
approach of CRISPR/HDR engineering of 
the Rat IgG2a NLDC-145 heavy chain locus 
on chromosome six (i) with the sgRNA_
Hinge targeting the hinge region upstream 
of CH2 (ii). After DSB generation the HDR template will integrate, thereby inactivating transcription of CH2 and 
CH3 and enabling the transcription and translation of CH1-hinge-histag-adjuvant mRNA (iii). Correctly modified 
clones are selected by antibiotic pressure and limiting dilution, yielding a monoclonal cell line, producing the 
desired target molecules (iv). Numbers 1-2 indicate the forward and reverse primer locations used in this study. 
PAM = Protospacer adjacent motif, HC = Heavy chain, HA = Homology arm, HDR = Homology directed repair, 
I = internal ribosomal entry site (IRES), B = Blasticidin-S deaminase, P = Poly A signal. (B) Geometric means 
(gMFI) representing kappa light chain (LC) signal of antibodies in NLDC-HMGB-1, -HP91 and -UC1018 culture 
supernatants. For NLDC-HMGB-1 only two clones were screened, while NLDC-HP91 and -UC1018 produced 60 
and 36 clones respectively, of which the gMFI is represented in a heatmap from left to right. Supernatants were 
diluted 100 times to prevent saturation of the assay. gMFI Values were compared to a standard of known antibody 
(Ctrl.). (C) Genomic PCR with primers 1 and 2, as indicated in (A), with DNA isolated from clones that were selected 
by flow cytometry (B, orange rectangles). - = WT NLDC-145, + = Fab’DEC205-srt-his (Chapter 3). 
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E12) and 36 (Fig. 1B clone C12) were chosen as production clones for Fab’-HMGB-1, -HP91 
and -UC1018, respectively (Fig. 1B). These antibody-adjuvant conjugates were then isolated 
by NiNTA-bead chromatography from the supernatant of hybridoma cultures, yielding the 
expected products (Fig. 2A). Finally, we asked whether the obtained conjugates were able 
to activate immature DCs. Therefore, we incubated 100 µM of each conjugate with either 





















































































































































































Figure 2 | Analysis of antibody-adjuvant protein structure and maturation efficacy on DCs. (A) SDS-page gel 
stained by Sypro-ruby gel stain visualizing the different products of NiNTA-bead chromatography of supernatant 
from NLDC-HMGB-1, -HP91 and -UC1018 containing fab’-HMGB-1, -HP91 and -UC1018 respectively. S = 
supernatant, FT = flow through fraction, W = wash fraction, E = eluted fraction, C = concentrated sample, + 
= fab’DEC205-srt-his, - = WT mAb DEC025. Frequency of CD86+ DCs and global CD86 expression represented 
as geometric mean (gMFI), after overnight incubation of JAWSII DCs (B) or BMDCs (C) with 100 µM of soluble 
adjuvants, conjugated adjuvants or LPS (0.5 µg/ml). 
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of CD80, CD86, CD83 and MHCII after one day by flow cytometry. While CD80, CD83 and 
MHCII expression was not affected by antibody-adjuvant conjugates (data not shown), the 
proportion of CD86+ JAWSII and BMDCs was increased after culture with Fab’-HP91 and 
-UC1018 compared to the untreated control (Fig. 2B and C). In BMDCs this increase was 
more pronounced when cultured with Fab’-HP91 and -UC1018 than with non-targeted pep-
tides, suggesting a beneficial effect of targeting adjuvants to DCs (Fig 2C). In JAWSII cells 
targeting adjuvants had no additive effect, as CD86+ percentages were similar to soluble 
HP91 and UC1018 peptides (Fig. 2B). For both cell types, the global CD86 expression did 
not change compared to the untreated control. 
Together these results suggest a mild effect of Fab’-HP91 and -UC1018, but not Fab’-
HMGB-1, on the maturation of DCs marked by an increase in CD86 expressing cells. Al-
though this was a pilot experiment, the trend we observed is in line with earlier studies 
showing enhanced adjuvant efficacy of HP91 and UC1018 compared to HMGB-117,18. More 
experiments are certainly needed, including different doses, time points, readouts (e.g., 
IL-6 or IL-12) and functional T cell assays, to investigate whether the observed effect holds 
true and can lead to a pronounced DC maturation with physiological meaning. Only when 
proper maturation is possible, we will continue to add antigen epitopes by CRISPR/HDR to 
the antibody-adjuvant conjugates. Eventually, it will be of interest on which antibody chain 
antigen and adjuvant have to be placed to allow optimal binding to the target DC recep-
tor without compromising ligation of the adjuvant receptor. It will be necessary to design 
conjugates with antigen and adjuvant placed on the same or different antibody chains to 
investigate how binding of both, DC target receptor and adjuvant receptor can be optimally 
facilitated. 
Next to including genetic adjuvants into our DEC205-targeting conjugates, we were inter-
ested in translating the hybridoma platform presented in Chapter 3 to a patient setting by 
generating a neoantigen-containing AA conjugate that targets DC receptors in humans. To 
achieve this, we chose to target the C-type lectin receptor V called CLEC9A, which is primar-
ily expressed on human myeloid CD141+ or BDCA3+ DCs21,22. This subset of DCs represents 
roughly 0.05% of all peripheral mononuclear cells (PBMCs) and is known to efficiently 
cross-present antigens to CD8+ T cells, thereby mounting a cytotoxic T cell response23,24. 
Since it is a very scarce subset in the pool of PBMCs, but very potent in cross-presenting 
exogenous antigens, we believe that it is a prime candidate for a DC-targeted vaccination 
approach. 
As an antigen payload we chose to include a shared neoantigen which is expressed by 
patients with Lynch Syndrome (LS), a form of hereditary colorectal cancer (CRC). These 
shared neoantigens can be present in large patient populations due to the unique molecu-
lar mechanisms underlying the disease. LS is an autosomal dominantly inherited syndrome 
caused by monoallelic germline aberrations affecting one of the DNA mismatch repair 
(MMR) genes. As a consequence, the DNA MMR pathway is inactivated and misincorpo-
rations, insertions and deletions that are introduced by DNA polymerase slippage cannot 
be properly recognized and corrected. Specific genomic regions, including repetitive DNA 
sequences called microsatellites, are more prone for DNA polymerase slippage and, there-
fore, more susceptible for the introduction of these mutations if the DNA MMR capacity is 
lost. This in turn leads to microsatellite instability (MSI). Some of microsatellites are located 
within the coding regions of genes. Insertions and deletions in these regions may alter their 
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reading frame, potentially resulting in the transcription and translation of frameshift pep-
tides with c-terminally altered amino acid sequences. The arising frameshift neoantigens 
are highly immunogenic, which explains the enhanced immunogenicity of MSI CRC. They 
are also the reason for an increased infiltration of activated neoantigen-specific cytotoxic T 
cells into the tumor tissue, a hallmark of MSI CRC and a rational to exploit such neoantigens 
in a vaccination setting25.
In 90% of LS patients mutations occur in the microsatellite of the gene encoding trans-
forming growth factor " receptor II (TGF"RII). Knowing that, pre-clinical studies have iden-
tified the CD8+ T cell epitope of the TGF"RII neoantigen (RLSSCVPVA) that is recognized 
by the T cell receptor (TCR) and showed that TGF"RII-TCR transduced T cells can induce a 
significant reduction of tumor growth and increase the survival of xenograft mouse mod-
els26,27. Currently, also a clinical trial (ClinicalTrials.gov identifier: NCT01885702) is under-
way evaluating the effect of injected DCs ex vivo loaded with LS neoantigens, including 
TGF"RII, on the anti-tumor immune response and LS patient survival. Given the high fre-
quency of patients harboring the TGF"RII neoantigen and the evidence for a benefit of 
neoantigen-specific T cells for the survival LS patients, we chose to conjugate the TGF"RII T 
cell epitope to a CLEC9A-targeting antibody, in order to form an off-the-shelf personalized 
DC-targeting LS vaccine. 
To do so, we performed the CRISPR/HDR approach, as described in Chapter 3, in the 
9A11 hybridoma which produces anti-human CLEC9A binding antibodies of the immuno-
globulin (Ig) G1 isotype, in order to insert the TGF"RII neoantigen sequence and a hexa-
histidine tag (histag) at the hinge region (Fab’TGF"RII, Fig. 3A). Additionally, we installed 
a LPETG sortag motif followed by a histag (Fab’TGF"RII-srt) on the C-terminus of the light 
chain enabling site-directed addition of adjuvants or tracking dyes in the future (Fig. 3A). 
Western blots stained for the histag sequence revealed that we obtained CLEC9A Fab’ frag-
ments with a histag on both heavy and light chain (clone 2 and 4), underlining successful 
integration of the HDR templates at the desired locations and formation of a molecularly 
defined AA conjugate (Fig. 3B). Since we were interested whether BDCA3+/CLEC9A+ DCs 
can be targeted in a pool of PBMCs, we installed a fluorescent peptide (MV4: GGGCK(FAM)) 
by sortase-mediated ligation (Chapter 5) on the light chain to directly visualize targeted 
DCs (Fig. 3C, top). Similar to the positive control (Fab’CLEC9A-HC-srt-his (obtained from an 
earlier study) sortagged with MV4) the MV4 fluorescent signal overlays with the light chain 
of Fab’TGF"RII-srt conjugates, indicating proper conjugation of MV4 to the AA conjugate 
(Fig. 3C, bottom). Finally, we incubated Fab’TGF"RII-MV4 conjugates with human PBMCs 
and measured their binding to CLEC9A on BDCA3+ DCs by flow cytometry. Compared to 
commercially available anti-CLEC9A-FITC labelled antibodies, Fab’TGF"RII-MV4 conjugates 
were equally efficient in separating a CLEC9A+/BDCA3+ from the BDCA3+/CLEC9A- DC pop-
ulation (Fig. 3D). 
To summarize, these results indicate that the CRISPR/HDR approach presented in Chap-
ter 3, can be adapted to generate AA conjugates with human DC targets and personalized 
neoantigens. We showed that these AA conjugates are molecularly defined and can specif-
ically target a rare subset of CLEC9A expressing DCs in a pool of human PBMCs. Addition-
ally, we presented a new CRISPR/HDR modification by installing a fully functional sortag on 
the light chain of these AA conjugates, that did not compromise CLEC9A binding, even after 
attachment of a dye. We are looking forward to using this modification handle to introduce 
DC adjuvants, as described in Chapter 5, to create the first generation of personalized, 
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Figure 3 | Generation of AA conjugates for Lynch syndrome patients. (A) Conceptual overview of the CRISPR/HDR 
strategy for the integration of the TGF"RII-histag sequence on the anti CLEC9A antibody heavy chain (HC) and a 
sortag-histag on the light chain (LC). (B) Western blot of supernatants from hybridoma cultures stained for histag 
and mouse proteins. L = Protein Ladder, - = WT mAb CLEC9A, + mAb CLEC9A-LC-his, ++ = Fab’CLEC9A-HC-his. 
(C) Top: Fab’-TGF"RII-srt + MV4 reaction overview including the chemical structure of MV4. Bottom: SDS PAGE gel 
of different intermediates of the sortase reaction, stained with SYPRO Ruby gel stain and scanned with a 488nm 
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human AAA conjugates. Until then it will be important to explore the effect of Fab’TGF"RII 
on the activation and proliferation of patient-derived TGF"RII-specific T cells and their cy-
totoxic effector functions with respect to patient-derived LS tumor cells. 
The adaptations and modifications of the existing platforms for the generation of AA and 
AAA conjugates as presented here, clearly demonstrate the flexibility and robustness of our 
approach to generate site-directedly modified DC-targeting antibodies in a standardized 
and defined fashion. We believe that, once these platforms and workflows are optimized, 
they will have the potential to advance the field of DC-targeting anti-cancer vaccines, by 
providing a versatile toolkit for the creation of molecularly defined DC-targeting antibody 
conjugates that co-deliver adjuvants and multiple patient-specific neoantigens to combat 
cancerous cells. 
               laser to visualize MV4 location. (D) Flow cytometry scatter plots of PBMCs after incubation 
without antibody, with  anti-CLEC9A-FITC, MV4 or fab’-TGF"RII-MV4. Cells were additionally stained with anti-BD-
CA3 antibodies to visualize the BDCA3+ DC population and plotted in the 488nm channel to capture the FITC and 
MV4 signal.
Figure 3 continuted  |
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The anti-DEC205 secreting NLDC-145 hybridoma cell line (ATCC, HB-290) and anti-CLE-
C9A secreting 9A11 (Tumor Immunology Department, RIMLS, Nijmegen, The Netherlands) 
were purchased from ATCC and cultured in RPMI1640 (Thermo Fisher Scientific, 11875093) 
supplemented with 10 % heat-inactivated fetal bovine serum (FBS, GE Life Science, 
sv30160.03), 2 mM ultraglutamine (Lonza, Be17-605E/u1), antibiotic-antimycotic (AA) 
(Gibco, 2211104, 100x) and 50 µM 2-mercaptoethanol (Sigma Aldrich, STBH7709), hereaf-
ter called hybridoma medium.
The DEC205 expressing cell line JAWSII (ATCC, CRL-11904) was purchased from ATCC 
and cultured in !MEM (Gibco, 2099595) supplemented with 20 % FBS, NEM (Gibco, 
2165257, 100x), AA, Sodium pyruvate (Gibco, 1881816, 100x), sodium bicarbonate (Gibco, 
2078819, 100x), 50 µM 2-mercaptoethanol, 2 mM Ultraglutamine and freshly added gra-
nylocyte-macrophage colony-stimulating factor (GM-CSF, Miltenyi Biotec, 130-095-735) (5 
ng/ml). NLDC-145, 9A11, its engineered subclones and JAWSII were tested negative for the 
presence of mycoplasma (Lonza, LT07-418).
sgRNA and HDR donor template design
The design and construction of the HDR donor template was performed as already de-
scribed in Chapter 3. Instead of OTIp and OTIIp antigen sequences, HMGB-1 (Uniprot id: 
P63158), HP91 (DPNAPKRPPSAFFLFCSE) or UC1018 (SAFFLFCSE) coding sequences were 
codon optimized and inserted in between the homology arms by BamHI and BsmBI (both 
NEB) sequential digestions. To ensure proper binding of HMGB-1, HP91 and UC1018 to its 
target, we inserted the histag at the 5’end of the coding sequence right after the hinge 
region and G4S linker. As in chapter 3, the sgRNA_Hinge (CCAAGGGAATGCAATCCTTG) was 
used for inserting these HDR templates in the target locus. 
To design HDR templates with homology arms targeting the hinge region of the mouse 
immunoglobulin G1 locus and the kappa light chain (Suppl. Table 1 and 2), genomic se-
quences were extracted from the NCBI gene database and synthesized by Integrated DNA 
Technologies (IDT). Obtained homology arms were inserted in the pSpCas9(BB)-2APuro 
(PX459) vector (Addgene plasmid #62988) along with the common genetic elements 
IRES, Blasticidin S deaminase and a bGH poly A signal sequence. SgRNAs targeting the 
mIgG1 hinge region  (sgRNA_mHinge: CTTGGTGCTGCTGGCCGGGT), and the kappa light 
chain (sgRNA- m(: GGAATGAGTGTTAGAGACAA) were designed by CRISPOR (http://crispor.
tefor.net28) and ordered as single-stranded DNA (Integrated DNA technologies) with BbsI 
restriction enzyme overhangs to be cloned in the Cas9 plasmid PX330-SpCas9-NG (Ad-
dgene plasmid: 117919). To do so, single-stranded DNA was phosphorylated by T4 PNK 
(New England Biolabs (NEB), M0201L, 10045209) for 30 minutes at 37 °C and annealed 
by increasing the temperature to 95 °C for 5 minutes and subsequently lowering the tem-
perature by 5 °C/minute to 25 °C in a thermocycler. Annealed and phosphorylated oligos 
were ligated in BbsI (NEB) digested, dephosphorylated and gel purified Cas9 plasmids. All 
plasmids were purified by midiprep, containing endotoxin removal steps (Macherey-Nagel, 
740420.50) and validated by sanger sequencing (Sequence Facility, Radboudumc). 
Generation of Fab’HMGB-1, -HP91, -UC1018, and -TGF"RII-srt hybridoma cell lines
Prior to transfection, NLDC-145 and 9A11 cells were cultured as described above, to ensure 
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high viability (>95 %). For all transfections the LONZA nucleofector system was used to-
gether with the appropriate SF transfection kit (Lonza, V4xc-2024) and Lonza cuvettes. On 
the day of transfection, 1x106 cells per condition were washed with PBS + 0,5 % BSA and 
resuspended in SF transfection buffer. 1 µg of HDR donor template and 1 µg of Cas9-sgRNA 
plasmids were added to the cell suspension and transferred to the nucleofection cuvette. 
Nucleofection performed using the program QV-104. Subsequently, cells were transferred 
to a 6-well plate with pre-warmed hybridoma medium and incubated at 37 °C for 3 days. 
On day 3, cells ware scraped gently and re-plated with fresh medium supplemented with 
15 µg/mL blasticidin in 10 cm petri dishes. Until a viable confluent culture was obtained, 
blasticidin containing medium was refreshed every 4 days. After ca. 10 to 14 days, a lim-
iting dilution was performed to create single cell clones (SCCs). At that same time, DNA 
was isolated (Macherey Nagel, 740952.250) for a PCR screening to confirm integration of 
the donor template in the target locus. Once SCC were grown out, after another 14 days, 
the medium was refreshed and after two days 50 µl of supernatant was sampled by flow 
cytometry for the presence of antibodies and the rate of production. Highest producing 
clones, secreting the desired product were chosen as final clones and used for large scale 
production of the target molecules. 
For the insertion of a sortag motif on the kappa light chain of the Fab’TGF"RII expressing 
hybridoma another transfection was performed as described above, using the kappa light 
chain HDR template and sgRNA_m(.
DNA isolation, genomic PCR and sequencing
For PCR, genomic material from cultured cells was isolated using NucleoSpin columns 
(Macherey Nagel, 740952.250) according to the manufacturer’s protocol. PCR were per-
formed with 100 ng of template DNA, using the high-fidelity Q5 polymerase (NEB, M0491) 
and the recommended concentrations for Q5 enhancer, reaction buffer, dNTPs and forward 
and reverse primers. Insert specific DNA amplification using primers 1 (TGTAGGAGCTTGG-
GTCCAGA) and 2 (ATACATTGACACCAGTGAAGATGC) was performed in a thermocycler with 
following cycling conditions: 98 °C for 30 s, then 30 cycles of [98 °C for 20 s, 66 °C for 20 
s, 72 °C for 120 s], followed by a final amplification at 72 °C for 5 min. 
Flow cytometry
Screening of antibody production by NLDC-HMGB-1, -HP91 and -UC1018 limiting dilution 
clones was performed by incubating JAWSII DEC205 expressing DCs with 50 µl undiluted or 
100x diluted supernatant for 30 min at 4 °C. Secondary antibody staining was performed in 
FACS buffer (PBS + 1% FBS) with PE conjugated anti-rat Kappa LC (Biolegend, 407806, di-
lution: 400x) for 20 min at 4°C in the dark. DEC205 expression of JAWSII cells was verified 
by staining with PE conjugated anti-DEC205 (Biolegend, 138214, dilution: 100x). Samples 
were acquired on the MACS Quant Analyzer 10 (Miltenyi Biotec) flow cytometer using the 
MACSQuantify software.
Maturation of JAWSII and BMDCs after incubation with antibody-adjuvant conjugates 
was assessed by staining with anti-CD80-488 (Biolegend, 104716, dilution: 1000x), an-
ti-CD86-APC/Cy7 (Biolegend, 105030, dilution: 100x), anti-CD83-BV510 (BD Biosciences, 
563222, dilution: 100x) and anti- H-2Kb/H-2Db(MHCI)-PE (Biolegend, 114608, dilution: 
800x). 
Targeting of Fab’TGF"RII-MV4 to CLEC9A+ DCs was assessed by staining treated PBMCs 
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with anti-BDCA3-APC (Miltenyi Biotec, 130-113-314, dilution: 10x) for 30 minutes at 4 °C. 
Cells stained with anti-CLEC9A-VioBright-FITC (Miltenyi Biotec, 130-106-095, dilution: 11x) 
served as positive control.
SDS-PAGE and western blot
Cell culture supernatants or purified and concentrated antibodies were analyzed by SDS-
PAGE and western blot to verify the size of heavy and light chains and the presence of a 
histag. For SDS-PAGE, samples were resolved under reducing conditions 12% SDS-PAGE 
and visualized by SYPRO Ruby Protein Gel Stain (Thermo Fisher Scientific, S12000) on the 
Typhon Trio+ gel scanner (GE Healthcare Life Sciences) and analyzed with Fiji29. For western 
blot, SDS-PAGE gels were transferred to a polyvinylidene difluoride membrane and blocked 
with 3 % bovine serum albumin in PBS-Tween20 0.1 %. Blots were subsequently stained 
with monoclonal rabbit anti-his-tag antibody (Abcam, ab213204, dilution: 5000x), goat 
anti-rabbit IgG (H + L) (IRD800) (LI-COR, 926-32211), and goat anti-mIgG (H + L) (AF680) 
(Thermo Fisher Scientific, A-28183). Western blots were imaged on the Odyssey CLx imag-
ing system (LI-COR) and analyzed in ImageStudio lite (v5.2.5).
Mice 
All animal procedures were approved by the Animal Welfare Body of the Animal Research 
Facility (Radboudumc, Nijmegen). For the generation bone-marrow derived DCs, 5-15 
weeks old female WT C57BL/6J mice (Charles River, France) were sacrificed and bone mar-
row cells were isolated from hindlegs as described below.
Generation of BMDCs
DEC205 expressing BMDCs were generated as described by Kirkling et al30. In short, bone 
marrow cells were flushed from femur and tibia of WT mice and red blood cells were lysed 
in ammonium chloride buffer. Subsequently 2x106 isolated cells were seeded in 2 ml of 
BMDC medium (RPMI1640 (Thermo Fisher Scientific, 11875093) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 2 mM ultraglutamine (Lonza, BE16-605E/U1), 
1$ antibiotic-antimycotic (AA) (Thermo Fisher Scientific, 15240062) and freshly added 50 
uM 2-mercaptoethanol (Thermo Fisher Scientific, 21985023)) and supplemented with hu-
man Flt3-ligand (80 ng/ml) (Miltenyi Biotec, 130-096-479) in a 24-well plate. Cells were 
incubated for three days at 37 °C and 5% CO2. On day two after bone marrow cell isolation 
12.5x103 OP9-DL1 cells (gift from Dr. M. Dalod, Centre National de la Recherche Scientifique 
(CNRS), Paris, France) were plated in a 24-well plate in 500 ul of a-MEM GlutaMAX sup-
plemented with HEPES (10 mM), sodium Pyruvate (1 mM), AA (1x), ultraglutamine (2 mM), 
2-mercaptoethanol (50 µM), NEAA (1x) and FBS (20 %). On day 3, supernatant of OP9-DL1 
was removed and 1 mL of isolated bone marrow cells was added per well on top of the OP9-
DL1 monolayer. On day 8, cells were harvested from the wells by gentle scraping. DEC205 
expressing BMDCs were isolated from the co-culture using CD11c MicroBeads following the 
manufacturer’s protocol (Miltenyi Biotec, 130-108-338). Purity and expression of DEC205 
was assessed by FACS, staining with PE conjugated anti-DEC205 (Biolegend, 138214, dilu-
tion: 100x) and anti-CD11c (BD, 553802, dilution: 100x).
DC activation assay
To investigate the effect of Fab’HMGB-1, -HP91 and -UC1018 on the expression of matu-
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ration markers of DCs, JAWSII DCs or BMDCs were incubated overnight in 200 µl of DC 
medium in a 96 round bottom well plates with 100 µM of Fab’HMGB-1, -HP91 and -UC1018 
or soluble recombinant HMGB-1 (Biolegend, 557804), or HP91 and UC1018 peptides (kind 
gift by I. Ramos Tomillero). As negative and positive control respectively, DCs were left un-
treated or incubated with LPS (0,5 µg/ml). After overnight incubation cells were removed 
by incubation with cold PBS/FBS/EDTA buffer and scraping.!Maturation markers were then 
analyzed by flow cytometry as described above.
Sortase mediated ligation of MV4 to Fab’TGF"RII-srt
To attach the MV4 fluorescent peptide (synthesized by Dr. M. Verdoes, Dept. Tumor Immu-
nology, RIMLS, Nijmegen) to Fab’TGF"RII-srt, 6 µM of Fab’TGF"RII-srt, 6 )M 3M Sortase31,32, 
600 )M MV4 and 10 mM CaCl2 were incubated in 10 µL sortase buffer (150 mM NaCl, 50 
mM Tris, pH 7.0) for 1 h at 37 °C. The reaction was terminated by the addition of EDTA (10 
mM). The reaction was then visualized by SDS-PAGE as described above and fluorescent 
scanning (Typhoon trio+, GE Healthcare Life Sciences) at a wavelength of 488 nm, fol-
lowed by SYPRO Ruby protein staining. The final product was concentrated and purified by 
size exclusion spin filtration in Amicon Ultra-15 Centrifugal Filter Devices (Merck Millipore, 
UFC9030) with a molecular weight cutoff of 30 kDa (3x [25 min, 4°C, 4000 rpm). 
Targeting of CLEC9A+ DCs in a pool of PBMCs
In order to analyse the targeting efficiency of Fab’TGF"RII-MV4 first human PBMCs were 
isolated from buffy coats by Ficoll gradient centrifugation (Fisher Scientific, 11508545) ac-
cording to the manufacturer’s protocol. Then, 2.5E106 PBMCs/well were incubated with 15 
µg/ml of Fab’TGF"RII-MV4  for 1 h at 4 °C. As negative control, cells were incubated with 
an excess of MV4. After 1 hour, cells were washed with PBS/EDTA/FBS and stained for flow 
cytometric analysis as described above.
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Supplementary Tables
Supplementary Table 1 | DNA Sequence of Fab’TGF!RII donor templates. The table depicts the different elements 





















































Supplementary Table 2 | DNA Sequence of HDR donor templates for the insertion of a C-terminal sortag and 
histag motif in the murine ( light chain. The table depicts the different elements of the HDR donor templates 
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Gedurende de eeuwenlange evolutie, van eencellig organisme tot 21e eeuw Homo Univer-
salis, beschermde de mens zichzelf voortdurend tegen ruwe levensomstandigheden door 
grotten te bewonen, vuur te maken of kastelen te bouwen. Onopgemerkt ontwikkelde de 
mens ook een systeem dat hem beschermt tegen onzichtbare vijanden zoals virussen, bac-
teriën of kanker. Dit is het immuunsysteem, een complex netwerk van moleculen, cellen 
en organen, dat voorkomt dat de mens ziekten ontwikkelt, of dat helpt om sneller van een 
ziekte te genezen.
Ondanks dit beschermende systeem is kanker in de 21e eeuw één van de meest levens-
bedreigende ziekten in de westerse wereld. Deskundigen voorspellen dat de incidentie en 
mortaliteit ervan in toekomst verder zal stijgen. Dit wordt ten eerste veroorzaakt door een 
langere levensverwachting en de daarmee samenhangede cellulaire defecten van de ou-
derdom. Ten tweede, heeft het te maken met een gebrek aan effectieve therapiemogelijk-
heden, naast de gebruikelijk behandeling zoals chirurgische verwijdering van een tumor of 
chemo- en radiotherapie. Een belangrijke factor die dit ook beïnvloedt is de evolutie van 
tumoren die, net zoals de mens, sluwe mechanismes ontwikkelen om het immuunsysteem 
te omzeilen en zich beter te kunnen beschermen. 
Normaalgesproken is het immuunsysteem in staat om een tumor op te sporen en op te 
ruimen. Bij een zogenaamde anti-tumorimmuunrespons staan cellen van het aangeboren 
immuunsysteem, de dendritische cellen (DCs), centraal. Zij herkennen de tumor aan de 
hand van tumorstukjes, oftewel tumorantigenen, die vrijkomen zodra tumorcellen kapot 
gaan. De DCs nemen deze tumorantigenen vervolgens op en presenteren ze onder andere 
aan cellen van het adaptieve of verworven immuunsysteem, de T-cellen. De herkenning 
van tumorantigenen door T-cellen zal leiden tot activatie en omvorming tot gespecialiseer-
de ‘killercellen’ die de tumor opsporen en vervolgens elimineren. DCs worden daarom ook 
wel de poortwachter en dirigent van het immuunsysteem genoemd, omdat zij constant 
omgevingssignalen scannen voor vijandige activiteit en in het geval van nood verschillende 
instrumenten kunnen bedienen die de vijand aanpakken. 
Een relatief nieuwe vorm van kankertherapie, de DC-immuuntherapie, maakt daarom 
gebruik van de unieke potentie van de DC om een anti-tumorimmuunrespons op gang te 
brengen. Eén manier om dit te bereiken is ex vivo DC-vaccinatie. Hierbij worden DCs uit de 
patiënt geïsoleerd en in het laboratorium gekweekt waar ze met tumorantigenen van de 
patiënt beladen worden. In een tweede stap worden deze geïnformeerde DCs, terugge-
plaatst in de patiënt om hier T-cellen te activeren en een sterke anti-tumorimmuunrespons 
op te zetten. 
Een therapie die op ex vivo DC-vaccinatie voortbouwt heet in vivo DC-vaccinatie of ge-
richte DC-vaccinatie. Deze vorm van kankertherapie maakt gebruik van speciale bood-
schappermoleculen. Dit zijn Y-vormige eiwitten, oftewel antistoffen, die op een hele spe-
cifieke manier aan een target in het lichaam binden. Het proces is vergelijkbaar met een 
geadresseerde brief die in een specifieke brievenbus terecht komt. In het geval van gerichte 
DC-vaccinatie worden antistoffen gebruikt om tumorantigenen specifiek aan de DCs van 
de patiënt te adresseren. In het laboratorium worden hiervoor eerst de antistoffen aan de 
tumorantigenen gekoppeld. Daarna kunnen ze als therapeutisch kankervaccin in de patiënt 
geïnjecteerd worden, waar ze voor een specifieke informatieoverdracht aan de DCs zorgen. 
Dit helpt de DC om een anti-tumorimmuunrespons op te zetten en voorkomt dat de DCs uit 




Onderzoek van de laatste twee decennia heeft aangetoond dat gerichte DC-vaccinatie 
bijzonder effectief kan zijn, maar dat het cruciaal is hoe de antistoffen en tumorantigenen 
aan elkaar gekoppeld worden. Zo kan een willekeurige, ongecontroleerde koppeling van 
antigen aan antistof de specifieke binding van de antistof aan de DC verstoren. Het gevolg 
hiervan kan zijn dat de tumorantigenen de DC niet meer bereiken en de DC door gebrek 
aan informatie geen T-cellen kan aansturen. Hierdoor zal uiteindelijk de effectiviteit van 
de therapie afnemen.  Tot op heden is er geen manier beschreven om de koppeling van 
een DC-gerichte antistof aan een tumorantigen op een gecontroleerde, betrouwbare en 
opschaalbare manier te laten plaatsvinden.
In deze dissertatie beschrijf ik studies waarin we voor het eerst demonstreren hoe an-
tistof-tumorantigen-koppelingen op een gecontroleerde manier, met moleculaire precisie, 
gemaakt kunnen worden. Het doel van deze koppelingen is dat de interactie tussen antistof 
en DC niet verstoord wordt en de in vivo levering van tumorantigenen enkel en alleen aan 
de DC plaatsvindt.
In hoofdstuk 1 beschrijf ik de centrale rol van de DC in de anti-tumorimmuunrespons, 
met nadruk op de beweegredenen voor het ontwikkelen van DC-gerichte kankervaccins. 
Hier bediscussieer ik baanbrekende studies in het veld van DC-vaccinatie die gericht zijn 
op het oppervlaktemolecuul DEC205 en bespreek ik algemene koppelingstechnieken van 
DEC205-antistoffen en tumorantigenen. Ten slotte zet ik de huidige status en de gebreken 
van DC-gerichte vaccins uiteen en benadruk ik het belang van nieuwe methodes voor het 
gecontroleerde koppelen van antistoffen aan antigenen. Hoofdstuk 1 eindigt met een over-
zicht van studies in deze dissertatie. 
In hoofdstuk 2 introduceer ik een overzicht van de historische ontwikkelingen van kan-
kervaccins en vat ik de meest belangrijke studies van het laatste decennium samen die 
gebruik maken van gepersonaliseerde, tumor-specifieke antigenen in DC-vaccins. Deze 
tumorantigenen worden neoantigenen genoemd en zijn uniek per patiënt en vaak per tu-
morcelpopulatie. Vervolgens beschrijf ik een trend in het onderzoeksveld waarbij meerdere 
verschillende neoantigenen in één vaccin gecombineerd worden, zogenoemde multiplex 
neoantigenvaccins. Deze vaccins tonen zowel in preklinische als klinische studies veelbe-
lovende resultaten. In deze context introduceer ik de hypothese dat het succes van multi-
plex neoantigenvaccins gebaseerd is op een beter begrip van het ontstaan van tumoren 
en de mogelijkheid dat er naar het individuele evolutietraject van een tumorcel binnen 
een tumormassa gekeken kan worden. Hierdoor is het mogelijk om een beter overzicht 
te verkrijgen over de genetisch verschillen binnen de tumor (intratumor heterogeniteit) en 
om vervolgens de juiste en meest effectieve tumor(neo-)antigenen te gebruiken voor een 
DC-gericht vaccin. Ten slotte geef ik een vooruitblik op de toekomst van multiplex neoan-
tigenvaccins en presenteer ik redenen om in dit concept te investeren in de context van 
DC-gerichte vaccinatiestrategieën.
In hoofdstuk 3, presenteer ik een vernieuwende moleculaire gereedschapskist voor het 
gecontroleerde koppelen van een antistof aan een antigen. Dit doe ik door gebruik te ma-
ken van de genetische schaar CRIPSR/Cas9 waarmee ik genen van antistof-producerende 
cellen (hybridomas) naar wens kan aanpassen. Op die manier bouw ik nieuwe stukjes DNA 
in, die de code van een tumorantigen bevatten, precies in het gen dat de informatie voor 
het bouwen van een antistof bevat. Zo kan ik de hybridomacellen instrueren om een anti-
stof te produceren die gekoppeld is aan een tumorantigen. Uiteindelijk karakteriseer ik de 
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gevormde antistof-antigen-fusies en laat ik zien dat ze functioneel zijn in het activeren van 
T-cellen. 
Om de CRISPR/Cas9-methode voor het maken van antistof-antigen-fusies verder te 
ontwikkelen en klaar te stomen voor de productie van multiplex neoantigenvaccins heb 
ik in hoofdstuk 4 gekeken naar het optimaliseren van CRISPR/Cas9 in hybridomacellen. 
Omdat het inbouwen van informatie in het antistof-gen niet altijd vlekkeloos werkt, zijn 
er selectiestappen nodig om gemodificeerde cellen te kiezen, waarbij een correcte inser-
tie van DNA-stukken heeft plaatsgevonden. Normaalgesproken duurt deze selectie meer-
dere weken waarbij ook potentieel verkeerde cellen geselecteerd kunnen worden. Door 
het selectiesysteem te optimaliseren wilde ik deze tijd verkorten naar 24 uur en ervoor 
zorgen dat alleen maar correct gemodificeerde cellen overblijven. Hiervoor heb ik een se-
lectieschakelaar in hybridomacellen gebouwd, die verkeerd gemodificeerde cellen binnen 
24 uur uitschakelt, en correct gemodificeerde cellen overhoudt. Ondanks het succesvolle 
inbouwen van deze schakelaar in de cellen, ben ik er niet in geslaagd om daar alleen cor-
rect gemodificeerde cellen mee te selecteren. Een genetische analyse van cellen die na 
de selectie overbleven liet zien dat mutaties in het antistof-gen als gevolg van de CRISPR/
Cas9-methode de selectieschakelaar deactiveren waardoor ook cellen overleven die niet 
de verwachte antistof-antigen-fusies produceren. Dit liet zien dat het CRISPR/Cas9-plat-
form in hybridomacellen nog verdere verbetering eist. Met de kennis die we in deze studie 
hebben opgedaan zijn er meerdere handvatten om het platform in de toekomst verder te 
ontwikkelen en te verbeteren.
In de tussentijd heb ik verder gekeken naar het uitbreiden van de huidige antistof-an-
tigen, DC-gerichte, vaccins. In hoofdstuk 5, presenteer ik daarom een nieuwe manier om 
niet alleen een tumorantigen op een gecontroleerde manier aan een antistof te koppelen, 
maar ook een DC-activatiesignaal, oftewel adjuvant. Deze adjuvanten zijn nodig om de DC 
te activeren en daarmee de T-celrespons maximaal te versterken. In huidige DC-gerichte, 
vaccins ontbreekt een fysieke koppeling tussen antistof-antigen en adjuvanten, waardoor 
deze extra aan de patiënt gegeven zullen worden. Als gevolg hiervan worden de ongeadres-
seerde adjuvanten niet gericht aan de DC geleverd, waardoor de DCs niet geactiveerd wor-
den en zo ook de T-cellen niet kunnen activeren. Om antistof-antigen-adjuvant-fusies te 
ontwerpen heb ik gebruik gemaakt van gerichte chemische en enzymatische koppelings-
reacties waarbij ik eerst het tumorantigen en dan de adjuvant met de antistof verbindt. In 
preliminaire experimenten laat ik voor het eerst zien dat deze fusies de verwachte structuur 
hebben en het oppervlaktemolecuul DEC205 op de DC kunnen binden. Ook demonstreer ik 
hier de functionaliteit van de vaccins en onderstreep ik de potentie van de koppelingstech-
niek voor de volgende generatie van DC-gerichte kankervaccines.
Afsluitend vat ik in hoofdstuk 6 de verschillende studies uit deze dissertatie samen en 
bespreek ik nieuwe onderzoeksvragen en resultaten die hieruit voortkomen in het kader 







Während der jahrtausendlangen Evolution, vom einzelligen Organismus bis zum Homo 
Universalis des 21. Jahrhunderts, schützte der Mensch sich ständig vor harten Lebensbe-
dingungen, indem er in Höhlen wohnte, Feuer entfachte oder Burgen erbaute. Unbemerkt 
entwickelte der Mensch zudem ein System, das ihn vor unsichtbaren Feinden wie Viren, 
Bakterien oder Krebs schützt. Dabei handelt es sich um das Immunsystem, ein komplexes 
Netzwerk aus Molekülen, Zellen und Organen, das Menschen davor beschützt Krankheiten 
zu entwickeln oder ihnen hilft sich schneller von einer Krankheit zu erholen.
Trotz diesem ausgeklügelten System ist Krebs im 21. Jahrhundert eine der lebensbed-
rohlichsten Krankheiten der westlichen Welt. Experten gehen davon aus, dass die Inzidenz 
und Mortalität in Zukunft noch zunehmen wird. Dies erklärt sich zum einen durch die stetig 
steigende Lebenserwartung und die daraus resultierenden altersbedingten Zelldefekte. Ein 
anderer Grund hierfür ist, dass neben den üblichen Behandlungsmethoden wie der oper-
ativen Entfernung eines Tumors oder der Chemo- und Strahlentherapie keine wirksamen 
Therapiemöglichkeiten vorhanden sind. Letzteres hängt außerdem zusammen mit einer 
konstanten Evolution des Tumors, der wie der Mensch, listige Mechanismen entwickeln, 
um dem Immunsystem zu entgehen und sich besser zu schützen. 
Normalerweise ist das Immunsystem in der Lage, einen Tumor zu erkennen und zu be-
seitigen. Bei einer sogenannten anti-Tumor-Immunantwort spielen Zellen des angeborenen 
Immunsystems, die dendritischen Zellen (DZs), eine zentrale Rolle. Sie erkennen den Tumor 
anhand von Tumorstücken oder Tumorantigenen, die freigesetzt werden, sobald Tumorzel-
len zerstört werden. Die DZs nehmen diese Tumorantigene auf und präsentieren sie unter 
anderem Zellen des adaptiven oder erworbenen Immunsystems, den T-Zellen. Die Erken-
nung von Tumorantigenen durch T-Zellen aktiviert sie und wandelt sie um in spezialisierte 
„Killerzellen“, die den Tumor erkennen und dann eliminieren. DZs werden daher auch als 
Schutzpatron und Dirigent des Immunsystems bezeichnet, da sie ständig die Umgebung 
auf feindliche Aktivitäten abtasten und im Notfall verschiedene Instrumente bedienen kön-
nen, die den Feind bekämpfen.
Eine relativ neue Form der Krebstherapie, die DZ-Immuntherapie, nutzt daher das 
einzigartige Potenzial der DZ, um eine anti-tumorale Immunantwort auszulösen. Eine 
Möglichkeit, dies zu erreichen, wird als ex vivo DZ-Impfung bezeichnet. DZs werden aus 
dem Patienten isoliert und im Labor kultiviert, wo sie mit Tumorantigenen des Patienten 
beladen werden. In einem zweiten Schritt werden diese maturierten und aktivierten DCs 
dem Patienten wieder injiziert, um T-Zellen zu aktivieren und eine starke Anti-Tumor-Immu-
nantwort aufzubauen.
Eine darauf aufbauende Therapie wird in vivo DZ-Impfung oder gezielte DZ-Impfung 
genannt. Diese Form der Krebstherapie verwendet spezielle Botenstoffe. Dies sind Y-för-
mige Proteine  oder Antikörper, die ganz spezifisch an ein Ziel im Körper binden, so wie ein 
adressierter Brief auch in dem zugehörigen Briefkasten landet. Bei der gezielten DZ-Imp-
fung werden Antikörper verwendet, um Tumorantigene spezifisch an die DZs des Patienten 
zu adressieren. Im Labor werden die Antikörper zunächst an die Tumorantigene gekoppelt. 
Sie können dem Patienten dann als therapeutischer Krebsimpfstoff injiziert werden, wo 
sie eine gezielte Informationsweitergabe an die DZs ermöglichen. Dies hilft den DZs, eine 
Anti-Tumor-Immunantwort aufzubauen und verhindert, dass sie wie bei der ex vivo DZ-Imp-
fung aus ihrer natürlichen Umgebung entnommen werden.




besonders effektiv sein kann, aber das dies entschieden wird durch die Orientierung in 
der Antikörper und Tumorantigene miteinander verbunden sind. Beispielsweise kann eine 
zufällige, unkontrollierte Kopplung von Antigen an Antikörper die spezifische Bindung des 
Antikörpers an die DZ stören. Dadurch kann das Tumorantigen die DZ nicht mehr gut er-
reichen und die DZs können mangels Information die T-Zellen nicht mehr kontrollieren. 
Letztlich lässt hierdurch die Wirksamkeit der Therapie nach. Bis heute wurde kein Weg 
beschrieben, um die Kopplung eines auf DZ gerichteten Antikörpers an ein Tumorantigen 
auf kontrollierte, robuste und skalierbare Weise zu ermöglichen.
In dieser Dissertation beschreibe ich Studien, in denen wir erstmals zeigen, wie Antikörp-
er-Tumorantigen-Kopplungen kontrolliert und mit molekularer Präzision hergestellt werden 
können. Das Ziel dieser Kopplungen ist, dass die Interaktion zwischen Antikörper und DZ 
nicht gestört wird und die in vivo Übertragung der Tumorinformationen ausschließlich an 
die DZ geschieht.
In Kapitel 1 beschreibe ich die zentrale Rolle der DZ bei der Antitumor-Immunantwort 
und betone ihre Wichtigkeit für die Entwicklung von DZ-gerichteten Krebsimpfstoffen. 
Hier diskutiere ich auch bahnbrechende Studien auf dem Gebiet der DZ-Impfung gegen 
das Oberflächenmolekül DEC205 und beschreibe ich allgemeine Kopplungstechniken von 
DEC205-Antikörpern und Tumorantigenen. Abschließend erläutere ich den aktuellen Stand 
und die Defizite von DZ-gerichteten Impfstoffen und unterstreiche die Bedeutung neuer 
Methoden zur kontrollierten Kopplung von Antikörpern an Antigenen. Kapitel 1 endet mit 
einem Überblick über die Studien dieser Dissertation.
In Kapitel 2 gebe ich einen Überblick über die historische Entwicklung von Krebsimpf-
stoffen und fasse die wichtigsten Studien des letzten Jahrzehnts zusammen die sich mit 
personalisierten, tumorspezifischen Antigenen in DZ-Impfstoffen befassen. Diese Tumor-
antigene werden Neoantigene genannt und sind patientenspezifisch und oft auch spezi-
fisch für jede Tumorzellpopulation. Als Nächstes beschreibe ich einen Forschungstrend, 
bei dem mehrere verschiedene Neoantigene in einem Impfstoff kombiniert werden, soge-
nannte Multiplex-Neoantigen-Impfstoffe, die sowohl in präklinischen als auch in klinischen 
Studien vielversprechende Ergebnisse erzielen. In diesem Zusammenhang stelle ich die Hy-
pothese auf, dass der Erfolg von Multiplex-Neoantigen-Impfstoffen auf einem verbessert-
en Verständnis der Tumorentstehung und der Möglichkeit der Betrachtung der individuel-
len Evolutionsbahn einer Tumorzelle innerhalb einer Tumormasse beruht. Dadurch ist es 
möglich geworden, einen besseren Überblick über die genetischen Unterschiede innerhalb 
des Tumors (intratumorale Heterogenität) zu erhalten und anschließend die richtigen und 
wirksamsten Tumor-(Neo-)Antigene für einen DZ-gerichteten Impfstoff zu verwenden. Ab-
schließend gebe ich einen Ausblick auf die Zukunft von Multiplex-Neoantigen-Impfstoffen 
und präsentiere Gründe, wieso das Konzept der DZ-gezielten Impfstrategien sehr vielver-
sprechend ist und Investitionen gerechtfertigt sind. 
In Kapitel 3 stelle ich einen innovativen molekularen Werkzeugkasten zur kontrollierten 
Kopplung eines Antikörpers an ein Antigen vor. Dazu verwenden ich die Genschere CRIPSR/
Cas9, mit der ich Gene von Antikörper-produzierenden Zellen (Hybridomen) beliebig an-
passen kann. Auf diese Weise baue ich neue DNA-Stücke, die den Code eines Tumoranti-
gens enthalten, genau in das Gen ein, das die Informationen zum Aufbau eines Antikörpers 
enthält. Dies ermöglicht es, um die Hybridomzellen zu beauftragen, einen Antikörper zu 
produzieren, der direkt an ein Tumorantigen gebunden ist. Schließlich charakterisiere ich 
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die gebildeten Antikörper-Antigen-Fusionen und zeige, dass sie funktionsfähig sind bei der 
Aktivierung von T-Zellen.
Um die CRISPR/Cas9-Methode zur Herstellung von Antikörper-Antigen-Fusionen weit-
erzuentwickeln und für die Herstellung von Multiplex-Neoantigen-Impfstoffen vorzubere-
iten, habe ich mich in Kapitel 4 mit der Optimierung von CRISPR/Cas9 in Hybridomzellen 
befasst. Da der Einbau von Informationen in das Antikörper-Gen nicht immer einwandfrei 
funktioniert, sind selektive Schritte notwendig, um modifizierte Zellen auszuwählen, in die 
eine korrekte Insertion von DNA-Stücken erfolgt ist. Normalerweise dauert diese Selektion 
mehrere Wochen, wobei auch potentiell falsche Zellen selektiert werden können. Durch 
Optimierung des Selektionssystems will ich diese Zeit auf 24 Stunden verkürzen und sicher-
stellen, dass nur korrekt modifizierte Zellen übrigbleiben. Dazu habe ich in Hybridomzellen 
einen Selektionsschalter eingebaut, der falsch modifizierte Zellen innerhalb von 24 Stund-
en ausschaltet und korrekt modifizierte Zellen zurücklässt. Trotz der erfolgreichen Einbind-
ung dieses Schalters in die Zellen konnte ich damit nicht nur korrekt modifizierte Zellen 
selektieren. Eine genetische Analyse von Zellen, die nach der Selektion verblieben, zeigte, 
dass dies durch Mutationen im Antikörper-Gen verursacht wird. Diese Mutationen result-
ierten wiederum aus unerwarteten, unspezifischen Nebeneffekten der CRISPR/Cas9-Meth-
ode. Folglich deaktivieren diese Mutationen den Selektionsschalter, was letztendlich dazu 
führt, dass Zellen überleben können, die nicht die erwarteten Antikörper-Antigen-Fusionen 
produzieren. Dies zeigte, dass die CRISPR/Cas9-Plattform in Hybridomzellen noch weiter 
verbessert werden muss.  Mit den Erkenntnissen, die wir in dieser Studie gewonnen haben, 
gibt es mehrere Ansatzpunkte, um die Plattform in Zukunft zu verbessern.
In der Zwischenzeit habe ich mich weiter mit der Verbesserung der derzeitigen DZ-
gerichteten Antikörper-Antigen-Impfstoffe befasst. In Kapitel 5 stelle ich daher eine neue 
Methode vor, um nicht nur ein Tumorantigen kontrolliert an einen Antikörper zu koppeln, 
sondern auch ein DZ-Aktivierungssignal oder Adjuvans. Diese Adjuvanzien werden benötigt, 
um die DZ zu aktivieren und dadurch die T-Zellantwort zu maximieren. Gegenwärtige DZ-
gerichtete Impfstoffe haben keine physische Verbindung zwischen Antikörper-Antigen und 
Adjuvanzien, was bedeutet, dass sie dem Patienten zusätzlich verabreicht werden müssen. 
Dies hat zur Folge, dass die unadressierten Adjuvanzien auch nicht an die DZ geschickt 
werden können, und die DZs somit nicht aktiviert werden und keine T-Zellen aktivieren kön-
nen. Um Antikörper-Antigen-Adjuvans-Fusionen zu entwerfen, habe ich gezielte chemische 
und enzymatische Kopplungsreaktionen verwendet, bei denen ich zunächst das Tumor-
antigen und dann erst das Adjuvans an den Antikörper kopple. In Pilotversuchen zeige ich 
erstmals, dass diese Fusionen die erwartete Struktur haben und das Oberflächenmolekül 
DEC205 auf DZs binden können. Hier demonstriere ich auch die Funktionalität der Impfst-
offe und unterstreichen das Potenzial der Kupplungstechnik für die nächste Generation von 
DZ-gerichteten Krebsimpfstoffen. 
Abschließend fasse ich in Kapitel 6 die verschiedenen Studien dieser Dissertation 
zusammen und bespreche ich neue Forschungsansätze und Ergebnisse, die sich aus diesen 
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